



**Colorado Department of Health Care Policy and Financing
 Preferred Drug List (PDL)
 Effective October 1, 2023**

Prior Authorization Forms: Available online at <https://www.colorado.gov/hcpf/pharmacy-resources>

Prior Authorization (PA) Requests: Colorado Pharmacy Call Center Phone Number: 800-424-5725 | Fax Number: 800-424-5881

Electronic Prior Authorization (ePA): Real Time Prior Authorization via Electronic Health Record (EHR)

The PDL applies to Medicaid fee-for-service members. It does not apply to members enrolled in Rocky Mountain Health HMO or Denver Health Medicaid Choice.

Initiation of pharmaceutical product subject to Prior Authorization: Please note that starting the requested drug, including a non-preferred drug, prior to a PA request being reviewed and approved, through either inpatient use, by using office “samples,” or by any other means, does not necessitate Medicaid approval of the PA request.

Covid-19 Related Treatment Override: Providers may call the Magellan Help Desk at 1-800-424-5725 to request a prior authorization override if a medication is related to the treatment or prevention of COVID-19 or the treatment of a condition that may seriously complicate the treatment of COVID-19.

Health First Colorado, at 25.5-5-501, requires the generic of a brand name drug be prescribed if the generic is therapeutically equivalent to the brand name drug. Exceptions to this rule are: 1) If the brand name drug is more cost effective than the generic as determined by the Department, 2) If the patient has been stabilized on a brand name drug and the prescriber believes that transition to a generic would disrupt care, and 3) If the drug is being used for treatment of mental illness, cancer, epilepsy, or human immunodeficiency virus and acquired immune deficiency syndrome.

Please see the [Brand Favored Product List](#) for a list of medications where the brand name drug is more cost effective than the generic drug.

**Brand Name Required = BNR, Prior Authorization = PA, AutoPA = authorization can be automated at the point-of-sale transaction if criteria are met
 Preferred drug list applies only to prescription (RX) products, unless specified.**

Preferred Agents	Non-preferred Agents	Prior Authorization Criteria (All Non-preferred products will be approved for one year unless otherwise stated.)
I. Analgesics		
Therapeutic Drug Class: NON-OPIOID ANALGESIA AGENTS - Oral - Effective 4/1/2023		
No PA Required	PA Required	
Duloxetine 20 mg, 30 mg, 60 mg capsule	CYMBALTA (duloxetine) capsule	Non-preferred oral non-opioid analgesic agents may be approved if member meets all of the following criteria: <ul style="list-style-type: none"> Member has trialed and failed duloxetine (20mg, 30mg, or 60mg) AND has trialed and failed gabapentin OR pregabalin capsule (Failure is defined as lack

<p>Gabapentin capsule, tablet, solution</p> <p>Pregabalin capsule</p> <p>SAVELLA (milnacipran) tablet, titration pack</p>	<p>DRIZALMA (duloxetine DR) sprinkle capsules</p> <p>Duloxetine 40 mg capsule</p> <p>GRALISE (gabapentin ER) tablet</p> <p>HORIZANT (gabapentin ER) tablet</p> <p>LYRICA (pregabalin) capsule, solution, CR tablet</p> <p>NEURONTIN (gabapentin) capsule, tablet, solution</p> <p>Pregabalin solution, ER tablet</p>	<p>of efficacy with 8-week trial, allergy, intolerable side effects, or significant drug-drug interaction)</p> <p>Prior authorization will be required for Lyrica (pregabalin) capsule dosages > 600mg per day (maximum of 3 capsules daily) and gabapentin dosages > 3600mg per day.</p>
---	--	---

Therapeutic Drug Class: NON-OPIOID ANALGESIA AGENTS - Topical - Effective 4/1/2023

<p align="center">No PA Required</p> <p>Lidocaine patch</p> <p>LIDODERM (lidocaine) patch</p>	<p align="center">PA Required</p> <p>ZTLIDO (lidocaine) topical system</p>	<p>Non-preferred topical products require a trial/failure with an adequate 8-week trial of gabapentin AND pregabalin AND duloxetine AND Lidoderm patch. Failure is defined as lack of efficacy with an 8-week trial, allergy, intolerable side effects, or significant drug-drug interaction.</p> <p>Prior authorization will be required for lidocaine patch quantities exceeding 90 patches per 30 days (maximum of 3 patches daily).</p>
--	---	---

Therapeutic Drug Class: NON-STEROIDAL ANTI-INFLAMMATORIES (NSAIDS) - Oral - Effective 4/1/2023

<p align="center">No PA Required</p> <p align="center"><i>Generic changes effective 07/31/2023*</i></p> <p>Celecoxib capsule</p> <p>Diclofenac potassium 50 mg tablet</p> <p>Diclofenac sodium EC/DR tablet</p> <p>Ibuprofen suspension, tablet (RX)</p> <p>Indomethacin capsule, ER capsule</p> <p>Ketorolac tablet**</p> <p>Meloxicam tablet</p> <p>Nabumetone tablet</p>	<p align="center">PA Required</p> <p>ANAPROX DS (naproxen) tablet</p> <p>ARTHROTEC (diclofenac sodium/misoprostol) tablet</p> <p>CELEBREX (celecoxib) capsule</p> <p>DAYPRO (oxaprozin) caplet</p> <p>Diclofenac potassium capsule, powder pack</p> <p>Diclofenac potassium 25 mg tablet*</p> <p>Diclofenac sodium ER/SR tablet</p> <p>Diclofenac sodium/misoprostol tablet</p>	<p>DUEXIS (ibuprofen/famotidine) or VIMOVO (naproxen/esomeprazole) may be approved if the member meets the following criteria:</p> <ul style="list-style-type: none"> • Trial and failure[‡] of all preferred NSAIDs at maximally tolerated doses AND • Trial and failure[‡] of three preferred proton pump inhibitors in combination with NSAID within the last 6 months AND • Has a documented history of gastrointestinal bleeding <p>Diclofenac potassium 25 mg immediate-release tablets may be approved if the following criteria are met:</p> <ul style="list-style-type: none"> • Member is ≥ 18 years of age AND • Member does not have any of the following medical conditions: <ul style="list-style-type: none"> ○ History of recent coronary artery bypass graft (CABG) surgery ○ History of myocardial infarction ○ Severe heart failure ○ Advanced renal disease
--	--	--

<p>Naproxen DR/ER, tablet (RX)</p> <p>Naproxen EC tablet (RX) (all manufacturers except <i>Woodward</i>)</p> <p>Naproxen suspension</p> <p>Sulindac tablet</p>	<p>Diflunisal tablet</p> <p>DUEXIS (ibuprofen/famotidine) tablet</p> <p>ELYXYB (celecoxib) solution</p> <p>Etodolac capsule; IR, ER tablet</p> <p>FELDENE (piroxicam) capsule</p> <p>Fenoprofen capsule, tablet</p> <p>Flurbiprofen tablet</p> <p>Ibuprofen/famotidine tablet</p> <p>Ketoprofen IR, ER capsule</p> <p>Meclofenamate capsule</p> <p>Mefenamic acid capsule</p> <p>Meloxicam suspension</p> <p>Meloxicam (submicronized) capsule</p> <p>NALFON (fenoprofen) capsule, tablet</p> <p>NAPRELAN (naproxen CR) tablet</p> <p>NAPROSYN (naproxen) EC tablet, suspension, tablet</p> <p>Naproxen EC tablet (<i>Woodward only</i>)</p> <p>Naproxen sodium CR, ER, IR tablet</p> <p>Naproxen/esomeprazole DR tablet</p> <p>Oxaprozin tablet</p> <p>Piroxicam capsule</p> <p>RELAFEN DS (nabumetone) tablet</p>	<ul style="list-style-type: none"> ○ History of gastrointestinal bleeding <p>AND</p> <ul style="list-style-type: none"> • Member has trial and failure[‡] of four preferred oral NSAIDs at maximally tolerated doses <p>All other non-preferred oral agents may be approved following trial and failure[‡] of four preferred agents. [‡]Failure is defined as lack of efficacy, contraindication to therapy, allergy, intolerable side effects, or significant drug-drug interactions.</p> <p>**Ketorolac tablets quantity limits: 5-day supply per 30 days and 20 tablets per 30 days</p>
--	---	--

	Tolmetin tablet	
	VIMOVO (naproxen/esomeprazole) DR tablet	

Therapeutic Drug Class: NON-STEROIDAL ANTI-INFLAMMATORIES (NSAIDS) - Non-Oral - Effective 4/1/2023

No PA Required	PA Required	
Diclofenac 1.5% topical solution Diclofenac sodium 1% gel (OTC/Rx)	Diclofenac 1.3% topical patch, 2% pump FLECTOR (diclofenac) 1.3% topical patch Ketorolac nasal spray LICART (diclofenac) 1.3% topical patch PENNSAID (diclofenac solution) 2% pump	<p>SPRIX (ketorolac) may be approved if meeting the following criteria:</p> <ul style="list-style-type: none"> Member is unable to tolerate, swallow or absorb oral NSAID formulations OR Member has trialed and failed three preferred oral or topical NSAID agents (failure is defined as lack of efficacy, allergy, intolerable side effects or significant drug-drug interactions) Quantity limit: 5-single day nasal spray bottles per 30 days <p>All other non-preferred topical agents may be approved for members who have trialed and failed one preferred agent. Failure is defined as lack of efficacy with 14-day trial, allergy, intolerable side effects, or significant drug-drug interaction.</p> <p>Diclofenac topical patch quantity limit: 2 patches per day</p> <p>Diclofenac 3% gel (generic Solaraze) prior authorization criteria can be found in the Antineoplastic agents, topical, section of the PDL.</p>

Opioid Utilization Policy (long-acting and short-acting opioids):

It is highly encouraged that the healthcare team utilize the Prescription Drug Monitoring Program (PDMP) to aid in ensuring safe and efficacious therapy for members using controlled substances.

Total Morphine Milligram Equivalent Policy Effective 10/1/17:

- The maximum allowable morphine milligram equivalent (MME) is 200 MME. Prescriptions for short-acting (SA) and long-acting (LA) opioids are cumulatively included in this calculation. The prescription that exceeds the cumulative MME limit of 200 MME for a member will require prior authorization and may require a provider-to-provider telephone consultation with the pain management physician (free of charge and provided by Health First Colorado).
- Prior authorization will be granted to allow for tapering
- Prior authorization for 1 year will be granted for diagnosis of sickle cell anemia
- Prior authorization for 1 year will be granted for admission to or diagnosis of hospice or end of life care
- Prior authorization for 1 year will be granted for pain associated with cancer

MME calculation is conducted using conversion factors from the following link: <https://pharmacypmp.az.gov/resources/mme-calculator>

Only one long-acting opioid agent (including different strengths) and one short-acting opioid agent (including different strengths) will be considered for a prior authorization.

Medicaid provides guidance on the treatment of pain, including tapering, on our webpage under the heading Pain Management Resources and Opioid Use at: <https://www.colorado.gov/pacific/hcpf/pain-management-resources-and-opioid-use>

Opioid Naïve Policy Effective 8/1/17 (Update effective 04/01/23 in Italics):

Members who have not filled a prescription for an opioid within the past 180 days will be identified as “opioid treatment naïve” and have the following limitations placed on the initial prescription(s):

- The prescription is limited to short-acting opioid agents *or Butrans (buprenorphine)*. Use of other long-acting opioid agents will require prior authorization approval for members identified as opioid treatment naïve.
- The days’ supply of the first, second, and third prescription for an opioid will be limited to 7 days, the quantity will be limited to 8 dosage forms per day (tablets, capsules), maximum #56 tablets/capsules for a 7-day supply
- The fourth prescription for an opioid will require prior authorization, filling further opioid prescriptions may require a clinical pharmacist review or provider to provider telephone consultation with a pain management physician (free of charge and provided by Health First Colorado).
- If a member has had an opioid prescription filled within the past 180 days, then this policy would not apply to that member and other opioid policies would apply as applicable.

Dental Prescriptions Opioid Policy Effective 11/15/18 (implemented in the claims system 01/07/19):

Members who receive an opioid prescribed by a dental provider will be subject to day supply limits and quantity per day limits for short acting opioids.

- The prescription is limited to short-acting opioid agents only. Use of long-acting opioid agents and short acting fentanyl agents will require prior authorization approval for members’ prescriptions written by a dental provider.
- The days’ supply of the first, second, and third prescription for an opioid will be limited to 4 days, the quantity will be limited to 6 dosage forms per day (tablets, capsules), maximum #24 tablets/capsules for a 4-day supply
- The fourth prescription for an opioid will require prior authorization. A prior authorization for the fourth fill may be approved for up to a 7-day supply and the quantity will be limited to 8 dosage forms per day (#56 tablets/capsules) for members with any of the following diagnoses/undergoing any of the following procedures:
 - Traumatic oro-facial tissue injury with major mandibular/maxillary surgical procedures
 - Severe cellulitis of facial planes
 - Severely impacted teeth with facial space infection necessitating surgical management
- Other potential exemptions that exceed the first 3 fill limits (day supply and quantity) may be evaluated with a provider-to-provider telephone consult with a pain management specialist (free of charge and provided by Health First Colorado)

If a member has had an opioid prescription prescribed by a non-dental provider, then this policy would not apply to that member and other opioid policies would apply as applicable. Dental prescriptions do not impact the opioid treatment naïve policy, but the prescriptions will be counted towards the Morphine Milligram Equivalent (MME) daily dose.

Opioid and Benzodiazepine Combination Effective 9/15/19:

Prior authorization will be required for members receiving long-term therapy with an opioid medication who are newly started on a benzodiazepine medication OR for members receiving long-term therapy with a benzodiazepine medication who are newly started on an opioid medication. Prior authorization may be approved if meeting the following:

- The member discontinued or is no longer taking either the opioid or benzodiazepine medication and will not be using these in combination **OR**
- The member will not be taking the prescribed opioid and benzodiazepine medications at the same time based on prescribed dosing interval (such as prn administration) for the regimen AND the prescriber attests that the member has received appropriate counseling* regarding the risks associated with combining opioid and benzodiazepine medications including increased risk for sedation, respiratory depression, overdose, and overdose-related death and counseling regarding the FDA Boxed Warning for combining these medications **OR**
- The prescriber has evaluated the regimen and attests that it is appropriate for the member to continue use of the concomitant opioid and benzodiazepine medication regimen as prescribed AND the prescriber attests that the member has received appropriate counseling* regarding the risks associated with combining opioid and benzodiazepine medications including increased risk for sedation, respiratory depression, overdose, and overdose-related death and counseling regarding the FDA Boxed Warning for combining these medications **OR**
- Prior authorization may be approved for members receiving palliative or hospice care **OR**
- For benzodiazepine prior authorizations, approval may be granted if the benzodiazepine is being prescribed for seizure disorder or convulsions.

**If counseling has not been provided, the prescriber attests that a reasonable effort will be made to contact the member or the member's pharmacy to ensure that counseling is provided.*

Opioid and Quetiapine Combination Effective 9/15/19:

Pharmacy claims for members receiving opioid and quetiapine medications in combination will require entry of point-of-sale DUR service codes (Reason for Service, Professional Service, Result of Service) for override of drug-drug interaction (DD) related to risk of increased sedation from concomitant use of this drug combination.

Opioid and Buprenorphine-Containing substance use disorder (SUD) Product Combination Effective 06/01/21:

Opioid claims submitted for members currently receiving buprenorphine-containing SUD medications will require entry of point-of-sale DUR service codes (Reason for Service, Professional Service, Result of Service) for override of drug-drug interaction (DD) with use of this drug combination.

Therapeutic Drug Class: OPIOIDS, Short Acting - Effective 4/1/2023

Preferred No PA Required* (If criteria and quantity limit are met)	Non-Preferred PA Required	
Acetaminophen/codeine tablets*	Acetaminophen / codeine elixir	<p>*Preferred codeine and tramadol products do not require prior authorization for adult members (18 years of age or greater) if meeting all other opioid policy criteria.</p> <p>Preferred codeine or tramadol products prescribed for members < 18 years of age must meet the following criteria:</p> <ul style="list-style-type: none"> • Preferred tramadol and tramadol-containing products may be approved for members < 18 years of age if meeting the following: <ul style="list-style-type: none"> ○ Member is 12 years to 17 years of age AND ○ Tramadol is NOT being prescribed for post-surgical pain following tonsil or adenoid procedure AND ○ Member's BMI-for-age is not > 95th percentile per CDC guidelines AND ○ Member does not have obstructive sleep apnea or severe lung disease OR ○ For members < 12 years of age with complex conditions or life-limiting illness who are receiving care under a pediatric specialist, tramadol and tramadol-containing products may be approved on a case-by-case basis • Preferred Codeine and codeine-containing products will receive prior authorization approval for members meeting the following criteria may be approved for members < 18 years of age if meeting the following: <ul style="list-style-type: none"> ○ Member is 12 years to 17 years of age AND ○ Codeine is NOT being prescribed for post-surgical pain following tonsil or adenoid procedure AND ○ Member's BMI-for-age is not > 95th percentile per CDC guidelines AND ○ Member does not have obstructive sleep apnea or severe lung disease AND ○ Member is not pregnant, or breastfeeding AND ○ Renal function is not impaired (GFR > 50 ml/min) AND ○ Member is not receiving strong inhibitors of CYP3A4 (such as erythromycin, clarithromycin, itraconazole, ketoconazole, posaconazole, fluconazole [≥ 200mg daily], voriconazole, delavirdine, and milk thistle) AND ○ Member meets <u>one</u> of the following: <ul style="list-style-type: none"> • Member has trialed codeine or codeine-containing products in the past with no history of allergy or adverse drug reaction to codeine • Member has not trialed codeine or codeine-containing products in the past and the prescriber acknowledges reading the following statement: "Approximately 1-2% of the population metabolizes codeine in a manner
Hydrocodone/acetaminophen solution, tablet	APADAZ (benzhydrocodone/acetaminophen) tablet	
Hydromorphone tablet	ASCOMP WITH CODEINE (codeine/butalbital/aspirin/caffeine)	
Morphine IR solution, tablet	Benzhydrocodone/acetaminophen tablet	
NUCYNTA (tapentadol) tablet**	Butalbital/caffeine/acetaminophen/codeine* capsule	
Oxycodone solution, tablet	Butalbital/caffeine/aspirin/codeine capsule	
Oxycodone/acetaminophen tablet	Butalbital compound/codeine	
Tramadol 50mg*	Butorphanol tartrate (nasal) spray	
Tramadol/acetaminophen tablet*	Carisoprodol/aspirin/codeine	
	Codeine tablet	
	Dihydrocodeine/acetaminophen/caffeine tablet	
	DILAUDID (hydromorphone) solution, tablet	

	<p>FIORICET/CODEINE (codeine/ butalbital/acetaminophen/caffeine) capsule</p> <p>Hydrocodone/ibuprofen tablet</p> <p>Hydromorphone solution</p> <p>Levorphanol tablet</p> <p>LORTAB (hydrocodone/acetaminophen) elixir</p> <p>Meperidine solution, tablet</p> <p>Morphine concentrated solution, oral syringe</p> <p>NALOCET (oxycodone/acetaminophen) tablet</p> <p>Oxycodone capsule, syringe, concentrated solution</p> <p>Oxymorphone tablet</p> <p>Oxycodone/acetaminophen solution</p> <p>Oxycodone/acetaminophen tablet (generic PROLATE)</p> <p>Pentazocine/naloxone tablet</p> <p>PERCOCET (oxycodone/ acetaminophen) tablet</p> <p>ROXICODONE (oxycodone) tablet</p> <p>ROXYBOND (oxycodone) tablet</p> <p>SEGLENTIS (tramadol/celecoxib) tablet</p> <p>Tramadol 100mg tablet</p> <p>Tramadol solution</p>	<p>that exposes them to a much higher potential for toxicity. Another notable proportion of the population may not clinically respond to codeine. We ask that you please have close follow-up with members newly starting codeine and codeine-containing products to monitor for safety and efficacy.”</p> <p>Non-preferred tramadol products may be approved following trial and failure of generic tramadol 50mg tablet AND generic tramadol/acetaminophen tablet.</p> <p>All other non-preferred short-acting opioid products may be approved following trial and failure of three preferred products. Failure is defined as allergy‡, lack of efficacy, intolerable side effects, or significant drug-drug interaction.</p> <p>‡Allergy: hives, maculopapular rash, erythema multiforme, pustular rash, severe hypotension, bronchospasm, and angioedema</p> <p><u>Quantity Limits:</u> Short-acting opioids will be limited to a total of 120 tablets per 30 days (4/day) per member for members who are not included in the opioid treatment naive policy.</p> <ul style="list-style-type: none"> • **Nucynta IR will have a maximum daily quantity of 6 tablets (180 tabs per 30 days). • Exceptions will be made for members with a diagnosis of a terminal illness (hospice or palliative care) or sickle cell anemia. • For members who are receiving more than 120 tablets currently and who do not have a qualifying exemption diagnosis, a 6-month prior authorization can be granted via the prior authorization process for providers to taper members. • Please note that if more than one agent is used, the combined total utilization may not exceed 120 units in 30 days. There may be allowed certain exceptions to this limit for acute situations (for example: post-operative surgery, fractures, shingles, car accident). <p><u>Maximum Doses:</u> Tramadol: 400mg/day Codeine: 360mg/day Butorphanol intranasal: 10ml per 30 days (four 2.5ml 10mg/ml package units per 30 days)</p>
--	---	---

Therapeutic Drug Class: **FENTANYL PREPARATIONS (buccal, transmucosal, sublingual) - Effective 4/1/2023**

	<p align="center">PA Required</p> <p>ACTIQ (fentanyl citrate) lozenge</p> <p>Fentanyl citrate lozenge, buccal tablet</p> <p>FENTORA (fentanyl citrate) buccal tablet</p>	<p>Fentanyl buccal, intranasal, transmucosal, and sublingual products:</p> <p>Prior authorization approval may be granted for members experiencing breakthrough cancer pain and those that have already received and are tolerant to opioid drugs for the cancer pain AND are currently being treated with a long-acting opioid drug. The prior authorization may be granted for up to 4 doses per day. For patients in hospice or palliative care, prior authorization will be automatically granted regardless of the number of doses prescribed.</p>
--	---	---

Therapeutic Drug Class: **OPIOIDS, Long Acting - Effective 4/1/2023**

<p align="center">Preferred No PA Required (*if dose met)</p> <p>BUTRANS^{BNR} (buprenorphine) transdermal patch</p> <p>*Fentanyl 12mcg, 25mcg, 50mcg, 75mcg, 100mcg transdermal patch</p> <p>Morphine ER (generic MS Contin) tablet</p> <p>*NUCYNTA ER (tapentadol ER)</p> <p>Tramadol ER (generic Ultram ER) tablet</p>	<p align="center">Non-Preferred PA Required</p> <p>**OXYCONTIN (oxycodone ER) tablet</p> <p>BELBUCA (buprenorphine) buccal film</p> <p>Buprenorphine buccal film, transdermal patch</p> <p>CONZIP (tramadol ER) capsule</p> <p>Fentanyl 37mcg, 62mcg, 87mcg transdermal patch</p> <p>Hydrocodone ER capsule, tablet</p> <p>Hydromorphone ER tablet</p> <p>HYSINGLA (hydrocodone ER) tablet</p> <p>KADIAN (morphine ER) capsule</p> <p>Methadone (all forms)</p> <p>Morphine ER capsule</p> <p>MS CONTIN (morphine ER) tablet</p> <p>Oxycodone ER tablet</p> <p>Oxymorphone ER tablet</p> <p>Tramadol ER (generic Ryzolt/Conzip)</p>	<p>**Oxycontin may be approved for members who have trialed and failed‡ treatment with TWO preferred agents.</p> <p>All other non-preferred products may be approved for members who have trialed and failed‡ three preferred products.</p> <p>‡Failure is defined as lack of efficacy with 14-day trial due to allergy (hives, maculopapular rash, erythema multiforme, pustular rash, severe hypotension, bronchospasm, and angioedema), intolerable side effects, or significant drug-drug interaction.</p> <p><u>Methadone:</u> Members may receive 30-day approval when prescribed for neonatal abstinence syndrome without requiring trial and failure of preferred agents or opioid prescriber consultation.</p> <p><u>Methadone Continuation:</u> Members who have been receiving methadone for pain indications do not have to meet non-preferred criteria. All new starts for methadone will require prior authorization under the non-preferred criteria listed above.</p> <p><i>If a prescriber would like to discuss strategies for tapering off methadone or transitioning to other pain management therapies for a Health First Colorado member, consultation with the Health First Colorado pain management physician is available free of charge by contacting the pharmacy call center helpdesk and requesting an opioid prescriber consult.</i></p> <p><u>Reauthorization:</u> Reauthorization for a non-preferred agent may be approved if the following criteria are met:</p> <ul style="list-style-type: none"> • Provider attests to continued benefit outweighing risk of opioid medication use AND • Member met original prior authorization criteria for this drug class at time of original authorization
--	--	---

	XTAMPZA ER (oxycodone) capsule	<p><u>Quantity/Dosing Limits:</u></p> <ul style="list-style-type: none"> • Oxycontin, Nucynta ER, and Hydrocodone ER (generic Zohydro ER) will only be approved for twice daily dosing. • Hysingla will only be approved for once daily dosing. • Fentanyl patches will require a PA for doses of more than 15 patches/30 days (if using one strength) or 30 patches for 30 days (if using two strengths). For fentanyl patch strengths of 37mcg/hr, 62mcg/hr, and 87mcg/hr, member must trial and fail two preferred strengths of separate patches that will provide the desired dose (such as 12mcg/hr + 50mcg/hr = 62mcg/hr).
--	--------------------------------	--

II. Anti-Infectives

Therapeutic Drug Class: **ANTIBIOTICS, INHALED** -Effective 1/1/2023

Preferred	Non-Preferred	
No PA Required (*Must meet eligibility criteria)	PA Required	
<p>Tobramycin inhalation solution (generic TOBI)</p> <p>*CAYSTON (aztreonam) inhalation solution</p>	<p>ARIKAYCE (amikacin liposomal) inhalation vial</p> <p>BETHKIS (tobramycin) inhalation ampule</p> <p>KITABIS (tobramycin) nebulizer pak</p> <p>TOBI (tobramycin) inhalation solution</p> <p>TOBI PODHALER (tobramycin) inhalation capsule</p> <p>Tobramycin inhalation ampule (generic Bethkis)</p> <p>Tobramycin nebulizer pak (generic Kitabis)</p>	<p>*CAYSTON (aztreonam) inhalation solution may be approved if the following criteria are met:</p> <ul style="list-style-type: none"> • Member has a history of trial and failure of preferred tobramycin solution for inhalation (failure is defined as lack of efficacy with a 4-week trial, intolerable side effects, or significant drug-drug interactions) OR provider attests that member cannot use preferred tobramycin solution for inhalation due to documented allergy or contraindication to therapy AND • The member has known colonization of <i>Pseudomonas aeruginosa</i> in the lungs AND • The member has been prescribed an inhaled beta agonist to use prior to nebulization of Cayston (aztreonam). <p>ARIKAYCE (amikacin) may be approved if the following criteria are met:</p> <ul style="list-style-type: none"> • Member has refractory mycobacterium avium complex (MAC) lung disease with limited or no alternative treatment options available AND • Member has trialed and failed 6 months of therapy with a 3-drug regimen that includes a macrolide (failure is defined as lack of efficacy, contraindication to therapy, allergy, intolerable side effects, or significant drug-drug interactions). <p>All other non-preferred inhaled antibiotic agents may be approved if the following criteria are met:</p> <ul style="list-style-type: none"> • The member has a diagnosis of cystic fibrosis with known colonization of <i>Pseudomonas aeruginosa</i> in the lungs AND • Member has history of trial and failure of preferred tobramycin solution for inhalation (failure is defined as lack of efficacy with a 4-week trial, contraindication to therapy, allergy, intolerable side effects or significant drug-drug interactions).

Table 1: Minimum Age, Maximum Dose, and Quantity Limitations			
Drug Name	Minimum Age	Maximum Dose	Quantity Limit (Based on day supply limitation for pack size dispensed)
ARIKAYCE (amikacin)	≥ 18 years	590 mg daily	Not applicable
BETHKIS (tobramycin)	Age ≥ 6 years	300 mg twice daily	28-day supply per 56-day period
CAYSTON (aztreonam)	≥ 7 years	225 mg daily	28-day supply per 56-day period
KITABIS PAK (tobramycin)	Age ≥ 6 years	300 mg twice daily	28-day supply per 56-day period
TOBI [†] (tobramycin)	Age ≥ 6 years	300 mg twice daily	28-day supply per 56-day period
TOBI PODHALER (tobramycin)	Age ≥ 6 years	112 mg twice daily	28-day supply per 56-day period

[†] Limitations apply to brand product formulation only

Members currently stabilized on any inhaled antibiotic agent in this class may receive approval to continue that agent.

Therapeutic Drug Class: ANTI-HERPETIC AGENTS - Oral - Effective 1/1/2023

No PA Required	PA Required	
Acyclovir tablet, capsule	Acyclovir suspension (<i>members over 5</i>)	<p>Non-preferred products may be approved for members who have failed an adequate trial with two preferred products with different active ingredients. Failure is defined as lack of efficacy with 14-day trial, allergy, intolerable side effects, or significant drug-drug interaction.</p> <p>Sitavig (acyclovir) buccal tablet may be approved for diagnosis of recurrent herpes labialis (cold sores) if member meets non-preferred criteria listed above AND has failed trial with oral acyclovir suspension. Failure is defined as lack of efficacy with 14-day trial, allergy, intolerable side effects, or significant drug-drug interaction.</p> <p>For members with a diagnosis of Bell's palsy, valacyclovir 1,000 mg three times daily may be approved for 7 days if member presents with severe facial palsy.</p> <p>Acyclovir suspension may be approved for:</p> <ul style="list-style-type: none"> • Members under 5 years of age OR • Members with a feeding tube OR • Members meeting non-preferred criteria listed above.
Acyclovir suspension (<i>members under 5 years or with a feeding tube</i>)	SITAVIG (acyclovir) buccal tablet	
Famciclovir tablet	VALTREX (valacyclovir) tablet	
Valacyclovir tablet	ZOVIRAX (acyclovir) suspension	

		<table border="1"> <thead> <tr> <th colspan="3">Maximum Dose Table</th> </tr> <tr> <th></th> <th>Adult</th> <th>Pediatric</th> </tr> </thead> <tbody> <tr> <td>Acyclovir</td> <td>4,000 mg daily</td> <td>3,200 mg daily</td> </tr> <tr> <td>Famciclovir</td> <td>2,000 mg/day</td> <td></td> </tr> <tr> <td>Valacyclovir</td> <td>4,000 mg daily</td> <td>Age 2-11 years: 3,000mg daily Age ≥ 12 years: 4,000mg daily</td> </tr> </tbody> </table>			Maximum Dose Table				Adult	Pediatric	Acyclovir	4,000 mg daily	3,200 mg daily	Famciclovir	2,000 mg/day		Valacyclovir	4,000 mg daily	Age 2-11 years: 3,000mg daily Age ≥ 12 years: 4,000mg daily
Maximum Dose Table																			
	Adult	Pediatric																	
Acyclovir	4,000 mg daily	3,200 mg daily																	
Famciclovir	2,000 mg/day																		
Valacyclovir	4,000 mg daily	Age 2-11 years: 3,000mg daily Age ≥ 12 years: 4,000mg daily																	
Therapeutic Drug Class: ANTI-HERPETIC AGENTS- Topical - Effective 1/1/2023																			
No PA Required	PA Required	<p>Non-Preferred Zovirax and acyclovir ointment/cream formulations may be approved for members who have failed an adequate trial with the preferred topical acyclovir ointment/cream product (diagnosis, dose and duration) as deemed by approved compendium. (Failure is defined as: lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction)</p> <p>Xerese (acyclovir/hydrocortisone) prior authorization may be approved for members that meet the following criteria:</p> <ul style="list-style-type: none"> • Documented diagnosis of recurrent herpes labialis AND • Member is immunocompetent AND • Member has failed treatment of at least 10 days with acyclovir (Failure is defined as significant drug-drug interaction, lack of efficacy, contraindication to or intolerable side effects) AND • Member has failed treatment of at least one day with famciclovir 1500 mg OR valacyclovir 2 grams twice daily (Failure is defined as significant drug-drug interaction, lack of efficacy, contraindication to or intolerable side effects) 																	
Acyclovir cream (<i>Teva only</i>) Acyclovir ointment DENAVIR (penciclovir) cream ^{BNR}	Acyclovir cream (<i>all other manufacturers</i>) Penciclovir cream XERESE (acyclovir/ hydrocortisone) cream ZOVIRAX (acyclovir) cream, ointment																		
Therapeutic Drug Class: FLUOROQUINOLONES – Oral - Effective 1/1/2023																			
Preferred No PA Required (*if meeting eligibility criteria)	Non-Preferred PA Required	<p>*CIPRO (ciprofloxacin) suspension may be approved for members < 5 years of age without prior authorization. For members ≥ 5 years of age, CIPRO (ciprofloxacin) suspension may be approved for members who cannot swallow a whole or crushed tablet.</p> <p>Non-preferred products may be approved for members who have failed an adequate trial (7 days) with at least one preferred product. (Failure is defined as: lack of efficacy, contraindication to therapy, allergy, intolerable side effects, or significant drug-drug interaction).</p> <p>Levofloxacin solution may be approved for members < 5 years of age with prescriber attestation that member is unable to take Cipro (ciprofloxacin) crushed tablet or suspension OR for members < 5 years of age for treatment of pneumonia.</p> <p>For members ≥ 5 years of age, levofloxacin solution may be approved for members who require administration via feeding tube OR who have failed an adequate trial (7 days) of ciprofloxacin suspension. Failure is defined as lack of efficacy, allergy, intolerable side effects, significant drug-drug interaction, or contraindication to therapy.</p>																	
*CIPRO (ciprofloxacin) oral suspension *Ciprofloxacin oral suspension Ciprofloxacin tablet Levofloxacin tablet Moxifloxacin tablet	BAXDELA (delafloxacin) tablet CIPRO (ciprofloxacin) tablet Ciprofloxacin ER tablet Levofloxacin oral solution Ofloxacin tablet																		

Therapeutic Drug Class: **HEPATITIS C VIRUS TREATMENTS** - *Effective 1/1/2023*

Direct Acting Antivirals (DAAs)

<p>Preferred No PA Required for initial treatment (*must meet eligibility criteria)</p>	<p>Non-Preferred PA Required</p>	
<p>EPCLUSA (sofosbuvir/velpatasvir) 200 mg -50 mg, 150 mg-37.5 mg tablet, pellet pack</p> <p>HARVONI (ledipasvir/sofosbuvir) 45mg-200mg tablet, pellet pack</p> <p>Ledipasvir/Sofosbuvir 90 mg-400 mg tablet (<i>Asequa only</i>)</p> <p>MAVYRET (glecaprevir/pibrentasvir) tablet, pellet pack</p> <p>Sofosbuvir/Velpatasvir 400mg-100mg (<i>Asequa only</i>)</p> <p>*VOSEVI tablet (sofosbuvir/velpatasvir/voxilaprevir)</p>	<p>EPCLUSA 400 mg-100 mg (sofosbuvir/velpatasvir) tablet</p> <p>HARVONI 90 mg-400 mg (ledipasvir/sofosbuvir) tablet</p> <p>SOVALDI (sofosbuvir) tablet, pellet packet</p> <p>VIEKIRA PAK (ombitasvir/paritaprevir/ ritonavir/dasabuvir) tablet</p> <p>ZEPATIER (elbasvir/grazoprevir) tablet</p>	<p>Pharmacy claims for preferred products prescribed for initial treatment will be eligible for up to a 90-day supply fill allowing for the appropriate days' duration for completing the initial treatment regimen (with no PA required). Subsequent fills will require prior authorization meeting re-treatment criteria below.</p> <p>*Second line preferred agents (Vosevi) may be approved for members 18 years of age or older with chronic HCV infection who are non-cirrhotic or have compensated cirrhosis (Child-Pugh A) AND meet the following criteria:</p> <ul style="list-style-type: none"> • GT 1-6 and has previously failed treatment with a regimen containing an NS5A inhibitor (such as ledipasvir, daclatasvir, or ombitasvir) OR • GT 1a or 3 and has previously failed treatment with a regimen containing sofosbuvir without an NS5A inhibitor <p>AND</p> <ul style="list-style-type: none"> • Request meets the applicable criteria below for re-treatment. <p>Re-treatment: All requests for HCV re-treatment for members who have failed therapy with a DAA will be reviewed on a case-by-case basis. Additional information may be requested for re-treatment requests including:</p> <ul style="list-style-type: none"> • Assessment of member readiness for re-treatment • Previous regimen medications and dates treated • Genotype of previous HCV infection • Any information regarding adherence to previously trialed regimen(s) and current chronic medications • Adverse effects experienced from previous treatment regimen • Concomitant therapies during previous treatment regimen • Vosevi regimens will require verification that member has been tested for evidence of active hepatitis B virus (HBV) infection and for evidence of prior HBV infection prior to initiating treatment. <p>Non-preferred agents may be approved if documentation is provided indicating an acceptable rationale for not prescribing a preferred treatment regimen (acceptable rationale may include patient-specific medical contraindications to a preferred treatment or cases where a member has initiated treatment on a non-preferred drug and needs to complete therapy).</p> <p>Members currently receiving treatment with a non-preferred agent will receive approval to finish their treatment regimen, provided required documentation is sent via normal prior authorization request process.</p>

Ribavirin Products

No PA Required		Non-preferred ribavirin products require prior authorizations which will be evaluated on a case-by-case basis.
Ribavirin capsule		
Ribavirin tablet		

Therapeutic Drug Class: **HUMAN IMMUNODEFICIENCY VIRUS (HIV) TREATMENTS, ORAL** - *Effective 1/1/2023*

Effective 01/14/22, oral products indicated for HIV pre-exposure prophylaxis (PrEP) or post-exposure prophylaxis (PEP) are eligible for coverage with a written prescription by an enrolled pharmacist. Additional information regarding pharmacist enrollment can be found at <https://hcpf.colorado.gov/pharm-serv>.

Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

No PA Required		All products are preferred and do not require prior authorization.
EDURANT (rilpivirine) tablet		
Efavirenz tablet		
Etravirine tablet		
INTELENCE (etravirine) tablet		
Nevirapine IR tablet, ER tablet		
PIFELTRO (doravirine) tablet		
SUSTIVA (efavirenz) capsule, tablet		
VIRAMUNE (nevirapine) suspension		
VIRAMUNE XR (nevirapine ER) tablet		

Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs)

No PA Required		All products are preferred and do not require prior authorization.
Abacavir solution, tablet		
Didanosine DR capsule		
Emtricitabine capsule		
EMTRIVA (emtricitabine) capsule, solution		
EPIVIR (lamivudine) solution, tablet		
Lamivudine solution, tablet		

<p>RETROVIR (zidovudine) capsule, syrup</p> <p>Stavudine capsule, solution</p> <p>Tenofovir (TDF) tablet</p> <p>VIREAD (TDF) oral powder, tablet</p> <p>ZIAGEN (abacavir) solution, tablet</p> <p>Zidovudine capsule, syrup, tablet</p> <p><i>*TDF – Tenofovir disoproxil fumarate</i></p>		
Protease Inhibitors (PIs)		
<p style="text-align: center;">No PA Required</p> <p>APTIVUS (tipranavir) capsule</p> <p>Atazanavir capsule</p> <p>CRIXIVAN (indinavir) capsule</p> <p>Fosamprenavir tablet</p> <p>INVIRASE (saquinavir) tablet</p> <p>LEXIVA (fosamprenavir) suspension, tablet</p> <p>NORVIR (ritonavir) powder packet, solution, tablet</p> <p>PREZISTA (darunavir) suspension, tablet</p> <p>REYATAZ (atazanavir) capsule, powder pack</p> <p>Ritonavir tablet</p> <p>VIRACEPT (nelfinavir) tablet</p>		<p>All products are preferred and do not require prior authorization.</p>
Other Agents		
<p style="text-align: center;">No PA Required</p> <p>ISENTRESS (raltegravir) chewable, powder pack, tablet</p> <p>ISENTRESS HD (raltegravir) tablet</p>		<p>All products are preferred and do not require prior authorization.</p>

<p>RUKOBIA (fostemsavir tromethamine ER) tablet</p> <p>SELZENTRY (maraviroc) solution, tablet</p> <p>TIVICAY (dolutegravir) tablet</p> <p>TIVICAY PD (dolutegravir) tablet for suspension</p> <p>TYBOST (cobicistat) tablet</p> <p>VOCABRIA (cabotegravir) tablet</p>		
---	--	--

Combination Agents

<p align="center">No PA Required*</p> <p align="center">*Dispense as written (DAW) should be indicated on the prescription</p> <p>Abacavir/Lamivudine tablet</p> <p>Abacavir/Lamivudine/Zidovudine tablet</p> <p>BIKTARVY (bictegravir/emtricitabine/TAF) tablet</p> <p>CIMDUO (lamivudine/TDF) tablet</p> <p>COMBIVIR (lamivudine/zidovudine) tablet</p> <p>COMPLERA (emtricitabine/rilpivirine/TDF) tablet</p> <p>DELSTRIGO (doravirine/lamivudine/TDF) tablet</p> <p>DESCOVY (emtricitabine/TAF) tablet</p> <p>DOVATO (dolutegravir/lamivudine) tablet</p> <p>Efavirenz/Emtricitabine/TDF tablet</p> <p>Efavirenz/Lamivudine/TDF tablet</p> <p>Emtricitabine/TDF tablet</p> <p>EPZICOM (abacavir/lamivudine) tablet</p> <p>EVOTAZ (atazanavir/cobicistat) tablet</p>		<p>All products are preferred and do not require prior authorization.</p>
--	--	---

<p>GENVOYA (elvitegravir/cobicistat/emtricitabine/TAF) tablet</p> <p>JULUCA (dolutegravir/rilpivirine) tablet</p> <p>KALETRA (lopinavir/ritonavir) solution, tablet</p> <p>Lamivudine/Zidovudine tablet</p> <p>Lopinavir/Ritonavir solution, tablet</p> <p>ODEFSEY (emtricitabine/rilpivirine/TAF) tablet</p> <p>PREZCOBIX (darunavir/cobicistat) tablet</p> <p>STRIBILD (elvitegravir/cobicistat/emtricitabine/TDF) tablet</p> <p>SYMFI/SYMFI LO (efavirenz/lamivudine/TDF) tablet</p> <p>SYMTUZA (darunavir/cobicistat/emtricitabine/TAF) tablet</p> <p>TEMIXYS (lamivudine/TDF) tablet</p> <p>TRIUMEQ (abacavir/dolutegravir/ lamivudine) tablet</p> <p>TRIZIVIR (abacavir/lamivudine/zidovudine) tablet</p> <p>TRUVADA* (emtricitabine/TDF) tablet</p> <p><i>TAF – Tenofovir alafenamide</i> <i>TDF – Tenofovir disoproxil fumarate</i></p>		
---	--	--

Therapeutic Drug Class: TETRACYCLINES - Effective 7/1/2023

No PA Required	PA Required	
Doxycycline hyclate capsules	Demeclocycline tablet	Prior authorization for non-preferred tetracycline agents may be approved if member has trialed/failed a preferred doxycycline product AND preferred minocycline. Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction.
Doxycycline hyclate tablets	DORYX (doxycycline DR) tablet	
Doxycycline monohydrate 50mg, 100mg capsule	Doxycycline hyclate DR tablet	Prior authorization for liquid oral tetracycline formulations may be approved if member has difficulty swallowing and cannot take solid oral dosage forms.
Doxycycline monohydrate tablets	Doxycycline monohydrate 75mg, 150mg capsule	
Minocycline capsules	Doxycycline monohydrate suspension	
	Minocycline IR, ER tablet	Nuzyra (omadacycline) prior authorization may be approved if member meets all of the following criteria: the above “non-preferred” prior authorization criteria and the following:

	<p>MINOLIRA (minocycline ER) tablet</p> <p>MORGIDOX (doxycycline/skin cleanser) kit</p> <p>NUZYRA (omadacycline) tablet</p> <p>SOLODYN ER (minocycline ER) tablet</p> <p>Tetracycline capsule</p> <p>VIBRAMYCIN (doxycycline) capsule, suspension, syrup</p> <p>XIMINO (minocycline ER) capsule</p>	<ul style="list-style-type: none"> Member has trialed and failed[†] therapy with a preferred doxycycline product and preferred minocycline OR clinical rationale is provided describing why these medications cannot be trialed (including resistance and sensitivity) AND Member has diagnosis of either Community Acquired Bacterial Pneumonia (CABP) or Acute Bacterial Skin and Skin Structure Infection (ABSSSI) or clinical rationale and supporting literature describing/supporting intended use AND one of the following: <ul style="list-style-type: none"> If member diagnosis is ABSSSI, member must have trial and failure[†] of sulfamethoxazole/trimethoprim product in addition to preferred tetracyclines OR If member diagnosis is CABP, member must have trial and failure[†] of either a beta-lactam antibiotic (amoxicillin/clavulanic acid) or a macrolide (azithromycin) <p>AND</p> <ul style="list-style-type: none"> Maximum duration of use is 14 days <p>[†]Failure is defined as lack of efficacy with 7-day trial, allergy, intolerable side effects, or significant drug-drug interaction.</p>
--	---	--

III. Cardiovascular

Therapeutic Drug Class: ALPHA-BLOCKERS - Effective 7/1/2023

No PA Required	PA Required	
Prazosin capsule	MINIPRESS (prazosin) capsule	Non-preferred products may be approved following trial and failure of one preferred product (failure is defined as lack of efficacy with 4-week trial, allergy or intolerable side effects).

Therapeutic Drug Class: BETA-BLOCKERS - Effective 7/1/2023

Beta-Blockers, Single Agent

No PA Required <i>Brand/generic changes effective 4/27/23</i>	PA Required	
<p>Acebutolol capsule</p> <p>Atenolol tablet</p> <p>Bisoprolol tablet</p> <p>BYSTOLIC (nebivolol) tablet</p> <p>Carvedilol IR tablet</p> <p>COREG CR (carvedilol ER) capsule^{BNR}</p> <p>Labetalol tablet</p>	<p>Betaxolol tablet</p> <p>Carvedilol ER capsule</p> <p>CORGARD (nadolol) tablet</p> <p>COREG (carvedilol) tablet</p> <p>HEMANGEOL (propranolol) solution</p> <p>INDERAL LA/XL (propranolol ER) capsule</p> <p>INNOPRAN XL (propranolol ER) capsule</p>	<p>Non-preferred products may be approved following trial and failure with two preferred products (failure is defined as lack of efficacy with 4-week trial, allergy, intolerable side effects or significant drug-drug interactions).</p> <p>HEMANGEOL (propranolol) oral solution may be approved for members between 5 weeks and 1 year of age with proliferating infantile hemangioma requiring systemic therapy. Maximum dose: 1.7 mg/kg twice daily</p> <p>KAPSPARGO SPRINKLE (metoprolol succinate) extended-release capsule may be approved for members ≥ 6 years of age that have difficulty swallowing or require medication administration via a feeding tube. Maximum dose: 200mg/day (adult); 50mg/day (pediatric)</p> <p>Members currently stabilized on timolol oral tablet non-preferred products may receive approval to continue on that product.</p>

Metoprolol tartrate tablet	KASPARGO (metoprolol succinate) sprinkle capsule	<table border="1"> <thead> <tr> <th colspan="5">Table 1: Receptor Selectivity and Other Properties of Preferred Beta Blockers</th> </tr> <tr> <th></th> <th>β_1</th> <th>β_2</th> <th>Alpha-1 receptor antagonist</th> <th>Intrinsic sympathomimetic activity (ISA)</th> </tr> </thead> <tbody> <tr> <td>Acebutolol</td> <td>X</td> <td></td> <td></td> <td>X</td> </tr> <tr> <td>Atenolol</td> <td>X</td> <td></td> <td></td> <td></td> </tr> <tr> <td>Betaxolol</td> <td>X</td> <td></td> <td></td> <td></td> </tr> <tr> <td>Bisoprolol</td> <td>X</td> <td></td> <td></td> <td></td> </tr> <tr> <td>Carvedilol</td> <td>X</td> <td>X</td> <td>X</td> <td></td> </tr> <tr> <td>Labetalol</td> <td>X</td> <td>X</td> <td>X</td> <td></td> </tr> <tr> <td>Metoprolol succinate</td> <td>X</td> <td></td> <td></td> <td></td> </tr> <tr> <td>Metoprolol tartrate</td> <td>X</td> <td></td> <td></td> <td></td> </tr> <tr> <td>Nadolol</td> <td>X</td> <td>X</td> <td></td> <td></td> </tr> <tr> <td>Nebivolol</td> <td>X</td> <td></td> <td></td> <td></td> </tr> <tr> <td>Pindolol</td> <td>X</td> <td>X</td> <td></td> <td>X</td> </tr> <tr> <td>Propranolol</td> <td>X</td> <td>X</td> <td></td> <td></td> </tr> </tbody> </table>	Table 1: Receptor Selectivity and Other Properties of Preferred Beta Blockers						β_1	β_2	Alpha-1 receptor antagonist	Intrinsic sympathomimetic activity (ISA)	Acebutolol	X			X	Atenolol	X				Betaxolol	X				Bisoprolol	X				Carvedilol	X	X	X		Labetalol	X	X	X		Metoprolol succinate	X				Metoprolol tartrate	X				Nadolol	X	X			Nebivolol	X				Pindolol	X	X		X	Propranolol	X	X		
Table 1: Receptor Selectivity and Other Properties of Preferred Beta Blockers																																																																								
	β_1		β_2	Alpha-1 receptor antagonist	Intrinsic sympathomimetic activity (ISA)																																																																			
Acebutolol	X				X																																																																			
Atenolol	X																																																																							
Betaxolol	X																																																																							
Bisoprolol	X																																																																							
Carvedilol	X		X	X																																																																				
Labetalol	X		X	X																																																																				
Metoprolol succinate	X																																																																							
Metoprolol tartrate	X																																																																							
Nadolol	X		X																																																																					
Nebivolol	X																																																																							
Pindolol	X	X		X																																																																				
Propranolol	X	X																																																																						
Metoprolol succinate ER tablet	LOPRESSOR (metoprolol tartrate) tablet																																																																							
Nadolol tablet	Pindolol tablet																																																																							
Nebivolol tablet	TENORMIN (atenolol) tablet																																																																							
Propranolol IR tablet, solution	Timolol tablet																																																																							
Propranolol ER capsule	TOPROL XL (metoprolol succinate) tablet																																																																							

Beta-Blockers, Anti-Arrhythmics

No PA Required	PA Required	<p>SOTYLIZE (sotalol) oral solution may be approved for members 3 days to < 5 years of age. For members \geq 5 years of age, SOTYLIZE (sotalol) oral solution may be approved for members who-cannot swallow a sotalol tablet OR members that have trialed and failed therapy with one preferred product. (Failure is defined as allergy or intolerable side effects.) Maximum dose: 320 mg/day</p>
Sotalol tablet	BETAPACE/AF (sotalol) tablet SOTYLIZE (sotalol) solution	

Beta-Blockers, Combinations

No PA Required	PA Required	<p>Non-preferred products may be approved following trial and failure with two preferred products (failure is defined as lack of efficacy with 4-week trial, allergy, intolerable side effects or significant drug-drug interactions).</p>
Atenolol/Chlorthalidone tablet	Propranolol/HCTZ tablet	
Bisoprolol/HCTZ tablet	TENORETIC (atenolol/chlorthalidone) tablet	
Metoprolol/HCTZ tablet	ZIAC (bisoprolol/HCTZ) tablet	

Therapeutic Drug Class: **CALCIUM CHANNEL-BLOCKERS** - Effective 7/1/2023

Dihydropyridines (DHPs)

No PA Required	PA Required	
<p>Amlodipine tablet</p> <p>Felodipine ER tablet</p> <p>Nifedipine IR capsule</p> <p>Nifedipine ER tablet</p>	<p>ADALAT CC (nifedipine ER) tablet</p> <p>NORLIQVA (amlodipine) suspension</p> <p>KATERZIA (amlodipine) suspension</p> <p>Isradipine capsule</p> <p>Nicardipine capsule</p> <p>Nimodipine capsule</p> <p>Nisoldipine ER tablet</p> <p>NORVASC (amlodipine) tablet</p> <p>NYMALIZE (nimodipine) solution, oral syringe</p> <p>PROCARDIA XL (nifedipine ER) tablet</p> <p>SULAR (nisoldipine ER) tablet</p>	<p>Non-preferred products may be approved following trial and failure of two preferred agents. Failure is defined as lack of efficacy, contraindication to therapy, allergy, intolerable side effects, or significant drug-drug interactions.</p> <p>NYMALIZE (nimodipine) oral syringe may be approved for adult members (≥ 18 years of age) with subarachnoid hemorrhage who also have a feeding tube or have difficulty swallowing solid dosage forms. Maximum dose: 360 mg/day for 21 days (6 syringes/day or 126 syringes/21 days)</p> <p>KATERZIA (amlodipine) suspension may be approved if meeting the following:</p> <ul style="list-style-type: none"> • The member has a feeding tube or confirmed difficulty swallowing solid oral dosage forms OR cannot obtain the required dose through crushed amlodipine tablets AND • For members < 6 years of age, the prescriber confirms that the member has already been receiving the medication following initiation in a hospital or other clinical setting

Non-Dihydropyridines (Non-DHPs)

No PA Required	PA Required	
<p>Diltiazem IR tablet</p> <p>Diltiazem CD/ER capsule</p> <p>Verapamil IR, ER tablet</p> <p>Verapamil ER 120 mg, 180 mg, 240 mg capsule</p>	<p>CALAN SR (verapamil ER) tablet</p> <p>CARDIZEM (diltiazem) tablet</p> <p>CARDIZEM CD/LA (diltiazem CD/ER) capsule, tablet</p> <p>Diltiazem ER/LA tablet</p> <p>TIAZAC ER (diltiazem ER) capsule</p> <p>Verapamil ER 360 mg capsule</p> <p>Verapamil PM ER 100 mg, 200 mg, 300 mg capsule</p> <p>VERELAN/PM (verapamil ER) pellet capsule</p>	<p>Non-preferred products may be approved following trial and failure of three preferred agents. Failure is defined as lack of efficacy, contraindication to therapy, allergy, intolerable side effects, or significant drug-drug interactions.</p>

Therapeutic Drug Class: **ANGIOTENSIN MODIFIERS** - *Effective 7/1/2023*

Angiotensin-converting enzyme inhibitors (ACE Inh)

No PA Required	PA Required	
<p>Benazepril tablet</p> <p>Enalapril tablet</p> <p>Fosinopril tablet</p> <p>Lisinopril tablet</p> <p>Quinapril tablet</p> <p>Ramipril tablet</p>	<p>ACCUPRIL (quinapril) tablet</p> <p>ALTACE (ramipril) capsule</p> <p>Captopril tablet</p> <p>Enalapril solution</p> <p>EPANED (enalapril) solution</p> <p>LOTENSIN (benazepril) tablet</p> <p>Moexipril tablet</p> <p>Perindopril tablet</p> <p>PRINIVIL (lisinopril) tablet</p> <p>QBRELIS (lisinopril) solution</p> <p>Trandolapril tablet</p> <p>VASOTEC (enalapril) tablet</p> <p>ZESTRIL (lisinopril) tablet</p>	<p>Non-preferred ACE inhibitors, ACE inhibitor combinations, ARBs, ARB combinations, renin inhibitors, and renin inhibitor combination products may be approved for members who have trialed and failed treatment with three preferred products (failure is defined as lack of efficacy with a 4-week trial, allergy, intolerable side effects, or significant drug-drug interaction).</p> <p>*Enalapril solution may be approved without trial and failure of three preferred agents for members who cannot swallow a whole or crushed tablet.</p> <p>*QBRELIS (lisinopril) solution may be approved for members 6 years of age or older who cannot swallow a whole or crushed tablet and have trialed and failed Epaned (enalapril) solution. Failure is defined as lack of efficacy with a 4-week trial, allergy, intolerable side effects, or significant drug-drug interaction.</p>

ACE Inhibitor Combinations

No PA Required	PA Required	
<p>Amlodipine/Benazepril capsule</p> <p>Enalapril/HCTZ tablet</p> <p>Lisinopril/HCTZ tablet</p>	<p>ACCURETIC (quinapril/HCTZ) tablet</p> <p>Benazepril/HCTZ tablet</p> <p>Captopril/HCTZ tablet</p> <p>Fosinopril/HCTZ tablet</p> <p>LOTENSIN HCT (benazepril/HCTZ) tablet</p> <p>LOTREL (amlodipine/benazepril) capsule</p> <p>Quinapril/HCTZ tablet</p>	<p>Non-preferred ACE inhibitors, ACE inhibitor combinations, ARBs, ARB combinations, renin inhibitors, and renin inhibitor combination products may be approved for members who have trialed and failed treatment with three preferred products (failure is defined as lack of efficacy with a 4-week trial, allergy, intolerable side effects, or significant drug-drug interaction).</p>

	VASERETIC (enalapril/HCTZ) tablet ZESTORETIC (lisinopril/HCTZ) tablet	
Angiotensin II receptor blockers (ARBs)		
No PA Required	PA Required	Non-preferred ACE inhibitors, ACE inhibitor combinations, ARBs, ARB combinations, renin inhibitors, and renin inhibitor combination products may be approved for members who have trialed and failed treatment with three preferred products (failure is defined as lack of efficacy with a 4-week trial, allergy, intolerable side effects, or significant drug-drug interaction).
Irbesartan tablet	ATACAND (candesartan) tablet	
Losartan tablet	AVAPRO (irbesartan) tablet	
Olmesartan tablet	BENICAR (olmesartan) tablet	
Telmisartan tablet	Candesartan tablet	
Valsartan tablet	COZAAR (losartan) tablet	
	DIOVAN (valsartan) tablet	
	EDARBI (azilsartan) tablet	
	Eprosartan tablet	
	MICARDIS (telmisartan) tablet	
ARB Combinations		
Preferred No PA Required (Unless indicated*)	Non-Preferred PA Required	Non-preferred ACE inhibitors, ACE inhibitor combinations, ARBs, ARB combinations, renin inhibitors, and renin inhibitor combination products may be approved for members who have trialed and failed treatment with three preferred products (failure is defined as lack of efficacy with a 4-week trial, allergy, intolerable side effects, or significant drug-drug interaction). * ENTRESTO (sacubitril/valsartan) may be approved for members if the following criteria are met: <ul style="list-style-type: none"> • Member is 1 to 17 years of age and has a diagnosis of symptomatic heart failure with systemic left ventricular systolic dysfunction (LVSD) and/or has chronic heart failure with a below-normal left ventricular ejection fraction (LVEF) OR • Member is ≥ 18 years of age and has a diagnosis of chronic heart failure. • Diagnosis will be verified through automated verification (AutoPA) of the appropriate corresponding ICD-10 diagnosis codes related to the indicated use of the medication.
ENTRESTO (sacubitril/valsartan) * tablet	ATACAND HCT (candesartan/HCTZ) tablet	
Irbesartan/HCTZ tablet	AVALIDE (irbesartan/HCTZ) tablet	
Losartan/HCTZ tablet	AZOR (olmesartan/amlodipine) tablet	
Olmesartan/Amlodipine tablet	BENICAR HCT (olmesartan/HCTZ) tablet	
Olmesartan/HCTZ tablet	Candesartan/HCTZ tablet	
Valsartan/Amlodipine tablet	DIOVAN HCT (valsartan/HCTZ) tablet	
Valsartan/HCTZ tablet	EDARBYCLOR (azilsartan/chlorthalidone) tablet	
	EXFORGE (valsartan/amlodipine) tablet	
	EXFORGE HCT (valsartan/amlodipine/HCTZ) tablet	

	<p>HYZAAR (losartan/HCTZ) tablet</p> <p>MICARDIS HCT (telmisartan/HCTZ) tablet</p> <p>Olmesartan/amlodipine/HCTZ tablet</p> <p>Telmisartan/amlodipine tablet</p> <p>Telmisartan/HCTZ tablet</p> <p>TRIBENZOR (olmesartan/amlodipine/HCTZ) tablet</p> <p>Valsartan/Amlodipine/HCTZ tablet</p>	
--	--	--

Renin Inhibitors & Renin Inhibitor Combinations

	PA Required	
	<p>Aliskiren tablet</p> <p>TEKTURNA (aliskiren) tablet</p> <p>TEKTURNA HCT (aliskiren/HCTZ) tablet</p>	<p>Non-preferred renin inhibitors and renin inhibitor combination products may be approved for members who have failed treatment with three preferred products from the angiotensin modifier class (failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction).</p> <p>Renin inhibitors and combinations will not be approved in patients with diabetes. Renin inhibitors are contraindicated when used in combination with an ACE-inhibitor, ACE-inhibitor combination, ARB, or ARB-combination.</p>

Therapeutic Drug Class: **PULMONARY ARTERIAL HYPERTENSION THERAPIES** - *Effective 7/1/2023*

Phosphodiesterase Inhibitors

<p>Preferred *Must meet eligibility criteria</p> <p><i>Brand/generic changes effective 4/27/23</i></p> <p>*REVATIO (sildenafil) oral suspension</p> <p>*Sildenafil tablet, oral suspension</p> <p>*Tadalafil 20mg tablet</p>	<p>Non-Preferred PA Required</p> <p>ADCIRCA (tadalafil) tablet</p> <p>ALYQ (tadalafil) tablet</p> <p>REVATIO (sildenafil) tablet</p>	<p>*Eligibility criteria for preferred products:</p> <p>Preferred sildenafil and tadalafil tablet formulations may be approved for a diagnosis of pulmonary hypertension or right-sided heart failure.</p> <p>REVATIO (sildenafil) suspension may be approved for a diagnosis of pulmonary hypertension for members < 5 years of age or members ≥ 5 years of age who are unable to take/swallow tablets.</p> <p>Non-preferred products may be approved if meeting the following:</p> <ul style="list-style-type: none"> • Member has a diagnosis of pulmonary hypertension AND • Member has trialed and failed treatment with preferred sildenafil tablet AND preferred tadalafil tablet. Failure is defined as lack of efficacy with 4-week trial, allergy, intolerable side effects, or significant drug-drug interaction. <p>Members who have been previously stabilized on a non-preferred product may receive approval to continue on the medication.</p>
--	--	---

Endothelin Receptor Antagonists

<p style="text-align: center;">Preferred *Must meet eligibility criteria</p> <p>*Ambrisentan tablet</p> <p>*Bosentan 62.5mg, 125mg tablet</p>	<p style="text-align: center;">Non-Preferred PA Required</p> <p>LETAIRIS (ambrisentan) tablet</p> <p>OPSUMIT (macitentan) tablet</p> <p>TRACLEER (bosentan) 32mg tablet for suspension</p> <p>TRACLEER (bosentan) 62.5mg, 125mg tablet</p>	<p>*Eligibility Criteria for all agents in the class</p> <p>Approval may be granted for a diagnosis of pulmonary hypertension. Member and prescriber should be enrolled in applicable REMS program for prescribed medication.</p> <p>Non-preferred agents may be approved for members who have trialed and failed two preferred agents. Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction.</p> <p>Members who have been previously stabilized on a non-preferred product may receive approval to continue the medication.</p>
---	---	--

Prostacyclin Analogues and Receptor Agonists

<p style="text-align: center;">Preferred *Must meet eligibility criteria</p> <p>*Epoprostenol vial</p> <p>*FLOLAN (epoprostenol) vial</p> <p>*ORENITRAM (treprostinil ER) tablet</p> <p>*VENTAVIS (iloprost) inhalation solution</p>	<p style="text-align: center;">Non-Preferred PA Required</p> <p>REMODULIN (treprostinil) vial</p> <p>Treprostinil vial</p> <p>TYVASO (treprostinil) inhalation solution</p> <p>UPTRAVI (selexipag) tablet, dose pack, vial</p> <p>VELETRI (epoprostenol) vial</p>	<p>*Eligibility Criteria for all agents in the class</p> <p>Approval will be granted for a diagnosis of pulmonary hypertension.</p> <p>Non-preferred products may be approved for members who have failed treatment with a Preferred Product. (Failure is defined as: lack of efficacy, allergy, intolerable side effects, contraindication to IV therapy or significant drug-drug interaction).</p> <p>Members who have been previously stabilized on a non-preferred product may receive approval to continue on the medication.</p>
--	--	---

Guanylate Cyclase (sGC) Stimulator

<p style="text-align: center;">Non-Preferred PA Required</p> <p>ADEMPAS (riociguat) tablet</p>	<p>ADEMPAS (riociguat) may be approved for members who meet the following criteria:</p> <ul style="list-style-type: none"> • For members of childbearing potential: <ul style="list-style-type: none"> ○ Member is not pregnant and is able to receive monthly pregnancy tests while taking ADEMPAS and one month after stopping therapy AND ○ Member and their partners are utilizing one of the following contraceptive methods during treatment and for one month after stopping treatment (IUD, contraceptive implants, tubal sterilization, a hormone method with a barrier method, two barrier methods, vasectomy with a hormone method, or vasectomy with a barrier method) <p>AND</p> <ul style="list-style-type: none"> • Member has a CrCl \geq 15 mL/min and is not on dialysis AND • Member does not have severe liver impairment (Child Pugh C) AND • Member has a diagnosis of persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) (WHO Group 4) after surgical treatment or has inoperable CTEPH OR
---	---

- Member has a diagnosis of pulmonary hypertension and has failed treatment with a preferred product for pulmonary hypertension. (Failure is defined as a lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction).

Therapeutic Drug Class: LIPOTROPICS - Effective 7/1/2023

Bile Acid Sequestrants

No PA Required	PA Required	
Colesevelam tablet	Colesevelam packet	Non-preferred bile acid sequestrants may be approved if the member has failed treatment with 2 preferred products in the last 12 months (failure is defined as lack of efficacy with 4-week trial, allergy, intolerable side effects or significant drug-drug interactions).
Colestipol tablet	COLESTID (colestipol) tablet, granules	Non-preferred lipotropic agents with a preferred product with same strength, dosage form, and active ingredient may be approved with adequate trial and/or failure of the preferred product with the same ingredient (such as preferred ezetimibe and Zetia) and 2 additional agents. (Failure is defined as: lack of efficacy with 4-week trial, allergy, intolerable side effects or significant drug-drug interactions).
Cholestyramine packet, light packet, powder	Colestipol granules	
	QUESTRAN (cholestyramine/sugar) packet, powder	
	QUESTRAN LIGHT (cholestyramine/aspartame) packet, powder	
	WELCHOL (colesevelam) tablet, packet	

Fibrates

No PA Required	PA Required	
Fenofibrate capsule, tablet (generic Lofibra/Tricor)	ANTARA (fenofibrate) capsule	Non-preferred fibrates may be approved if the member has failed treatment with generic gemfibrozil or generic fenofibrate and niacin ER in the last 12 months (failure is defined as lack of efficacy with 4-week trial of each drug, allergy, intolerable side effects or significant drug-drug interactions).
Gemfibrozil tablet	Fenofibric acid DR capsule	
	Fenofibric acid tablet	Non-preferred lipotropic agents with a preferred product with same strength, dosage form, and active ingredient may be approved with adequate trial and/or failure of the preferred product with the same ingredient (such as preferred ezetimibe and Zetia) and 2 additional agents. (Failure is defined as: lack of efficacy with 4-week trial, allergy, intolerable side effects or significant drug-drug interactions).
	Fenofibrate capsule (generic Antara/Fenoglide/Lipofen)	
	FENOGLIDE (fenofibrate) tablet	
	LIPOFEN (fenofibrate) capsule	
	LOPID (gemfibrozil) tablet	
	TRICOR (fenofibrate nano) tablet	
	TRILIPIX (fenofibric acid) capsule	

Other Lipotropics

No PA Required	PA Required	
<p>Ezetimibe tablet</p> <p>Niacin ER tablet</p> <p>*Omega-3 ethyl esters capsule (generic Lovaza)</p>	<p>Icosapent ethyl capsule</p> <p>LOVAZA (omega-3 ethyl esters) capsule</p> <p>NEXLETOL (bempedoic acid) tablet</p> <p>NEXLIZET (bempedoic acid/ezetimibe) tablet</p> <p>VASCEPA (icosapent ethyl) capsule</p> <p>ZETIA (ezetimibe) tablet</p>	<p>Non-preferred lipotropic agents with a preferred product with same strength, dosage form, and active ingredient may be approved with adequate trial and/or failure of the preferred product with the same ingredient (such as preferred ezetimibe and Zetia) and 2 additional agents. (Failure is defined as: lack of efficacy with 4-week trial, allergy, intolerable side effects or significant drug-drug interactions).</p> <p>*Omega-3 ethyl esters (generic Lovaza) may be approved for members who have a baseline triglyceride level \geq 500 mg/dL</p> <p>Lovaza (brand name) may be approved if meeting the following:</p> <ul style="list-style-type: none"> • Member has a baseline triglyceride level \geq 500 mg/dl AND • Member has failed an adequate trial of omega-3 Ethyl Esters AND an adequate trial of gemfibrozil or fenofibrate (failure is defined as lack of efficacy with 4-week trial, allergy, intolerable side effects or significant drug-drug interactions) <p>Nexletol (bempedoic acid) or Nexlizet (bempedoic acid/ezetimibe) may be approved if meeting the following criteria:</p> <ul style="list-style-type: none"> • Member is \geq 18 years of age AND • Member is not pregnant AND • Member is not receiving concurrent simvastatin > 20 mg daily or pravastatin > 40 mg daily AND • Member has a diagnosis of either heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease (see definition below), AND <div style="border: 1px solid black; padding: 5px; margin: 5px 0;"> <p style="text-align: center; margin: 0;">Conditions Which Define Clinical Atherosclerotic Cardiovascular Disease</p> <ul style="list-style-type: none"> • Acute Coronary Syndrome • History of Myocardial Infarction • Stable or Unstable Angina • Coronary or other Arterial Revascularization • Stroke • Transient Ischemic Attack • Peripheral Arterial Disease of Atherosclerotic Origin </div> <ul style="list-style-type: none"> • Member is concurrently adherent (> 80% of the past 180 days) on a maximally tolerated dose of a high intensity statin therapy (atorvastatin \geq 40 mg daily OR rosuvastatin \geq 20 mg daily [as a single-entity or as a combination product]) AND ezetimibe (as a single-entity or as a combination product) concomitantly for \geq 8 continuous weeks), AND • If intolerant to a statin due to side effects, member must have a one month documented trial with at least two other maximally dosed statins in addition to ezetimibe. For members with a past or current incidence of rhabdomyolysis, a one-month trial and failure of a statin is not required, AND • Member has a treated LDL > 70 mg/dL for a clinical history of ASCVD OR LDL > 100 mg/dL if familial hypercholesterolemia <p><u>Initial Approval:</u> 1 year</p>

		<p>Reauthorization: Reauthorization may be approved for 1 year with provider attestation of medication safety and efficacy during the initial treatment period</p> <p>Vascepa (icosapent ethyl) may be approved if meeting the following:</p> <ul style="list-style-type: none"> • Member has a baseline triglyceride level > 500 mg/dl AND • Member has failed an adequate trial of generic omega-3 ethyl esters AND an adequate trial of gemfibrozil or fenofibrate (failure is defined as lack of efficacy with 4-week trial, allergy, intolerable side effects or significant drug-drug interactions) <p>OR</p> <ul style="list-style-type: none"> • Medication is being prescribed to reduce CV risk for members on maximally tolerated statin therapy with triglyceride levels \geq 150mg/dL and LDL-C levels between 41-100 mg/dL AND member meets <u>one</u> of the following: <ul style="list-style-type: none"> ○ Member is \geq 45 years of age and has established atherosclerotic CV disease (e.g., coronary artery disease, cerebrovascular/carotid disease, peripheral arterial disease) OR ○ Member is \geq 50 years of age with diabetes mellitus and has <u>one or more</u> of the following additional risk factors for CV disease: <ul style="list-style-type: none"> ▪ Male \geq 55 years of age or female \geq 65 years of age ▪ Cigarette smoker ▪ Hypertension ▪ HDL-C \leq 40 mg/dL for men or \leq 50 mg/dL for women ▪ hsCRP >3.00 mg/L (0.3 mg/dL) ▪ CrCl 30 to 59 mL/min ▪ Retinopathy ▪ Micro- or macroalbuminuria ▪ ABI <0.9 without symptoms of intermittent claudication <p>Maximum Dose: 4g daily</p>
Therapeutic Drug Class: STATINS -Effective 7/1/2023		
No PA Required	PA Required	<p>Non-preferred Statins may be approved following trial and failure of treatment with two preferred products (failure is defined as lack of efficacy, allergy, intolerable side effects or significant drug-drug interactions).</p> <p>Age Limitations: Altoprev will not be approved for members < 18 years of age. Fluvastatin will not be approved for members < 10 years of age. Livalo will not be approved for members < 8 years of age.</p>
<p>Atorvastatin tablet</p> <p>Lovastatin tablet</p> <p>Pravastatin tablet</p> <p>Rosuvastatin tablet</p> <p>Simvastatin tablet</p>	<p>ALTOPREV (lovastatin ER) tablet</p> <p>CRESTOR (rosuvastatin) tablet</p> <p>EZALLOR (rosuvastatin) sprinkle capsule</p> <p>Fluvastatin capsule, ER tablet</p> <p>LESCOL XL (fluvastatin ER) tablet</p> <p>LIPITOR (atorvastatin) tablet</p> <p>LIVALO (pitavastatin) tablet</p>	

	ZOCOR (simvastatin) tablet ZYPITAMAG (pitavastatin) tablet		
Therapeutic Drug Class: STATIN COMBINATIONS -Effective 7/1/2023			
	PA Required Atorvastatin/Amlodipine tablet CADUET (atorvastatin/amlodipine) tablet Simvastatin/Ezetimibe tablet VYTORIN (simvastatin/ezetimibe) tablet	Non-preferred Statin combinations may be approved following trial and failure of treatment with two preferred products (failure is defined as lack of efficacy, allergy, intolerable side effects or significant drug-drug interactions). Age Limitations: Vytorin (ezetimibe/simvastatin) will not be approved for members < 18 years of age. Caduet (amlodipine/atorvastatin) will not be approved for members < 10 years of age.	
IV. Central Nervous System			
Therapeutic Drug Class: ANTICONVULSANTS -Oral-Effective 4/1/2023			
No PA Required	PA Required <i>Non-preferred brand name medications do not require a prior authorization when the equivalent generic is preferred and “dispense as written” is indicated on the prescription.</i>	Members currently stabilized (in outpatient or acute care settings) on any non-preferred medication in this class may receive prior authorization approval to continue on that medication. Non-preferred brand name medications do not require a prior authorization when the equivalent generic is preferred and “dispense as written” is indicated on the prescription.	
Barbiturates			
Phenobarbital elixir, solution, tablet Primidone tablet	MYSOLINE (primidone) tablet	<u>Non-Preferred Products Newly Started for Treating Seizure Disorder or Convulsions:</u> Non-preferred medications newly started for members with a diagnosis of seizure disorder/convulsions may be approved if the following criteria are met: <ul style="list-style-type: none"> • The requested medication is being prescribed by a practitioner who has sufficient education and experience to safely manage treatment AND • The request meets minimum age and maximum dose limits listed in Table 1 AND • For medications indicated for use as adjunctive therapy, the medication is being used in conjunction with another medication indicated for treatment of seizure disorder/convulsions AND • The request meets additional criteria listed for any of the following: APTIOM (eslicarbazepine): <ul style="list-style-type: none"> • Member has history of trial and failure‡ of any carbamazepine-containing product BRIVIACT (brivaracetam): <ul style="list-style-type: none"> • Member has history of trial and failure‡ of any levetiracetam-containing product 	
Hydantoins			
DILANTIN (phenytoin) 30 mg capsules DILANTIN (phenytoin) suspension PHENYTEK (phenytoin ER) capsule Phenytoin suspension, chewable, ER capsule	DILANTIN (phenytoin ER) Infatab, 100 mg capsules		
Succinamides			
Ethosuximide capsule, solution	CELONTIN (methsuximide) Kapseal		

	ZARONTIN (ethosuximide) capsule, solution	<p>DIACOMIT (stiripentol):</p> <ul style="list-style-type: none"> Member is concomitantly taking clobazam AND Member has diagnosis of seizures associated with Dravet syndrome <p>ELEPSIA XR (levetiracetam ER) tablet</p> <ul style="list-style-type: none"> Member has history of trial and failure‡ of levetiracetam ER (KEPPRA XR) <p>EPIDIOLEX (cannabidiol):</p> <ul style="list-style-type: none"> Member has diagnosis of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet Syndrome OR Member has a diagnosis of seizures associated with tuberous sclerosis complex (TSC). <p>FINTEPLA (fenfluramine):</p> <ul style="list-style-type: none"> Member has a diagnosis of seizures associated with Dravet syndrome or Lennox-Gastaut syndrome <p>OXTELLAR XR (oxcarbazepine ER):</p> <ul style="list-style-type: none"> Member is being treated for partial-onset seizures AND Member has history of trial and failure‡ of any carbamazepine or oxcarbazepine-containing product <p>SPRITAM (levetiracetam) tablet for suspension</p> <ul style="list-style-type: none"> Member has history of trial and failure‡ of levetiracetam solution <p>SYMPAZAN (clobazam) film:</p> <ul style="list-style-type: none"> Member has history of trial and failure‡ of clobazam tablet or solution OR Provider attests that member cannot take clobazam tablet or solution <p><u>Non-Preferred Products Newly Started for Non-Seizure Disorder Diagnoses:</u> Non-preferred medications newly started for non-seizure disorder diagnoses may be approved if meeting the following criteria:</p> <ul style="list-style-type: none"> Member has history of trial and failure‡ of two preferred agents AND The prescription meets minimum age and maximum dose limits listed in Table 1. <p>‡Failure is defined as lack of efficacy, allergy, intolerable side effects, significant drug-drug interaction, documented contraindication to therapy, or inability to take preferred formulation. Members identified as HLA-B*15:02 positive, carbamazepine and oxcarbazepine should be avoided per Clinical Pharmacogenetics Implementation Consortium Guideline. This may be considered a trial for prior authorization approvals of a non-preferred agent.</p>
Benzodiazepines		
Clobazam tablet, suspension	KLONOPIN (clonazepam) tablet	
Clonazepam tablet, ODT	ONFI (clobazam) suspension, tablet	
	SYMPAZAN (clobazam) SL film	
Valproic Acid and Derivatives		
DEPAKOTE (divalproex DR) sprinkle capsule, tablet	DEPAKOTE ER (divalproex ER) tablet	
Divalproex sprinkle capsule, DR tablet, ER tablet		
Valproic acid capsule, solution		
Carbamazepine Derivatives		
Carbamazepine IR tablet, ER tablet, chewable, ER capsule, suspension	APTIOM (eslicarbazepine) tablet	
CARBATROL ER (carbamazepine) capsule	EQUETRO (carbamazepine) capsule	
Oxcarbazepine tablet, suspension	OXTELLAR XR (oxcarbazepine) tablet	
TEGRETOL (carbamazepine) suspension, tablet	TRILEPTAL (oxcarbazepine) tablet	
TEGRETOL XR (carbamazepine ER) tablet		
TRILEPTAL (oxcarbazepine) suspension		

Lamotrigines		Table 1: Non-preferred Product Minimum Age and Maximum Dose		
LAMICTAL (lamotrigine) chewable/dispersible tablet, tablet	LAMICTAL (lamotrigine) ODT, ODT dose pack		Minimum Age**	Maximum Dose**
LAMICTAL ^{BNR} (lamotrigine) dose pack	LAMICTAL XR (lamotrigine ER) tablet, dose pack			
Lamotrigine IR tablet, ER tablet, chewable/dispersible tablet, ODT	Lamotrigine ER/IR/ODT dose packs			
Topiramates		Barbiturates		
TOPAMAX (topiramate) sprinkle capsule	EPRONTIA (topiramate) solution	primidone (MYSOLINE)		
Topiramate tablet, sprinkle capsule	QUDEXY XR (topiramate) capsule	Benzodiazepines		
	TOPAMAX (topiramate) tablet	clobazam (ONFI) suspension, tablet		
	Topiramate ER capsule	clobazam film (SYMPAZAN)		
	TROKENDI XR (topiramate ER) capsule	clonazepam (KLONOPIN)		
Brivaracetam/Levetiracetam		Brivaracetam/Levetiracetam		
Levetiracetam IR tablet, ER tablet, solution	BRIVIACT (brivaracetam) solution, tablet	brivaracetam (BRIVIACT)		
	ELEPSIA XR (levetiracetam ER) tablet	levetiracetam (KEPPRA)		
	KEPPRA (levetiracetam) tablet, solution	levetiracetam (SPRITAM)		
	KEPRA XR (levetiracetam ER) tablet	levetiracetam ER (ELEPSIA XR)		
	SPRITAM (levetiracetam) tablet	levetiracetam ER (KEPPRA XR)		
Other		Carbamazepine Derivatives		
FELBATOL ^{BNR} (felbamate) tablet, suspension	BANZEL (rufinamide) suspension, tablet	carbamazepine (EPITOL)		
Lacosamide solution, tablet	DIACOMIT (stiripentol) capsule, powder packet	carbamazepine ER (EQUETRO)		
Zonisamide capsule	EPIDIOLEX (cannabidiol) solution	eslicarbazepine (APTIOM)		
	Felbamate tablet, suspension	oxcarbazepine ER (OXTELLAR XR)		
		Hydantoins		
		phenytoin ER (DILANTIN) 100mg capsules, suspension, Infatab		
		phenytoin ER (DILANTIN) 100mg capsules, suspension, Infatab		
		Lamotrigines		
		lamotrigine IR (LAMICTAL)		
		lamotrigine (LAMICTAL ODT)		
		lamotrigine ER (LAMICTAL XR)		
		Succinamides		
		ethosuximide (ZARONTIN)		
		methsuximide (CELONTIN)		
		Valproic Acid and Derivatives		
		divalproex ER (DEPAKOTE ER)		
		Topiramates		
		topiramate (TOPAMAX)		
		topiramate ER (QUDEXY XR)		
		topiramate ER (TROKENDI XR)		
		Other		
		cannabidiol (EPIDIOLEX)		
		cenobamate (XCOPRI)		
		felbamate tablet, suspension		
		fenfluramine (FINTEPLA)		
		lacosamide (VIMPAT)		

FINTEPLA (fenfluramine) solution FYCOMPA (perampanel) suspension, tablet GABITRIL (tiagabine) tablet Lacosamide UD solution Rufinamide suspension, tablet SABRIL (vigabatrin) powder packet, tablet Tiagabine tablet Vigabatrin tablet, powder packet VIMPAT (lacosamide) solution, kit, tablet XCOPRI (cenobamate) tablet, pack ZONISADE (zonisamide) suspension ZTALMY (ganaxolone) suspension	perampanel (FYCOMPA)	4 years	12 mg per day
	rufinamide (BANZEL) tablet and suspension	1 year	3,200 mg per day
	stiripentol (DIACOMIT)	6 months (weighing ≥ 7 kg)	3,000 mg per day
	tiagabine	12 years	56 mg per day
	tiagabine (GABITRIL)	12 years	56 mg per day
	vigabatrin	1 month	3,000 mg per day
	vigabatrin (SABRIL)	1 month	3,000 mg per day
	vigabatrin (VIGADRONE) powder packet	1 month	3,000 mg per day
	zonisamide (ZONEGRAN)	16 years	600 mg per day
	**Limits based on data from FDA package insert. Approval for age/dosing that falls outside of the indicated range may be evaluated on a case-by-case basis.		

Therapeutic Drug Class: NEWER GENERATION ANTI-DEPRESSANTS -Effective 4/1/2023

No PA Required	PA Required	
Bupropion IR, SR, XL tablet	<p align="center"><i>Non-preferred brand name medications do not require a prior authorization when the equivalent generic is preferred and "dispense as written" is indicated on the prescription.</i></p> APLENZIN (bupropion ER) tablet AUVELITY ER (dextromethorphan/bupropion) tablet Bupropion XL (generic Forfivo XL) tablet CELEXA (citalopram) tablet Citalopram hydrobromide capsule CYMBALTA (duloxetine) capsule Desvenlafaxine fumarate ER tablet	<p>Non-preferred products may be approved for members who have failed adequate trial with two preferred newer generation anti-depressant products. If two preferred newer generation anti-depressant products are not available for indication being treated, approval of prior authorization for non-preferred products will require adequate trial of all preferred products FDA approved for that indication (failure is defined as lack of efficacy with 6-week trial, allergy, intolerable side effects, or significant drug-drug interaction).</p> <p>Citalopram doses higher than 40mg/day for ≤60 years of age and 20mg/day for >60 years of age will require prior authorization. Please see the FDA guidance at: https://www.fda.gov/drugs/drugsafety/ucm297391.htm for important safety information.</p> <p>Members currently stabilized on a non-preferred newer generation antidepressant may receive approval to continue on that agent for one year if medically necessary. Verification may be provided from the prescriber or the pharmacy.</p>
Citalopram tablet, solution		
Desvenlafaxine succinate ER (generic Pristiq) tablet		
Duloxetine (generic Cymbalta) capsule		
Escitalopram tablet		
Fluoxetine capsule, solution		
Fluvoxamine tablet		
Mirtazapine tablet, ODT		
Paroxetine IR tablet		

Sertraline tablet, solution	DRIZALMA (duloxetine) sprinkle capsule	
Trazodone tablet	EFFEXOR XR (venlafaxine ER) capsule	
Venlafaxine IR tablet	Escitalopram solution	
Venlafaxine ER capsules	FETZIMA (levomilnacipran ER) capsule, titration pack	
	Fluoxetine IR tablet, 60 mg capsule, DR capsule	
	Fluvoxamine ER capsule	
	FORFIVO XL (bupropion ER) tablet	
	LEXAPRO (escitalopram) tablet	
	Nefazodone tablet	
	Paroxetine CR/ER tablet, suspension	
	PAXIL (paroxetine) tablet, suspension	
	PAXIL CR (paroxetine ER) tablet	
	PEXEVA (paroxetine mesylate) tablet	
	PRISTIQ (desvenlafaxine succinate ER) tablet	
	PROZAC (fluoxetine) Pulvule	
	REMERON (mirtazapine) tablet, Soltab (ODT)	
	Sertraline capsule	
	TRINTELLIX (vortioxetine) tablet	
	Venlafaxine ER tablet	
	Venlafaxine besylate ER tablet	
	VIIBRYD (vilazodone) tablet, dose pack	

	<p>Vilazodone tablet</p> <p>WELLBUTRIN SR, XL (bupropion) tablet</p> <p>ZOLOFT (sertraline) tablet, oral concentrate</p>	
Therapeutic Drug Class: MONOAMINE OXIDASE INHIBITORS (MAOIs) -Effective 4/1/2023		
	<p style="text-align: center;">PA Required</p> <p>EMSAM (selegiline) patch</p> <p>MARPLAN (isocarboxazid) tablet</p> <p>NARDIL (phenelzine) tablet</p> <p>PARNATE (tranylcypromine) tablet</p> <p>Phenelzine tablet</p> <p>Tranylcypromine tablet</p>	<p>Non-preferred products may be approved for members who have failed adequate trial (8 weeks) with three preferred anti-depressant products. If three preferred anti-depressant products are not available for indication being treated, approval of prior authorization for non-preferred products will require adequate trial of all preferred anti-depressant products FDA approved for that indication. (Failure is defined as: lack of efficacy after 8-week trial, allergy, intolerable side effects, or significant drug-drug interaction)</p> <p>Members currently stabilized on a Non-preferred MAOI antidepressant may receive approval to continue that agent for one year if medically necessary. Verification may be provided from the prescriber or the pharmacy.</p>
Therapeutic Drug Class: TRICYCLIC ANTI-DEPRESSANTS (TCAs) -Effective 4/1/2023		
<p style="text-align: center;">No PA Required</p> <p>Amitriptyline tablet</p> <p>Clomipramine capsule</p> <p>Desipramine tablet</p> <p>Doxepin 10mg, 25mg, 50mg, 75mg, 100mg, 150mg capsule</p> <p>Doxepin oral concentrate</p> <p>Imipramine HCl tablet</p> <p>Nortriptyline capsule</p>	<p style="text-align: center;">PA Required</p> <p><i>Non-preferred brand name medications do not require a prior authorization when the equivalent generic is preferred and “dispense as written” is indicated on the prescription.</i></p> <p>Amoxapine tablet</p> <p>ANAFRANIL (clomipramine) capsule</p> <p>Imipramine pamoate capsule</p> <p>Maprotiline tablet</p> <p>NORPRAMIN (desipramine) tablet</p> <p>Nortriptyline solution</p> <p>PAMELOR (nortriptyline) capsule</p> <p>Protriptyline tablet</p> <p>Trimipramine capsule</p>	<p>Non-preferred products may be approved for members who have failed adequate trial (8 weeks) with three preferred tricyclic products. If three preferred products are not available for indication being treated, approval of prior authorization for non-preferred products will require adequate trial of all tricyclic preferred products FDA approved for that indication. (Failure is defined as: lack of efficacy after 8-week trial, allergy, intolerable side effects, or significant drug-drug interaction)</p> <p>Members currently stabilized on a non-preferred tricyclic antidepressant may receive approval to continue on that agent for one year if medically necessary. Verification may be provided from the prescriber or the pharmacy.</p>

Therapeutic Drug Class: ANTI-PARKINSON'S AGENTS -Effective 4/1/2023

Dopa decarboxylase inhibitors, dopamine precursors and combinations

No PA Required	PA Required	
Carbidopa/Levodopa IR, ER tablet	Carbidopa tablet	<p>Non-preferred agents may be approved with adequate trial and failure of carbidopa-levodopa IR and ER formulations (failure is defined as lack of efficacy with a 4-week trial, allergy, intolerable side effects or significant drug-drug interactions).</p> <p>Carbidopa or levodopa single agent products may be approved for members with diagnosis of Parkinson's Disease as add-on therapy to carbidopa-levodopa.</p> <p>Non-preferred medications that <u>are not</u> prescribed for Parkinson's Disease (or an indication related to Parkinson's Disease) may receive approval for other FDA-labeled indications without meeting trial and failure step therapy criteria.</p> <p>Members with history of trial and failure of a non-preferred Parkinson's Disease agent that is the brand/generic equivalent of a preferred product (same strength, dosage form and active ingredient) may be considered as having met a trial and failure of the equivalent preferred.</p> <p>Members currently stabilized on a non-preferred product may receive approval to continue therapy with that product.</p>
Carbidopa/Levodopa/Entacapone tablet	Carbidopa/Levodopa ODT	
	DHIVY (carbidopa/levodopa) tablet	
	DUOPA (carbidopa/levodopa) suspension	
	INBRIJA (levodopa) capsule for inhalation	
	LODOSYN (carbidopa) tablet	
	RYTARY ER (carbidopa/levodopa) capsule	
	SINEMET (carbidopa/levodopa) IR tablet	
	STALEVO (carbidopa/levodopa/entacapone) tablet	

MAO-B inhibitors

No PA Required	PA Required	
Rasagiline tablet	AZILECT (rasagiline) tablet	<p>Non-preferred agents may be approved with adequate trial and failure of selegiline capsule or tablet (failure is defined as lack of efficacy with a 4-week trial, allergy, intolerable side effects or significant drug-drug interactions).</p> <p>Non-preferred medications that are not prescribed for Parkinson's Disease (or an indication related to Parkinson's Disease) may receive approval for other FDA-labeled indications without meeting trial and failure step therapy criteria.</p> <p>Members with history of trial and failure of a non-preferred Parkinson's Disease agent that is the brand/generic equivalent of a preferred product (same strength, dosage form and active ingredient) may be considered as having met a trial and failure of the equivalent preferred.</p> <p>Members currently stabilized on a non-preferred product may receive approval to continue therapy with that product.</p>
Selegiline capsule	XADAGO (safinamide) tablet	
Selegiline tablet	ZELAPAR (selegiline) ODT	

Dopamine Agonists

No PA Required	PA Required	
Pramipexole IR tablet	APOKYN (apomorphine) SC cartridge	<p>Non-preferred agents may be approved with adequate trial and failure of ropinirole IR AND pramipexole IR (failure is defined as lack of efficacy with 4-week trial, documented contraindication to therapy, allergy, intolerable side effects or significant drug-drug interactions).</p>
Ropinirole IR tablet	Apomorphine SC cartridge	

	<p>Bromocriptine capsule, tablet</p> <p>KYNMOBI (apomorphine) SL film</p> <p>MIRAPEX (pramipexole) ER tablet</p> <p>NEUPRO (rotigotine) patch</p> <p>PARLODEL (bromocriptine) capsule, tablet</p> <p>Pramipexole ER tablet</p> <p>Ropinirole ER tablet</p>	<p>APOKYN (apomorphine subcutaneous cartridge) may be approved if meeting the following:</p> <ul style="list-style-type: none"> • APOKYN (apomorphine) is being used as an adjunct to other medications for acute, intermittent treatment of hypomobility, “off” episodes ("end-of-dose wearing off" and unpredictable "on/off" episodes) in patients with advanced Parkinson’s disease AND • Due to the risk of profound hypotension and loss of consciousness, member is not concomitantly using a 5HT3 antagonist such as ondansetron, granisetron, dolasetron, palonosetron or alosetron. <p>Maximum dose: 6mg (0.6mL) three times per day</p> <p>KYNMOBI (apomorphine sublingual film) may be approved if meeting the following:</p> <ul style="list-style-type: none"> • KYNMOBI (apomorphine) is being used for the acute, intermittent treatment of “off” episodes in patients with Parkinson's disease AND • Due to the risk of profound hypotension and loss of consciousness, member must not be concomitantly using a 5HT3 antagonist such as ondansetron, granisetron, dolasetron, palonosetron or alosetron. <p>Maximum dose: 30mg five times per day</p> <p>Non-preferred medications that <u>are not</u> prescribed for Parkinson’s Disease (or an indication related to Parkinson’s Disease) may receive approval for other FDA-labeled indications without meeting trial and failure step therapy criteria.</p> <p>Members with history of trial and failure of a non-preferred Parkinson’s Disease agent that is the brand/generic equivalent of a preferred product (same strength, dosage form and active ingredient) may be considered as having met a trial and failure of the equivalent preferred.</p> <p>Members currently stabilized on a non-preferred product may receive approval to continue therapy with that product.</p>
Other Parkinson’s agents		
<p style="text-align: center;">No PA Required</p> <p>Amantadine capsule, solution/syrup</p> <p>Benztropine tablet</p> <p>Trihexyphenidyl tablet, elixir</p>	<p style="text-align: center;">PA Required</p> <p>Amantadine tablet</p> <p>COMTAN (entacapone) tablet</p> <p>Entacapone tablet</p> <p>GOCOVRI ER (amantadine ER) capsule</p> <p>NOURIANZ (istradefylline) tablet</p> <p>ONGENTYS (opicapone) capsule</p>	<p>Non-preferred agents may be approved with adequate trial and failure of two preferred agents (failure is defined as lack of efficacy with 4-week trial, documented contraindication to therapy, allergy, intolerable side effects or significant drug-drug interactions).</p> <p>Non-preferred medications that <u>are not</u> prescribed for Parkinson’s Disease (or an indication related to Parkinson’s Disease) may receive approval for other FDA-labeled indications without meeting trial and failure step therapy criteria.</p> <p>Members with history of trial and failure of a non-preferred Parkinson’s Disease agent that is the brand/generic equivalent of a preferred product (same strength, dosage form</p>

	OSMOLEX ER (amantadine) tablet TASMAR (tolcapone) tablet Tolcapone tablet	and active ingredient) may be considered as having met a trial and failure of the equivalent preferred. Members currently stabilized on a non-preferred product may receive approval to continue therapy with that product.
--	---	--

Therapeutic Drug Class: BENZODIAZEPINES (NON-SEDATIVE HYPNOTIC) Effective 4/1/2023

No PA Required (*may be subject to age limitations)	PA Required															
Alprazolam IR, ER tablet*	Alprazolam ODT, oral concentrate	<p>Non-preferred products may be approved following trial and failure of three preferred agents. Failure is defined as lack of efficacy, contraindication to therapy, allergy, intolerable side effects, or significant drug-drug interactions.</p> <p><u>Children:</u> Prior authorization will be required for all agents when prescribed for children <18 years of age (with the exception of oral solution products) and may be approved with prescriber verification of necessity of use for member age.</p> <p>Diazepam Intensol may be approved following trial and failure of the preferred 5 mg/5 mL oral solution. Failure is defined as intolerable side effects, drug-drug interaction, or lack of efficacy.</p> <p>All benzodiazepine anxiolytics will require prior authorization for members ≥ 65 years of age when exceeding 90 days of therapy.</p> <p>Continuation of Therapy:</p> <ul style="list-style-type: none"> Members < 65 years of age who are currently stabilized on a non-preferred benzodiazepine medication may receive approval to continue that medication. Members < 18 years of age who are currently stabilized on a non-preferred oral solution product may receive authorization to continue that medication. <p>Prior authorization will be required for prescribed doses that exceed the maximum (Table 1).</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th colspan="3" style="text-align: left;">Table 1 Maximum Doses</th> </tr> <tr> <th style="width: 33%;">Product</th> <th style="width: 33%;">Maximum Daily Dose</th> <th style="width: 34%;">Maximum Monthly Dose</th> </tr> </thead> <tbody> <tr> <td>Alprazolam tablet</td> <td rowspan="6" style="text-align: center; vertical-align: middle;"> <u>Adults ≥ 18 years:</u> 10 mg/day </td> <td rowspan="6" style="text-align: center; vertical-align: middle;"> Total of 300 mg from all dosage forms per 30 days </td> </tr> <tr> <td>Alprazolam ER tablet</td> </tr> <tr> <td>Alprazolam ODT</td> </tr> <tr> <td>XANAX (alprazolam) tablet</td> </tr> <tr> <td>XANAX XR (alprazolam ER) tablet</td> </tr> <tr> <td>Alprazolam Intensol oral concentrate 1 mg/mL</td> </tr> </tbody> </table>	Table 1 Maximum Doses			Product	Maximum Daily Dose	Maximum Monthly Dose	Alprazolam tablet	<u>Adults ≥ 18 years:</u> 10 mg/day	Total of 300 mg from all dosage forms per 30 days	Alprazolam ER tablet	Alprazolam ODT	XANAX (alprazolam) tablet	XANAX XR (alprazolam ER) tablet	Alprazolam Intensol oral concentrate 1 mg/mL
Table 1 Maximum Doses																
Product	Maximum Daily Dose		Maximum Monthly Dose													
Alprazolam tablet	<u>Adults ≥ 18 years:</u> 10 mg/day		Total of 300 mg from all dosage forms per 30 days													
Alprazolam ER tablet																
Alprazolam ODT																
XANAX (alprazolam) tablet																
XANAX XR (alprazolam ER) tablet																
Alprazolam Intensol oral concentrate 1 mg/mL																
Chlordiazepoxide capsule*	ATIVAN (lorazepam) tablet															
Clonazepam tablet, ODT	Diazepam Intensol															
Clorazepate tablet*	KLONOPIN (clonazepam) tablet															
Diazepam tablet*, solution	LOREEV (lorazepam ER) capsule															
Lorazepam tablet*, oral concentrate	XANAX (alprazolam) tablet															
Oxazepam capsule*	XANAX XR (alprazolam ER) tablet															

		Clorazepate tablet	<u>>12 years:</u> 90 mg/day <u>Children 9-12 years:</u> up to 60 mg/day	Total of 2,700 mg (adults) and 1,800 mg (children) from all tablet strengths per 30 days
		TRANXENE (clorazepate) T-Tab		
		Chlordiazepoxide capsule	<u>Adults ≥ 18 years:</u> 300 mg/day <u>Children 6-17 years:</u> up to 40 mg/day (pre-operative apprehension and anxiety)	Total of 9,000 mg (adults) and 120 mg (children, pre-op therapy) from all tablet strengths per 30 days
		Diazepam Intensol oral concentrate 5 mg/mL	<u>Adults ≥ 18 years:</u> 40 mg/day <u>Members age 6 months to 17 years:</u> up to 10 mg/day	Total of 1200 mg (adults) and 300 mg (pediatrics) from all dosage forms per 30 days
		Diazepam solution 5 mg/5 mL		
		Diazepam tablet		
		ATIVAN (lorazepam) Intensol concentrate 2 mg/mL	<u>Adults ≥ 18 years:</u> 10 mg/day <u>Children:</u> N/A	Total of 300 mg from all dosage forms per 30 days
		ATIVAN (lorazepam) tablet		
		Lorazepam oral concentrated soln 2 mg/mL		
		Lorazepam tablet		
Oxazepam capsule	<u>Adults ≥ 18 years:</u> 120 mg/day <u>Children 6-18 years:</u> absolute dosage not established	Total of 3600 mg from all dosage forms per 30 days		

Therapeutic Drug Class: ANXIOLYTIC, NON- BENZODIAZEPINES - Effective 4/1/2023

No PA Required		
Buspirone tablet		Non-preferred products may be approved following trial and failure of buspirone. Failure is defined as lack of efficacy, contraindication to therapy, allergy, intolerable side effects, or significant drug-drug interactions.

Therapeutic Drug Class: **ATYPICAL ANTI-PSYCHOTICS - Oral and Topical- Effective 4/1/2023**

The following injectable products are not self-administered and are dispensed according to FDA label without being subject to PDL criteria: **Aristada (aripiprazole lauroxil) IM, Aristada Initio (aripiprazole lauroxil) IM, Abilify Maintena (aripiprazole) IM, Invega Sustenna (paliperidone palmitate) IM, Invega Trinza (paliperidone palmitate) IM, Invega Hafyera (paliperidone palmitate) IM, Zyprexa Relprevv (olanzapine pamoate) IM, Risperdal Consta (risperidone) IM, Perseris (risperidone) SC, Geodon (ziprasidone) IM. See appendix P for more information.**

No PA Required*	PA Required		
Aripiprazole tablet	<p><i>Non-preferred brand name medications do not require a prior authorization when the equivalent generic is preferred and “dispense as written” is indicated on the prescription.</i></p>	<p>Non-preferred products may be approved for members meeting all of the following:</p> <ul style="list-style-type: none"> • Medication is being prescribed for an FDA-Approved indication AND • Prescription meets dose and age limitations (Table 1) AND • Member has history of trial and failure of two preferred products with FDA approval for use for the prescribed indication (failure defined as lack of efficacy with 6-week trial, allergy, intolerable side effects, significant drug-drug interactions, or known interacting genetic polymorphism that prevents safe preferred product dosing) <p>*Age Limits: All products including preferred products will require a PA for members younger than the FDA approved age for the agent (Table 1). Members younger than the FDA approved age for the agent who are currently stabilized on an atypical antipsychotic will be eligible for approval.</p> <p>Atypical Antipsychotic prescriptions for members under 5 years of age may require a provider-provider telephone consult with a child and adolescent psychiatrist (provided at no cost to provider or member).</p> <p>***Quetiapine IR when given at subtherapeutic doses may be restricted for therapy. Low-dose quetiapine (<150mg/day) is only FDA approved as part of a drug titration schedule to aid patients in getting to the target quetiapine dose. PA will be required for quetiapine < 150mg per day except for utilization (when appropriate) in members 65 years or older. PA will be approved for members 10-17 years of age with approved diagnosis (Table 1) stabilized on <150mg quetiapine IR per day.</p> <p>****Aripiprazole solution: Aripiprazole <u>tablet</u> quantity limit is 2 tablets/day for pediatric members to allow for incremental dose titration and use of the preferred tablet formulation should be considered for dose titrations when possible and clinically appropriate. If incremental dose cannot be achieved with titration of the aripiprazole tablet for members < 18 years of age OR for members unable to swallow solid tablet dosage form, aripiprazole solution may be approved. For all other cases, aripiprazole solution is subject to meeting non-preferred product approval criteria listed above.</p> <p>Nuplazid (pimavanserin tartrate) may be approved for the treatment of hallucinations and delusions associated with Parkinson’s Disease psychosis AND following trial and failure of therapy with quetiapine or clozapine (failure will be defined as intolerable side effects, drug-drug interaction, or lack of efficacy).</p> <p>Abilify MyCite may be approved if meeting all of the following:</p> <ul style="list-style-type: none"> • Member has history of adequate trial and failure of 5 preferred agents (one trial must include aripiprazole tablet). Failure is defined as lack of efficacy with 6-week trial on maximally tolerated dose, allergy, intolerable side effects, significant drug-drug interactions AND 	
Clozapine tablet			
Lurasidone tablet			
Olanzapine tablet, ODT			ABILIFY (aripiprazole) tablet, MyCite
Paliperidone ER tablet			Aripiprazole oral solution****, ODT
Quetiapine IR tablet***			Asenapine SL tablet
Quetiapine ER tablet			CAPLYTA (lumateperone) capsule
Risperidone tablet, ODT, oral solution			Clozapine ODT
SAPHRIS ^{B^{NR}} (asenapine) SL tablet			CLOZARIL (clozapine) tablet, ODT
Ziprasidone capsule			FANAPT (iloperidone) tablet, pack
	GEODON (ziprasidone) capsule		
	INVEGA ER (paliperidone) tablet		
	LATUDA (lurasidone) tablet		
	LYBALVI (olanzapine/samidorphan) tablet		
	NUPLAZID (pimavanserin) capsule, tablet		
	Olanzapine/Fluoxetine capsule		
	REXULTI (brexpiprazole) tablet		
	RISPERDAL (risperidone) tablet, oral solution		
	SECUADO (asenapine) patch		
	SEROQUEL IR (quetiapine IR)*** tablet		

	<p>SEROQUEL XR (quetiapine ER)*** tablet</p> <p>SYMBYAX (olanzapine/fluoxetine) capsule</p> <p>VERSACLOZ (clozapine) suspension</p> <p>VRAYLAR (cariprazine) capsule</p> <p>ZYPREXA (olanzapine) tablet</p> <p>ZYPREXA ZYDIS (olanzapine) ODT</p>	<ul style="list-style-type: none"> • Information is provided regarding adherence measures being recommended by provider and followed by member (such as medication organizer or digital medication reminders) AND • Member has history of adequate trial and failure of 3 long-acting injectable formulations of atypical antipsychotics, one of which must contain aripiprazole (failure is defined as lack of efficacy with 8-week trial, allergy, intolerable side effects, significant drug-drug interactions) AND • Abilify MyCite is being used with a MyCite patch and member is using a compatible mobile application. AND • Medication adherence information is being shared with their provider via a web portal or dashboard. <p><u>Quantity Limits:</u> Quantity limits will be applied to all products (Table 1). In order to receive approval for off-label dosing, the member must have an FDA approved indication and must have tried and failed on the FDA approved dosing regimen.</p> <p>Members currently stabilized on a non-preferred atypical antipsychotic may receive approval to continue therapy with that agent for one year.</p>
--	---	---

Table 1 Atypical Antipsychotics – FDA Approved Indication, Age Range, Quantity and Maximum Dose					
Brand	Generic	Approved Indications	Age Range	Maximum Daily Dose by Age/Indication	Quantity and Maximum Dose Limitations
ABILIFY	aripiprazole	Schizophrenia Bipolar I Disorder Bipolar I Disorder Irritability w/autistic disorder Tourette’s disorder Adjunctive treatment of MDD	≥ 13 years ≥ 18 years 10-17 years 6-17 years 6-18 years ≥ 18 years	30 mg 30 mg 30 mg 15 mg 20 mg (weight-based) 15 mg	Maximum one tablet per day (maximum of two tablets per day allowable for members < 18 years of age to accommodate for incremental dose changes)
CLOZARIL	clozapine	Treatment-resistant schizophrenia Recurrent suicidal behavior in schizophrenia or schizoaffective disorder	≥ 18 years	900 mg	Maximum dosage of 900mg per day
CAPLYTA	lumateperone	Schizophrenia Bipolar I Disorder Bipolar II Disorder	≥ 18 years	42 mg	Maximum dosage of 42mg per day
	clozapine	Treatment-resistant schizophrenia Recurrent suicidal behavior in schizophrenia or schizoaffective disorder	≥ 18 years	900 mg	Maximum dosage of 900mg per day
FANAPT	iloperidone	Schizophrenia	≥ 18 years	24 mg	Maximum two tablets per day
GEODON	ziprasidone	Schizophrenia Bipolar I Disorder	≥ 18 years ≥ 18 years	200 mg 160 mg	Maximum two capsules per day

INVEGA	paliperidone	Schizophrenia & schizoaffective disorder	≥ 12 years and weight ≥ 51 kg ≥ 12 years and weight < 51 kg	12 mg 6 mg	Maximum one capsule per day
LATUDA	lurasidone	Schizophrenia Schizophrenia Bipolar I disorder Bipolar I disorder	≥ 18 years 13-17 years ≥ 18 years 10-17 years	160 mg 80 mg 120 mg 80 mg	Maximum one tablet per day (If dosing 160mg for schizophrenia, then max of two tablets per day)
NUPLAZID	pimavanserin	Parkinson's disease psychosis	≥ 18 years	34 mg	Maximum dosage of 34mg per day
RISPERDAL	risperidone	Schizophrenia Schizophrenia Bipolar mania Irritability w/autistic disorder	≥ 18 years 13-17 years ≥ 10 years 5-17 years	16 mg 6 mg 6 mg 3 mg	Maximum dosage of 16mg/day (4 tablet/day limitation applied in claims system to allow for dose escalation and tapering)
REXULTI	brexpiprazole	Schizophrenia Adjunctive treatment of MDD	≥ 13 years ≥ 18 years	4 mg 3 mg	Maximum of 3mg/day for MDD adjunctive therapy, Maximum of 4mg/day for schizophrenia
SAPHRIS	asenapine	Schizophrenia Bipolar mania or mixed episodes	≥ 18 years ≥ 10 years	20 mg 20 mg	Maximum two tablets per day
SECUADO	asenapine patch	Schizophrenia	≥ 18 years	7.6 mg/ 24 hours	Maximum 1 patch per day
SEROQUEL	quetiapine	Schizophrenia Schizophrenia Bipolar I mania or mixed Bipolar I mania or mixed Bipolar I depression Bipolar I Disorder Maintenance	≥ 18 years 13-17 years ≥ 18 years 10-17 years ≥ 18 years ≥ 18 years	750 mg 800 mg 800 mg 600 mg 300 mg 800 mg	Maximum three tablets per day
SEROQUEL XR	quetiapine ER	Schizophrenia Bipolar I mania Bipolar I mania Bipolar I depression Adjunctive treatment of MDD	≥ 13 years ≥ 18 years 10-17 years ≥ 18 years ≥ 18 years	800 mg 800 mg 600 mg 300 mg 300 mg	Maximum one tablet per day (for 300mg & 400mg tablets max 2 tablets per day)
SYMBYAX	olanzapine/ fluoxetine	Acute depression in Bipolar I Disorder Treatment resistant depression (MDD)	≥ 10 years	12 mg olanzapine/ 50 mg fluoxetine	Maximum three capsules per day (18mg olanzapine/75mg fluoxetine)
VRAYLAR	cariprazine	Schizophrenia Acute manic or mixed episodes with Bipolar I disorder Depressive episodes with Bipolar I disorder Adjunctive treatment of MDD	≥ 18 years ≥ 18 years ≥ 18 years ≥ 18 years	6 mg 6 mg 3 mg 3 mg	Maximum dosage of 6mg/day
ZYPREXA ZYPREXA ZYDIS	olanzapine	Schizophrenia Acute manic or mixed episodes with Bipolar I disorder	≥ 13 years	20 mg	Maximum one tablet per day

Therapeutic Drug Class: CALCITONIN GENE – RELATED PEPTIDE INHIBITORS (CGRPs) -Effective 4/1/2023

PA Required for all agents

Preferred	Non-Preferred
* AIMOVIG (erenumab-aooe) auto-injector	EMGALITY (galcanezumab-gnlm) 100 mg syringe
* AJOVY (fremanezumab-vfrm) auto-injector, syringe	QULIPTA (atogepant) tablet
* EMGALITY (galcanezumab-gnlm) pen, 120 mg syringe	UBRELVY (ubrogepant) tablet
* NURTEC (rimegepant) ODT	

*Preferred agents may be approved if meeting the following criteria:

Preferred Medications for Migraine Prevention (must meet all of the following):

- The requested medication is being used as preventive therapy for episodic or chronic migraine AND
- Member has diagnosis of migraine with or without aura AND
- Member has tried and failed 2 oral preventive pharmacological agents listed as Level A per the most current American Headache Society/American Academy of Neurology guidelines (such as divalproex, topiramate, metoprolol, propranolol). Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction OR
- If the prescribed medication is Nurtec, the member has tried and failed two preferred injectable product formulations. Failure is defined as lack of efficacy, contraindication to therapy, allergy, intolerable side effects, or significant drug-drug interaction.

Preferred Medications for Acute Migraine Treatment (must meet all of the following):

- The requested medication is being used as acute treatment for migraine headache AND
- Member has history of trial and failure of two triptans (failure is defined as lack of efficacy with 4-week trial, contraindication to therapy, allergy, intolerable side effects, or significant drug-drug interaction).

Non-Preferred Medications for Migraine Prevention (must meet all of the following):

- The requested medication is being used as preventive therapy for episodic or chronic migraine AND
- Member has diagnosis of migraine with or without aura AND
- Member has tried and failed two oral preventive pharmacological agents listed as Level A per the most current American Headache Society/American Academy of Neurology guidelines (such as divalproex, topiramate, metoprolol, propranolol). Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction AND
- The requested medication is not being used in combination with another CGRP medication AND
- The member has history of adequate trial and failure of all preferred products indicated for preventive therapy (failure is defined as lack of efficacy with 4-week trial, contraindication to therapy, allergy, intolerable side effects, or significant drug-drug interaction).

Non-Preferred Medications for Acute Migraine Treatment (must meet all of the following):

- Member is 18 years of age or older AND
- Medication is being prescribed to treat migraine headache with moderate to severe pain AND
- The requested medication is not being used in combination with another CGRP medication AND
- Member has history of trial and failure with all of the following (failure is defined as lack of efficacy with 4-week trial, allergy, contraindication, intolerable side effects, or significant

drug-drug interaction):

- Two triptans AND
- One NSAID agent AND
- One preferred agent indicated for acute migraine treatment

Non-Preferred Medications for Treatment of Episodic Cluster Headache (must meet all of the following):

- Member is 19-65 years of age AND
- Member meets diagnostic criteria for episodic cluster headache (has had no more than 8 attacks per day, a minimum of one attack every other day, and at least 4 attacks during the week prior to this medication being prescribed) AND
- Member is not taking other preventive medications to reduce the frequency of cluster headache attacks AND
- Member has history of trial and failure of all of the following (failure is defined as lack of efficacy with 4-week trial, contraindication to therapy, allergy, intolerable side effects, or significant drug-drug interaction):
 - Oxygen therapy AND
 - Sumatriptan subcutaneous or intranasal AND
 - Zolmitriptan intranasal AND
- Initial authorization will be limited to 8 weeks. Continuation (12-month authorization) will require documentation of clinically relevant improvement with no less than 30% reduction in headache frequency in a 4-week period.

Age Limitations:

Emgality 100mg: 19-65 years
All other products: ≥ 18 years

Maximum Dosing:

Aimovig (erenumab): 140mg per 30 days

Emgality 120mg (galcanezumab): 240mg once as first loading dose then 120mg monthly

Emgality 100mg (galcanezumab): 300mg per 30 days

Ajovy (fremanezumab): 225mg monthly or 675mg every three months

Nurtec (rimegepant): Prevention: 16 tablets/30 days; Acute Treatment: 8 tablets/30 days

Qulipta (atogepant): 30 tablets/30 days

Ubrelvy 50 mg (ubrogepant): 16 tablets/30 days (800 mg per 30 days)

Ubrelvy 100 mg (ubrogepant): 16 tablets/30 days (1,600 mg per 30 days)

Members with current prior authorization approval on file for a preferred agent may receive approval for continuation of therapy with the preferred agent.

Therapeutic Drug Class: LITHIUM AGENTS -Effective 4/1/2023		
<p align="center">No PA Required</p> <p>Lithium carbonate capsule, tablet</p> <p>Lithium ER tablet</p>	<p align="center">PA Required</p> <p align="center"><i>Non-preferred brand name medications do not require a prior authorization when the equivalent generic is preferred and “dispense as written” is indicated on the prescription.</i></p> <p>LITHOBID ER (lithium ER) tablet</p>	<p>Non-preferred products may be approved with trial and failure of one preferred agent (failure is defined as lack of efficacy with 6-week trial, allergy, intolerable side effects, significant drug-drug interactions, intolerance to dosage form).</p> <p>Members currently stabilized on a non-preferred product may receive approval to continue therapy with that product.</p>
Therapeutic Drug Class: NEUROCOGNITIVE DISORDER AGENTS -Effective 4/1/2023		
<p align="center">Preferred</p> <p align="center">*Must meet eligibility criteria</p> <p>*Donepezil 5mg, 10mg tablet</p> <p>*Donepezil ODT</p> <p>*Galantamine IR tablet</p> <p>*Memantine IR tablet, dose pack</p> <p>* Memantine ER capsule</p> <p>*Rivastigmine capsule, patch</p>	<p align="center">Non-Preferred</p> <p align="center">PA Required</p> <p>ADLARITY (donepezil) patch</p> <p>ARICEPT (donepezil) tablet</p> <p>Donepezil 23mg tablet</p> <p>EXELON (rivastigmine) patch</p> <p>Galantamine solution, ER capsule</p> <p>Memantine IR solution</p> <p>MESTINON (pyridostigmine) IR/ER tablet, syrup</p> <p>NAMENDA (memantine) tablet, dose pack</p> <p>NAMENDA XR (memantine ER) capsule</p> <p>NAMZARIC (memantine/donepezil ER) capsule, dose pack</p> <p>Pyridostigmine syrup, IR/ER tablet</p> <p>RAZADYNE ER (galantamine) capsule</p>	<p>*Eligibility criteria for Preferred Agents – Preferred products may be approved for a diagnosis of neurocognitive disorder (eligible for AutoPA automated approval).</p> <p>Non-preferred products may be approved if the member has failed treatment with one of the preferred products in the last 12 months. (Failure is defined as lack of efficacy, allergy, intolerable side effects or significant drug-drug interactions)</p> <p>Members currently stabilized on a non-preferred product may receive approval to continue on that agent for one year if medically necessary and if there is a diagnosis of neurocognitive disorder.</p>

Therapeutic Drug Class: **SEDATIVE HYPNOTICS** -Effective 4/1/2023

Non-Benzodiazepines

<p>Preferred No PA Required* (Unless age, dose, or duplication criteria apply)</p>	<p>Non-Preferred PA Required</p>	
<p>Eszopiclone tablet Ramelteon tablet Zaleplon capsule Zolpidem IR tablet Zolpidem ER tablet</p>	<p>AMBIEN (zolpidem) tablet AMBIEN CR (zolpidem ER) tablet BELSOMRA (suvorexant) tablet DAYVIGO (lemoborexant) tablet Doxepin tablet EDLUAR (zolpidem) SL tablet HETLIOZ (tasimelteon) capsule HETLIOZ LQ (tasimelteon) suspension LUNESTA (eszopiclone) tablet QUVIVIQ (daridorexant) tablet ROZEREM (ramelteon) tablet SILENOR (doxepin) tablet Tasimelteon capsule Zolpidem SL tablet</p>	<p>Non-preferred non-benzodiazepine sedative hypnotics may be approved for members who have failed treatment with two preferred non-benzodiazepine agents (failure is defined as lack of efficacy with a 2-week trial, allergy, intolerable side effects, or significant drug-drug interaction).</p> <p><u>Children:</u> Prior authorization will be required for all agents for children < 18 years of age.</p> <p><u>Duplications:</u> Only one agent in the sedative hypnotic drug class will be approved at a time (concomitant use of agents in the same sedative hypnotic class or differing classes will not be approved).</p> <p>All sedative hypnotics will require prior authorization for members ≥ 65 years of age when exceeding 90 days of therapy.</p> <p>Belsomra (suvorexant) may be approved for adult members that meet the following:</p> <ul style="list-style-type: none"> • Member has trialed and failed therapy with two preferred agents (failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction) AND • Member is not receiving strong inhibitors (such as erythromycin, clarithromycin, telithromycin, itraconazole, ketoconazole, posaconazole, fluconazole, voriconazole, delavirdine, and milk thistle) or inducers (such as carbamazepine, oxcarbazepine, phenobarbital, phenytoin, rifampin, rifabutin, rifapentine, dexamethasone, efavirenz, etravirine, nevirapine, darunavir/ritonavir, ritonavir, and St John’s Wort) of CYP3A4 AND • Member does not have a diagnosis of narcolepsy <p>Dayvigo (lemborexant) may be approved for adult member that meet the following:</p> <ul style="list-style-type: none"> • Member has trialed and failed therapy with two preferred agents AND Belsomra (surovexant). Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction AND • Member is not receiving strong inhibitors (such as erythromycin, clarithromycin, telithromycin, itraconazole, ketoconazole, posaconazole, fluconazole, voriconazole, delavirdine, and milk thistle) or inducers (such as carbamazepine, oxcarbazepine, phenobarbital, phenytoin, rifampin, rifabutin, rifapentine, dexamethasone, efavirenz, etravirine, nevirapine, darunavir/ritonavir, ritonavir, and St John’s Wort) of CYP3A4 AND • Member does not have a diagnosis of narcolepsy <p>Hetlioz (tasimelteon) capsules may be approved for members meeting the following criteria:</p> <ul style="list-style-type: none"> • Member is ≥18 years of age and has a documented diagnosis of Non-24-hour sleep wake disorder (Non-24) OR • Member is ≥16 years of age and has a documented diagnosis of nighttime sleep disturbances in Smith-Magenis syndrome (SMS)

		<p>AND</p> <ul style="list-style-type: none"> The requested medication is being prescribed by a sleep specialist or a practitioner who has sufficient education and experience to safely prescribe tasimelteon <p>Hetlioz LQ (tasimelteon) oral suspension may be approved for members meeting the following criteria:</p> <ul style="list-style-type: none"> Member is 3 to 15 years of age and has a documented diagnosis of nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) AND the requested medication is being prescribed by a sleep specialist or a practitioner who has sufficient education and experience to safely prescribe tasimelteon. <p>Silenor (doxepin) may be approved for adult members that meet ONE of the following criteria:</p> <ul style="list-style-type: none"> Member has tried and failed two preferred oral sedative hypnotics (Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction) OR Provider attests to the medical necessity of prescribing individual doxepin doses of less than 10 mg, OR Member's age is ≥ 65 years <p>Prior authorization will be required for prescribed doses exceeding maximum (Table 1).</p>
--	--	--

Benzodiazepines

Preferred	Non-Preferred	
No PA Required* (Unless age, dose, or duplication criteria apply)	PA Required	
Temazepam 15mg, 30mg capsule Triazolam tablet	DORAL (quazepam) tablet Estazolam tablet Flurazepam capsule HALCION (triazolam) tablet Quazepam tablet RESTORIL (temazepam) capsule Temazepam 7.5mg, 22.5mg capsule	<p>Non-preferred benzodiazepine sedative hypnotics may be approved for members who have trialed and failed therapy with two preferred benzodiazepine agents (failure is defined as lack of efficacy with a 2-week trial, allergy, intolerable side effects, or significant drug-drug interaction).</p> <p>Temazepam 22.5 mg may be approved if the member has trialed and failed temazepam 15mg or 30mg AND one other preferred product (failure is defined as lack of efficacy with a 2-week trial, allergy, intolerable side effects, or significant drug-drug interaction).</p> <p>Temazepam 7.5 mg may be approved if provider attests to the medical necessity of prescribing individual temazepam doses of less than 15 mg.</p> <p><u>Children:</u> Prior authorization will be required for all sedative hypnotic agents when prescribed for children < 18 years of age.</p> <p><u>Duplications:</u> Only one agent in the sedative hypnotic drug class will be approved at a time (concomitant use of agents in the same sedative hypnotic class or differing classes will not be approved).</p> <p>All sedative hypnotics will require prior authorization for member's ≥ 65 years of age when exceeding 90 days of therapy.</p>

Members currently stabilized on a non-preferred benzodiazepine medication may receive authorization to continue that medication.

Prior authorization will be required for prescribed doses exceeding maximum (Table 1).

Table 1: Sedative Hypnotic Maximum Dosing		
Brand	Generic	Maximum Dose
Non-Benzodiazepine		
Ambien CR	Zolpidem CR	12.5 mg/day
Ambien IR	Zolpidem IR	10 mg/day
Belsomra	Suvorexant	20 mg/day
Dayvigo	Lemborexant	10 mg/day
Edluar	Zolpidem sublingual	10 mg/day
-	Zolpidem sublingual	Men: 3.5mg/day Women: 1.75 mg/day
Hetlioz	Tasimelteon capsule	20 mg/day
Hetlioz LQ	Tasimelteon liquid	≤ 28 kg: 0.7 mg/kg/day > 28 kg : 20 mg/day
Lunesta	Eszopiclone	3 mg/day
Quviviq	Daridorexant	50 mg/day
-	Zaleplon	20 mg/day
Rozerem	Ramelteon	8 mg/day
Benzodiazepine		
Halcion	Triazolam	0.5 mg/day
Restoril	Temazepam	30 mg/day
Silenor	Doxepin	6mg/day
-	Estazolam	2 mg/day
-	Flurazepam	30 mg/day
Doral	Quazepam	15 mg/day

Therapeutic Drug Class: SKELETAL MUSCLE RELAXANTS -Effective 4/1/2023

No PA Required (if under 65 years of age) *	PA Required	
Baclofen tablet	AMRIX ER (cyclobenzaprine ER) capsule	<p>All agents in this class will require a PA for members 65 years of age and older. The maximum allowable approval will be for a 7-day supply.</p> <p>Authorization for any CARISOPRODOL product will be given for a maximum 3-week one-time authorization for members with acute, painful musculoskeletal conditions who have failed treatment with three preferred products within the last 6 months.</p> <p>*Dantrolene may be approved for members who have trialed and failed‡ one preferred agent and meet the following criteria:</p> <ul style="list-style-type: none"> • Documentation of age-appropriate liver function tests AND
Cyclobenzaprine tablet	Carisoprodol tablet	
Methocarbamol tablet	Carisoprodol/Aspirin tablet	
Tizanidine tablet	Chlorzoxazone tablet	
	Cyclobenzaprine ER capsule	

	<p>DANTRIUM (dantrolene) capsule</p> <p>*Dantrolene capsule</p> <p>FEXMID (cyclobenzaprine) tablet</p> <p>FLEQSUVY (baclofen) solution</p> <p>LORZONE (chlorzoxazone) tablet</p> <p>LYVISPAH (baclofen) granules</p> <p>Metaxalone tablet</p> <p>NORGESIC FORTE (orphenadrine/aspirin/caffeine) tablet</p> <p>Orphenadrine ER tablet</p> <p>SOMA (carisoprodol) tablet</p> <p>Tizanidine capsule</p> <p>ZANAFLEX (tizanidine) capsule, tablet</p>	<ul style="list-style-type: none"> • One of following diagnoses: Multiple Sclerosis, Cerebral Palsy, stroke, upper motor neuron disorder, or spinal cord injury • Dantrolene will be approved for the period of one year • If a member is stabilized on dantrolene, they may continue to receive approval <p>All other non-preferred skeletal muscle relaxants may be approved for members who have trialed and failed‡ three preferred agents. ‡Failure is defined as: lack of efficacy with 14-day trial, allergy, intolerable side effects, contraindication to, or significant drug-drug interactions.</p>
--	---	---

Therapeutic Drug Class: STIMULANTS AND RELATED AGENTS -Effective 4/1/2023

<p align="center">Preferred</p>	<p align="center">Non-Preferred</p>	
<p align="center">*No PA Required (if age, max daily dose, and diagnosis met)</p>	<p align="center">PA Required</p>	<p>*Preferred medications may be approved through AutoPA for indications listed in Table 1 (preferred medications may also receive approval for off-label use for fatigue associated with multiple sclerosis).</p>
<p>ADDERALL XR^{BNR} (mixed amphetamine salts ER) capsule</p> <p>Amphetamine salts, mixed (generic Adderall) tablet</p> <p>Armodafinil tablet</p> <p>Atomoxetine capsule</p> <p>CONCERTA^{BNR} (methylphenidate ER) tablet</p> <p>DAYTRANA^{BNR} (methylphenidate) patch</p>	<p>ADHANSIA XR (methylphenidate ER) capsule</p> <p>ADZENYS XR-ODT (amphetamine)</p> <p>Amphetamine salts, mixed ER (generic Adderall XR) capsule</p> <p>Amphetamine tablet (generic Evekeo)</p> <p>APTENSIO XR (methylphenidate ER) capsule</p> <p>AZSTARYS (serdexmethylphenidate/dexmethylphenidate) capsule</p>	<p>Non-preferred medications may be approved for members meeting the following criteria (for Sunosi (solriamfetol) and Wakix (pitolisant), refer to specific criteria listed below):</p> <ul style="list-style-type: none"> • Prescription meets indication/age limitation criteria (Table 1) AND • <u>If member is ≥ 6 years of age:</u> <ul style="list-style-type: none"> ○ Has documented trial and failure‡ with three preferred products in the last 24 months AND ○ If the member is unable to swallow solid oral dosage forms, two of the trials must be methylphenidate solution, dexmethylphenidate ER, Vyvanse, Adderall XR, or any other preferred product that can be taken without the need to swallow a whole capsule. <p>OR</p> <ul style="list-style-type: none"> • <u>If member is 3–5 years of age:</u> <ul style="list-style-type: none"> ○ Has documented trial and failure‡ with one preferred product in the last 24 months AND

<p>Dexmethylphenidate IR tablet</p> <p>Dexmethylphenidate ER capsule</p> <p>Guanfacine ER tablet</p> <p>Methylphenidate (generic Methylin/Ritalin) solution, tablet</p> <p>Modafinil tablet</p> <p>VYVANSE^{BNR} (lisdexamfetamine) capsule</p>	<p>Clonidine ER tablet</p> <p>COTEMPLA XR-ODT (methylphenidate ER)</p> <p>DESOXYN (methamphetamine) tablet</p> <p>DEXEDRINE (dextroamphetamine) Spansule</p> <p>Dextroamphetamine ER capsule, solution, tablet</p> <p>DYANAVEL XR (amphetamine) suspension</p> <p>EVEKEO (amphetamine) ODT, tablet</p> <p>FOCALIN (dexmethylphenidate) tablet, XR capsule</p> <p>INTUNIV (guanfacine ER) tablet</p> <p>JORNAY PM (methylphenidate) capsule</p> <p>Methamphetamine tablet</p> <p>METHYLIN (methylphenidate) solution</p> <p>Methylphenidate CD/ER/LA capsule, tablet, chewable tablet, ER tablet (generic Relexxi/Ritalin), ER tablet (generic Concerta), patch</p> <p>MYDAYIS ER (dextroamphetamine/amphetamine) capsule</p> <p>NUVIGIL (armodafinil) tablet</p> <p>PROCENTRA (dextroamphetamine) solution</p> <p>PROVIGIL (modafinil) tablet</p> <p>QELBREE (viloxazine ER) capsule</p>	<ul style="list-style-type: none"> ○ If the member is unable to swallow solid oral dosage forms, the trial must be methylphenidate solution, dexmethylphenidate ER, Vyvanse, Adderall XR, or any other preferred product that can be taken without the need to swallow a whole capsule. <p>SUNOSI (solriamfetol) prior authorization may be approved if member meets the following criteria:</p> <ul style="list-style-type: none"> ● Member is 18 years of age or older AND ● Member has diagnosis of either narcolepsy or obstructive sleep apnea (OSA) and is experiencing excessive daytime sleepiness AND ● Member does not have end stage renal disease AND ● If Sunosi is being prescribed for OSA, member has 1 month trial of CPAP AND ● Member has trial and failure[‡] of modafinil AND armodafinil AND one other agent in stimulant PDL class. <p>WAKIX (pitolisant) prior authorization may be approved if member meets the following criteria:</p> <ul style="list-style-type: none"> ● Member is 18 years of age or older AND ● Member has diagnosis of narcolepsy and is experiencing excessive daytime sleepiness AND ● Member does not have end stage renal disease (eGFR <15 mL/minute) AND ● Member does not have severe hepatic impairment AND ● Member has trial and failure[‡] of modafinil AND armodafinil AND one other agent in the stimulant PDL class AND ● Member has been counseled that Wakix may reduce the efficacy of hormonal contraceptives and regarding use an alternative non-hormonal method of contraception during Wakix therapy and for at least 21 days after discontinuing treatment. <p>Maximum Dose (all products): See Table 2</p> <p>Exceeding Max Dose: Prior authorization may be approved for doses that are higher than the listed maximum dose (Table 2) for members meeting the following criteria:</p> <ul style="list-style-type: none"> ● Member is taking medication for indicated use listed in Table 1 AND ● Member has 30-day trial and failure[‡] of three different preferred or non-preferred agents at maximum doses listed in Table 2 AND ● Documentation of member's symptom response to maximum doses of three other agents is provided AND ● Member is not taking a sedative hypnotic medication (such as temazepam, triazolam, or zolpidem from the Sedative Hypnotic PDL class). <p>[‡]Failure is defined as: lack of efficacy with 4-week trial, allergy, intolerable side effects, or significant drug-drug interaction.</p>
---	--	---

<p>QUILLICHEW ER (methylphenidate) chewable tablet, XR suspension</p> <p>RELEXXII (methylphenidate ER) tablet</p> <p>RITALIN (methylphenidate) IR/ER tablet, ER capsule</p> <p>STRATTERA (atomoxetine) capsule</p> <p>SUNOSI (solriamfetol) tablet</p> <p>VYVANSE (lisdexamfetamine) chewable tablet</p> <p>WAKIX (pitolisant) tablet</p> <p>XELSTRYM (dextroamphetamine) patch</p> <p>ZENZEDI (dextroamphetamine) tablet</p>

Table 1: Diagnosis and Age Limitations

- Approval for medically accepted indications not listed in Table 1 may be given with prior authorization review and may require submission of peer-reviewed literature or medical compendia showing safety and efficacy of the medication used for the prescribed indication.
- Preferred medications may also receive approval for off-label use for fatigue associated with multiple sclerosis if meeting all other criteria for approval.
- **Bolded drug names are preferred** (subject to preferential coverage changes for brand/generic equivalents)

Drug	Diagnosis and Age Limitations
Stimulants–Immediate Release	
Amphetamine sulfate (EVEKEO)	ADHD (Age ≥ 3 years), Narcolepsy (Age ≥ 6 years)
Dexmethylphenidate IR (FOCALIN)	ADHD (Age ≥ 6 years)
Dextroamphetamine IR (ZENZEDI)	ADHD (Age 3 to ≤ 16 years), Narcolepsy (Age ≥ 6 years)
Dextroamphetamine solution (PROCENTRA)	ADHD (Age 3 to ≤ 16 years), Narcolepsy (Age ≥ 6 years)
Methamphetamine (DESOXYN)	ADHD (Age ≥ 6 years)
methylphenidate IR (generic METHYLIN, RITALIN)	ADHD (Age ≥ 6 years [†]), Narcolepsy (Age ≥ 6 years), OSA. [†] Prior Authorization for members 3-6 years of age with a diagnosis of ADHD may be approved with prescriber attestation to the following: <ul style="list-style-type: none"> • Member’s symptoms have not significantly improved despite adequate behavior interventions AND • Member experiences moderate-to-severe continued disturbance in functioning AND • Prescriber has determined that the potential benefits of starting methylphenidate before the age of 6 years outweigh the potential harm of delaying treatment.
Mixed amphetamine salts IR (generic ADDERALL)	ADHD (Age ≥ 3 years), Narcolepsy (Age ≥ 6 years)

Stimulants –Extended-Release	
Amphetamine ER (ADZENYS XR-ODT and ADZENYS ER suspension)	ADHD (Age ≥ 6 years)
Amphetamine ER (DYANAVEL XR)	ADHD (Age ≥ 6 years)
Mixed-amphetamine salts ER (ADDERALL XR)	ADHD (Age ≥ 6 years)
Dexmethylphenidate ER (generic Focalin XR)	ADHD (Age ≥ 6 years)
Dextroamphetamine ER (DEXEDRINE)	ADHD (Age 6 to ≤ 16 years), Narcolepsy (Age ≥ 6 years)
Dextroamphetamine ER/amphetamine ER (MYDAYIS ER)	ADHD (Age ≥ 13 years)
Dextroamphetamine IR and ER	ADHD and Narcolepsy (IR ≥ 3 years, ER ≥ 6 years)
Lisdexamfetamine dimesylate (VYVANSE capsule , Vyvanse chewable)	ADHD (Age ≥ 6 years), Moderate to severe binge eating disorder in adults (Age ≥ 18 years)
Methylphenidate ER OROS (CONCERTA)	ADHD (Age ≥ 6 years), Narcolepsy (Age ≥ 6 years), OSA
Methylphenidate patch (DAYTRANA)	ADHD (Age ≥ 6 years)
Methylphenidate SR (METADATE ER)	ADHD (Age ≥ 6 years), Narcolepsy (Age ≥ 6 years)
Methylphenidate ER (METADATE CD)	ADHD (Age ≥ 6 years)
Methylphenidate ER (QUILLICHEW ER)	ADHD (Age 6 years to ≤ 65 years), Narcolepsy (Age ≥ 6 years)
Methylphenidate ER (QUILLIVANT XR)	ADHD (Age ≥ 6 years), Narcolepsy (Age ≥ 6 years)
Methylphenidate ER (RITALIN LA)	ADHD (Age ≥ 6 years)
Methylphenidate ER (ADHANSIA XR)	ADHD (Age ≥ 6 years)
Non-Stimulants	
Atomoxetine (generic STRATTERA)	ADHD (Age ≥ 6 years)
Clonidine ER (KAPVAY)	ADHD as monotherapy OR adjunctive therapy to stimulants (Age ≥ 6 years)
Guanfacine ER (generic INTUNIV)	ADHD as monotherapy OR adjunctive therapy to stimulants (Age ≥ 6 years)
Viloxazine ER (QELBREE)	ADHD (Age ≥ 6 years)
Wakefulness-promoting Agents	
Armodafinil (generic NUVIGIL)	Excessive sleepiness associated with narcolepsy, OSA, SWD, and adjunct therapy to treat fatigue and sleepiness in patients with major depressive disorder (MDD) (Age ≥ 18 years)
Modafinil (PROVIGIL)	Excessive sleepiness associated with narcolepsy, OSA, SWD, and adjunct therapy to treat fatigue and sleepiness in patients with major depressive disorder (MDD), antipsychotic medication-related fatigue (Age ≥ 18 years)
Pitolisant (WAKIX)	Excessive sleepiness associated with narcolepsy (Age ≥ 18 years)
Solriamfetol (SUNOSI)	Excessive sleepiness associated with narcolepsy, OSA (Age ≥ 18 years)
KEY: ADHD –attention-deficit/hyperactivity disorder, OSA –obstructive sleep apnea, SWD –shift work disorder	

Table 2: Maximum Dose

Drug	Maximum Daily Dose
ADDERALL	60 mg
ADDERALL XR	60 mg

ADHANSIA XR	85 mg
ADZENYS XR ODT	18.8 mg (age 6-12)
ADZENYS ER SUSPENSION	12.5 mg (age ≥ 13)
AMPHETAMINE SALTS	40 mg
APTENSIO XR	60 mg
CONCERTA	54 mg (age 6-12) or 72 mg (≥ age 13)
COTEMPLA XR-ODT	51.8 mg
DEXTROAMPHETAMINE ER	60 mg
DAYTRANA	30 mg/9 hour patch (3.3 mg/hr)
DESOXYN	25 mg
DEXEDRINE	60 mg
DYANAVEL XR	20 mg
EVEKEO	60 mg
FOCALIN	20 mg
FOCALIN XR	40 mg
INTUNIV ER	4 mg (age 6-12) or 7 mg (age ≥ 13)
JORNAY PM	100 mg
KAPVAY ER	0.4 mg
METADATE CD	60 mg
METADATE ER	60 mg
METHYLIN	60 mg
METHYLIN ER	60 mg
METHYLIN SUSPENSION	60 mg
METHYLPHENIDATE	60 mg
METHYLPHENIDATE ER	60 mg
MYDAYIS ER	25 mg (age 13-17) or 50 mg (age ≥ 18)
NUVIGIL	250 mg
PROCENTRA	60 mg
PROVIGIL	400 mg
QELBREE	400 mg (age 6-17) or 600 mg (age ≥ 18)
QUILLICHEW ER	60 mg
QUILLIVANT XR	60 mg
RITALIN IR	60 mg
RITALIN SR	60 mg
RITALIN LA	60 mg
STRATTERA	1.4 mg/kg or 100mg, whichever is less (age ≥ 6 years with weight < 70 kg) or 100mg (adults and children/adolescents with weight > 70 kg)
SUNOSI	150 mg
VYVANSE CAPSULES AND CHEWABLE TABLETS	70 mg
WAKIX	35.6 mg
ZENZEDI	60 mg

Therapeutic Drug Class: TRIPTANS, DITANS AND OTHER MIGRAINE TREATMENTS - Oral -Effective 4/1/2023

No PA Required (Quantity limits may apply)	PA Required											
Eletriptan tablet (generic Relpax) Naratriptan tablet (generic Amerge) Rizatriptan tablet, ODT (generic Maxalt) Sumatriptan tablet (generic Imitrex) Zolmitriptan tablet	Almotriptan tablet FROVA (frovatriptan) tablet Frovatriptan tablet IMITREX (sumatriptan) tablet MAXALT/MAXALT MLT (rizatriptan) tablet, ODT RELPAX (eletriptan) tablet REYVOW (lasmiditan) tablet Sumatriptan/Naproxen tablet TREXIMET (sumatriptan/naproxen) tablet Zolmitriptan ODT ZOMIG (zolmitriptan) tablet	<p>Non-preferred oral products may be approved for members who have trialed and failed three preferred oral products. Failure is defined as lack of efficacy with 4-week trial, allergy, documented contraindication to therapy, intolerable side effects, or significant drug-drug interaction.</p> <p><u>Note:</u> The safety, tolerability, and efficacy of coadministering lasmiditan with a triptan or a gepant has not been assessed.</p> <p>Quantity Limits:</p> <table border="1" data-bbox="1087 440 1942 630"> <tr> <td>Amerge (naratriptan), Frova (frovatriptan), Imitrex (sumatriptan), Zomig (zolmitriptan)</td> <td>9 tabs/30 days</td> </tr> <tr> <td>Treximet (sumatriptan/naproxen)</td> <td>9 tabs/30 days</td> </tr> <tr> <td>Axert (almotriptan) and Relpax (eletriptan)</td> <td>6 tabs/30 days</td> </tr> <tr> <td>Maxalt (rizatriptan)</td> <td>12 tabs/30 days</td> </tr> <tr> <td>Reyvow (lasmiditan)</td> <td>8 tabs/30 days</td> </tr> </table>	Amerge (naratriptan), Frova (frovatriptan), Imitrex (sumatriptan), Zomig (zolmitriptan)	9 tabs/30 days	Treximet (sumatriptan/naproxen)	9 tabs/30 days	Axert (almotriptan) and Relpax (eletriptan)	6 tabs/30 days	Maxalt (rizatriptan)	12 tabs/30 days	Reyvow (lasmiditan)	8 tabs/30 days
Amerge (naratriptan), Frova (frovatriptan), Imitrex (sumatriptan), Zomig (zolmitriptan)	9 tabs/30 days											
Treximet (sumatriptan/naproxen)	9 tabs/30 days											
Axert (almotriptan) and Relpax (eletriptan)	6 tabs/30 days											
Maxalt (rizatriptan)	12 tabs/30 days											
Reyvow (lasmiditan)	8 tabs/30 days											

Therapeutic Drug Class: TRIPTANS, DITANS, AND OTHER MIGRAINE TREATMENTS - Non-Oral -Effective 4/1/2023

No PA Required (Quantity limits may apply)	PA Required											
IMITREX ^{BNR} (sumatriptan) nasal spray IMITREX ^{BNR} (sumatriptan) cartridge, pen injector MIGRANAL ^{BNR} (dihydroergotamine) nasal spray Sumatriptan vial Zolmitriptan nasal spray (<i>Amneal only</i>)	Dihydroergotamine injection, nasal spray ONZETRA XSAIL (sumatriptan) nasal powder Sumatriptan cartridge, nasal spray, pen injector TOSYMRA (sumatriptan) nasal spray TRUDHESA (dihydroergotamine) nasal spray ZEMBRACE SYMTOUCH (sumatriptan) auto-injector	<p>Zembrace Symtouch injection, Tosymra nasal spray, or Onzetra Xsail nasal powder may be approved for members who have trialed and failed one preferred non-oral triptan products AND two oral triptan agents with different active ingredients. Failure is defined as lack of efficacy with 4-week trial, allergy, intolerable side effects, significant drug-drug interaction, or documented inability to take alternative dosage form.</p> <p>All other non-preferred products may be approved for members who have trialed and failed one preferred non-oral triptan product AND one preferred oral triptan product. Failure is defined as lack of efficacy with 4-week trial, allergy, intolerable side effects or significant drug-drug interactions, documented inability to tolerate dosage form.</p> <p>Quantity Limits:</p> <table border="1" data-bbox="1087 1333 2003 1521"> <tr> <td>Dihydroergotamine mesylate vial 1mg/mL</td> <td>24 vials/ 28 days</td> </tr> <tr> <td>Imitrex (sumatriptan) injection</td> <td>4 injectors / 30 days</td> </tr> <tr> <td>Imitrex (sumatriptan) nasal spray</td> <td>6 inhalers / 30 days</td> </tr> <tr> <td>Migranal (dihydroergotamine mesylate) nasal spray</td> <td>8 nasal spray devices/ 30 days</td> </tr> <tr> <td>Onzetra Xsail (sumatriptan) nasal powder</td> <td>16 nosepieces / 30 days</td> </tr> </table>	Dihydroergotamine mesylate vial 1mg/mL	24 vials/ 28 days	Imitrex (sumatriptan) injection	4 injectors / 30 days	Imitrex (sumatriptan) nasal spray	6 inhalers / 30 days	Migranal (dihydroergotamine mesylate) nasal spray	8 nasal spray devices/ 30 days	Onzetra Xsail (sumatriptan) nasal powder	16 nosepieces / 30 days
Dihydroergotamine mesylate vial 1mg/mL	24 vials/ 28 days											
Imitrex (sumatriptan) injection	4 injectors / 30 days											
Imitrex (sumatriptan) nasal spray	6 inhalers / 30 days											
Migranal (dihydroergotamine mesylate) nasal spray	8 nasal spray devices/ 30 days											
Onzetra Xsail (sumatriptan) nasal powder	16 nosepieces / 30 days											

	Zolmitriptan nasal spray (all other manufacturers)	Tosymra (sumatriptan) nasal spray	12 nasal spray devices / 30 days
		Zembrace Symtouch (sumatriptan) injection	36mg / 30 days
	ZOMIG (zolmitriptan) nasal spray	Zomig (zolmitriptan) nasal spray	6 inhalers / 30 days

Members currently utilizing a non-oral dihydroergotamine product formulation (based on recent claims history) may receive one year approval to continue therapy with that medication.

V. Dermatological

Therapeutic Drug Class: ACNE AGENTS– Topical -Effective 7/1/2023

Preferred No PA Required (if age and diagnosis criteria are met*)	Non-Preferred PA Required	
*Adapalene gel	ACANYA (clindamycin/benzoyl peroxide) gel, pump	Authorization for all acne agents prescribed solely for cosmetic purposes will not be approved.
*Adapalene/benzoyl peroxide gel (generic Epiduo)	Adapalene cream, gel pump, solution	Preferred topical clindamycin and erythromycin products may be approved by AutoPA verification of ICD-10 diagnosis code for acne vulgaris, psoriasis, cystic acne, comedonal acne, disorders of keratinization, neoplasms, folliculitis, hidradenitis suppurativa, or perioral dermatitis (erythromycin only). Approval of preferred topical clindamycin and erythromycin products for other medically accepted indications may be considered following clinical prior authorization review by a call center pharmacist.
*Clindamycin phosphate solution, medicated swab/pledget	Adapalene/Benzoyl Peroxide gel pump	
*Clindamycin/benzoyl peroxide gel jar (generic Benzacilin)	ALTRENO (tretinoin) lotion	All other preferred topical acne agents may be approved if meeting the following criteria:
*Clindamycin/benzoyl peroxide gel tube (generic Duac)	AMZEEQ (minocycline) foam	<ul style="list-style-type: none"> For members > 25 years of age, may be approved following prescriber verification that the medication is not being utilized for cosmetic purposes AND prescriber verification that the indicated use is for acne vulgaris, psoriasis, cystic acne, disorders of keratinization, neoplasms, or comedonal acne. These medications are only eligible for prior authorization approval for the aforementioned diagnoses. For members ≤ 25 years of age, may be approved for a diagnosis of acne vulgaris, psoriasis, cystic acne, disorders of keratinization, neoplasms, or comedonal acne. Diagnosis will be verified through automated verification (AutoPA) of the appropriate corresponding ICD-10 diagnosis code related to the indicated use of the medication.
*Dapsone gel	ARAZLO (tazarotene) lotion	Non-preferred topical products may be approved for members meeting all of the following criteria:
*Erythromycin solution	ATRALIN (tretinoin) gel	
*Erythromycin/Benzoyl peroxide gel (generic Benzamycin)	BENZACLIN (clindamycin/benzoyl peroxide) gel, pump	<ul style="list-style-type: none"> Member has trialed/failed three preferred topical products with different mechanisms (such as tretinoin, antibiotic). Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction AND Prescriber verification that the medication is being prescribed for one of the following diagnoses: acne vulgaris, psoriasis, cystic acne, disorders of keratinization, neoplasms, or comedonal acne.
*Sulfacetamide sodium suspension	BENZAMYCIN (erythromycin/benzoyl peroxide) gel	
*RETIN-A ^{BNR} (tretinoin) cream, gel	BP (sulfacetamide sodium/sulfur/urea) cleansing wash	
	CLEOCIN (clindamycin) lotion	
	CLINDACIN ETZ/PAC (clindamycin phosphate) kit	
	Clindamycin phosphate foam, gel, lotion	

	<p>Clindamycin/Benzoyl peroxide gel pump</p> <p>Clindamycin/tretinoin gel</p> <p>Dapsone pump</p> <p>ERY/ERYGEL (erythromycin/ethanol) gel, medicated swabs/pads</p> <p>Erythromycin gel</p> <p>EVOCLIN (clindamycin) foam</p> <p>FABIOR (tazarotene) foam</p> <p>KLARON (sulfacetamide) suspension</p> <p>NEUAC (clindamycin/benzoyl peroxide/emollient) kit</p> <p>ONEXTON (clindamycin/benzoyl peroxide) gel, gel pump</p> <p>RETIN-A MICRO (tretinoin) (all products)</p> <p>ROSULA (sulfacetamide sodium/sulfur) cloths, wash</p> <p>SSS 10-5 (sulfacetamide sodium/sulfur) foam</p> <p>Sulfacetamide sodium cleanser, cleansing gel, lotion, shampoo, wash</p> <p>Sulfacetamide sodium/sulfur cleanser, cream, pad, suspension, wash</p> <p>SUMADAN/XLT (sulfacetamide sodium/sulfur) kit, wash</p> <p>SUMAXIN/ CP/TS (sulfacetamide sodium/sulfur) kit, pads, suspension, wash</p> <p>Tazarotene cream, foam</p> <p>Tretinoin (all products)</p>	
--	---	--

	Tretinoin microspheres (all products) WINLEVI (clascoterone) cream ZIANA (clindamycin/tretinoin) gel	
Therapeutic Drug Class: ACNE AGENTS– ORAL ISOTRETINOIN -Effective 7/1/2023		
PA Required for all agents		Preferred products may be approved for adults and children ≥ 12 years of age for treating severe acne vulgaris or for treating moderate acne vulgaris in members unresponsive to conventional therapy. Non-preferred products may be approved for members meeting the following: <ul style="list-style-type: none"> • Member has trialed/failed one preferred agent (failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction) AND • Member is an adult or child ≥ 12 years of age with severe, recalcitrant nodulocystic acne and has been unresponsive to conventional therapy.
Preferred	Non-Preferred	
AMNESTEEM capsule CLARAVIS capsule Isotretinoin 10 mg, 20 mg, 30 mg, 40 mg capsule (<i>all manufacturers except Amneal</i>)	ABSORICA capsule ABSORICA LD capsule Isotretinoin 10 mg, 20 mg, 30 mg, 40 mg capsule (<i>Amneal</i>) Isotretinoin 25 mg, 35 mg capsule MYORISAN capsule ZENATANE capsule	
Therapeutic Drug Class: ANTI-PSORIATICS - Oral -Effective 7/1/2023		
No PA Required	PA Required	Prior authorization for non-preferred oral agents may be approved with failure of two preferred anti-psoriatic agents, one of which must be a preferred oral agent. Failure is defined as lack of efficacy of a 4-week trial, allergy, intolerable side effects or significant drug-drug interaction.
Acitretin capsule	Methoxsalen capsule SORIATANE (acitretin) capsule	
Therapeutic Drug Class: ANTI-PSORIATICS -Topical -Effective 7/1/2023		
No PA Required	PA Required	Prior authorization for non-preferred topical agents may be approved with failure of two preferred topical agents. If non-preferred topical agent being requested is a combination product, trial of two preferred agents must include a preferred combination agent. Failure is defined as lack of efficacy of a 4-week trial, allergy, intolerable side effects or significant drug-drug interaction. Preferred and non-preferred products that contain a corticosteroid ingredient (such as betamethasone) will be limited to 4 weeks of therapy. Continued use will require one week of steroid-free time in between treatment periods. Members with >30% of their body surface area affected may not use Enstilar (calcipotriene/betamethasone DP) foam or Taclonex (calcipotriene/betamethasone DP) ointment products as safety and efficacy have not been established.
Calcipotriene cream, solution DOVONEX (calcipotriene) cream TACLONEX SCALP ^{BNR} (calcipotriene/betamethasone) suspension TACLONEX ^{BNR} (calcipotriene/betamethasone) ointment	Calcipotriene foam, ointment Calcipotriene/betamethasone dipropionate ointment, suspension Calcitriol ointment DUOBRII (halobetasol/tazarotene) lotion ENSTILAR (calcipotriene/betamethasone) foam SORILUX (calcipotriene) foam	

Atopic Dermatitis

No PA Required	PA Required	
<p>ELIDEL^{BNR} (pimecrolimus) cream</p> <p>PROTOPIC (tacrolimus) ointment</p> <p>Tacrolimus ointment</p>	<p>EUCRISA (crisaborole) ointment</p> <p>OPZELURA (ruxolitinib) cream</p> <p>Pimecrolimus cream</p>	<p>EUCRISA (crisaborole) may be approved if the following criteria are met:</p> <ul style="list-style-type: none"> • Member is at least 3 months of age and older AND • Member has a diagnosis of mild to moderate atopic dermatitis AND • Member has a history of failure, contraindication, or intolerance to at least two medium-to high-potency topical corticosteroids for a minimum of 2 weeks OR is not a candidate for topical corticosteroids AND • Member must have tried and failed pimecrolimus and tacrolimus. Failure is defined as a lack of efficacy, allergy, intolerable side effects, contraindication to, or significant drug-drug interactions. AND • Eucrisa (crisaborole) must be prescribed by or in consultation with a dermatologist or allergist/immunologist. <p>OPZELURA (ruxolitinib) may be approved if the following criteria are met:</p> <ul style="list-style-type: none"> • Member is ≥ 12 years of age AND • Member is immunocompetent AND • Member has a diagnosis of mild to moderate atopic dermatitis AND • Member has a history of failure, contraindication, or intolerance to at least two medium-to high-potency topical corticosteroids for a minimum of 2 weeks OR is not a candidate for topical corticosteroids AND • Member must have trialed and/or failed pimecrolimus and tacrolimus. Failure is defined as a lack of efficacy, allergy, intolerable side effects, contraindication to, or significant drug-drug interactions AND • Must be prescribed by or in consultation with a dermatologist or allergist/immunologist. • <u>Quantity limit:</u> 60 grams/week <p>All other non-preferred topical immunomodulator products may be approved for atopic dermatitis following adequate trial and failure[‡] of one prescription topical corticosteroid AND two preferred agents. [‡]Failure is defined as a lack of efficacy with one month trial, allergy, intolerable side effects, contraindication to, or significant drug-drug interactions.</p> <p>For members under 18 years of age, must be prescribed by or in consultation with a dermatologist or allergist/immunologist.</p> <p>Note: Prior authorization requests for Opzelura (ruxolitinib) prescribed solely for treating nonsegmental vitiligo will not be approved.</p>

Antineoplastic Agents

<p>Preferred No PA Required (Unless indicated*)</p> <p>*Diclofenac 3% gel (generic Solaraze)</p> <p>Fluorouracil 5% cream (generic Efudex)</p> <p>Fluorouracil 2%, 5% solution</p>	<p>Non-Preferred PA Required</p> <p>CARAC (fluorouracil) cream</p> <p>EFUDEX (fluorouracil) cream</p> <p>Fluorouracil 0.5% (generic Carac) cream</p> <p>PANRETIN (alitretinoin) gel</p> <p>TARGRETIN (bexarotene) gel</p> <p>TOLAK (fluorouracil) cream</p> <p>VALCHLOR (mechlorethamine) gel</p>	<p>*Diclofenac 3% gel (generic Solaraze) may be approved if the member has a diagnosis of actinic keratosis (AK).</p> <p>TARGRETIN (bexarotene) gel or VALCHLOR (mechlorethamine) gel may be approved for members who meet the following criteria:</p> <ul style="list-style-type: none"> • Member is ≥ 18 years of age AND • Member has been diagnosed with Stage IA or IB cutaneous T-cell lymphoma (CTCL) AND • Member has refractory or persistent CTCL disease after other therapies OR has not tolerated other therapies AND • Member and partners have been counseled on appropriate use of contraception <p>Non-preferred agents may be approved for members who have failed an adequate trial of all preferred products FDA-approved for that indication. Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction.</p>
---	--	--

Other Agents

<p>No PA Required</p> <p>CONDYLOX (podofilox) gel</p> <p>Imiquimod (generic Aldara) cream</p> <p>Podofilox solution</p>	<p>PA Required</p> <p>ALDARA (imiquimod) cream</p> <p>HYFTOR (sirolimus) gel</p> <p>Imiquimod cream pump</p> <p>VEREGEN (sinecatechins) ointment</p> <p>ZYCLARA (imiquimod) cream, cream pump</p>	<p>Hyftor (sirolimus) gel</p> <ul style="list-style-type: none"> • Member has a diagnosis of facial angiofibroma associated with tuberous sclerosis AND • Member is ≥ 6 years of age AND • Provider has evaluated, and member has received, all age-appropriate vaccinations as recommended by current immunization guidelines prior to initiating treatment with HYFTOR <p><u>Initial approval:</u> 6 months</p> <p><u>Reauthorization:</u> An additional 6 months may be approved based on provider attestation that symptoms improved during the initial 6 months of treatment and the provider has assessed use of all vaccinations recommended by current immunization guidelines.</p> <p><u>Maximum dose:</u> one 10-gram tube/28 days</p> <p>Veregen (sinecatechins) may be approved if the following criteria are met:</p> <ul style="list-style-type: none"> • Member has a diagnosis of external genital and/or perianal warts (Condylocumata acuminata) AND • Member is ≥ 18 years of age AND Member is immunocompetent AND • Member has tried and failed two preferred products. Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction.
--	--	--

		<p>Zyclara (imiquimod) 2.5% cream may be approved if the following criteria are met:</p> <ul style="list-style-type: none"> • Member has a diagnosis of clinically typical visible or palpable actinic keratoses (AK) of the full face or balding scalp AND • Member is ≥ 18 years of age AND • Member is immunocompetent AND • Member has tried and failed one preferred product in the Antineoplastic Agents class (such as diclofenac gel or fluorouracil) AND the preferred imiquimod (generic Aldara) product. Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction. <p>Zyclara (imiquimod) 3.75% cream may be approved for:</p> <ul style="list-style-type: none"> • Treatment of clinically typical visible or palpable, actinic keratoses (AK) of the full face or balding scalp if the following criteria are met: <ul style="list-style-type: none"> • Member is ≥ 18 years of age AND • Member is immunocompetent AND • Member has tried and failed one preferred product from the Antineoplastic Agents class (such as diclofenac gel or fluorouracil) AND the preferred imiquimod (generic Aldara) product. Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction. <p>OR</p> <ul style="list-style-type: none"> • Treatment of external genital and/or perianal warts (Condylomata acuminata) if the following criteria are met: <ul style="list-style-type: none"> • Member is ≥ 12 years of age AND • Member has tried and failed two preferred products. Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction. <p>All other non-preferred products may be approved for members who have trialed and failed all preferred products that are FDA-approved for use for the prescribed indication. Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction.</p> <p><u>Quantity Limits:</u> Aldara (imiquimod) cream has a quantity limit of 12 packets/28 days.</p>
--	--	---

Therapeutic Drug Class: ROSACEA AGENTS -Effective 7/1/2023

No PA Required	PA Required	
FINACEA ^{BNR} (azelaic acid) gel FINACEA (azelaic acid) foam Metronidazole cream, lotion Metronidazole 0.75% gel	Azelaic acid gel *Doxycycline monohydrate DR capsule (generic Oracea) Metronidazole 1% gel, gel pump	Prior authorization for non-preferred products in this class may be approved if member meets the following criteria: <ul style="list-style-type: none"> • Member has a diagnosis of persistent (non-transient) facial erythema with inflammatory papules and pustules due to rosacea AND • Prescriber attests that medication is not being used solely for cosmetic purposes AND

	<p>NORITATE (metronidazole) cream</p> <p>RHOFADE (oxymetazoline) cream</p> <p>ROSADAN (metronidazole/skin cleanser) cream kit, gel kit</p> <p>ZILXI (minocycline) foam</p>	<ul style="list-style-type: none"> Member has tried and failed two preferred agents of different mechanisms of action (Failure is defined as lack of efficacy with 4-week trial, allergy, intolerable side effects) <p>*Doxycycline monohydrate DR (generic Oracea) may be approved if the following criteria are met:</p> <ul style="list-style-type: none"> Member has taken generic doxycycline for a minimum of three months and failed therapy in the last 6 months. Failure is defined as: lack of efficacy, allergy, intolerable side effects or significant drug-drug interactions AND Member has history of an adequate trial/failure (8 weeks) of 2 other preferred agents (oral or topical). Failure is defined as lack of efficacy, allergy, intolerable side effects or significant drug-drug interactions AND Member is ≥ 18 years of age and has been diagnosed with rosacea with inflammatory lesions (papules and pustules)
--	--	--

Therapeutic Drug Class: TOPICAL STEROIDS – Effective 7/1/2023

Low potency

<p align="center">No PA Required</p> <p>Hydrocortisone (Rx) cream, ointment, lotion</p> <p>DERMA-SMOOTHIE-FS ^{BNR} (fluocinolone) 0.01% oil</p> <p>Desonide 0.05% cream, ointment</p> <p>Fluocinolone 0.01% cream</p>	<p align="center">PA Required</p> <p>Alclometasone 0.05% cream, ointment</p> <p>CAPEX (fluocinolone) 0.01% shampoo</p> <p>Desonide 0.05% lotion</p> <p>Fluocinolone 0.01% body oil, 0.01% scalp oil, 0.01% solution</p> <p>PROCTOCORT (hydrocortisone) (Rx) 1% cream</p> <p>SYNALAR (fluocinolone) 0.01% solution</p> <p>SYNALAR TS (fluocinolone/skin cleanser) Kit</p> <p>TEXACORT (hydrocortisone) 2.5% solution</p>	<p>Non-preferred Low Potency topical corticosteroids may be approved following adequate trial and failure of two preferred agents in the Low Potency class (failure is defined as lack of efficacy with 4-week trial, allergy, intolerable side effects or significant drug-drug interactions).</p>
---	--	---

Medium potency

<p align="center">No PA Required</p> <p>Betamethasone dipropionate 0.05% lotion</p> <p>Betamethasone valerate 0.1% cream, ointment</p>	<p align="center">PA Required</p> <p>BESER (fluticasone) lotion, emollient kit</p> <p>Betamethasone dipropionate 0.05% cream</p> <p>Betamethasone valerate 0.1% lotion, 0.12% foam</p>	<p>Non-preferred Medium Potency topical corticosteroids may be approved following adequate trial and failure of two preferred agents in the Medium Potency class (failure is defined as: lack of efficacy with 4-week trial, allergy, intolerable side effects or significant drug-drug interactions).</p>
---	---	--

<p>Fluocinolone 0.025% cream</p> <p>Fluticasone 0.05% cream, 0.005% ointment</p> <p>Mometasone 0.1% cream, 0.1% ointment, 0.1% solution</p> <p>Triamcinolone acetonide 0.025% cream, 0.1% cream, 0.025% ointment, 0.05% ointment, 0.1% ointment, 0.025% lotion, 0.1% lotion</p> <p>Triamcinolone 0.1% dental paste</p>	<p>Clocortolone 0.1% cream, cream pump</p> <p>CLODERM (clocortolone) 0.1% cream, cream pump</p> <p>CUTIVATE (fluticasone) 0.05% cream, lotion</p> <p>Diflorasone 0.05% cream</p> <p>Fluocinolone 0.025% ointment</p> <p>Fluocinonide-E 0.05% cream</p> <p>Flurandrenolide 0.05% cream, lotion, ointment</p> <p>Fluticasone 0.05% lotion</p> <p>Hydrocortisone butyrate 0.1% cream, lotion, solution, ointment, lipid/lipocream</p> <p>Hydrocortisone valerate 0.2% cream, ointment</p> <p>KENALOG (triamcinolone) spray</p> <p>LOCOID (hydrocortisone butyrate) 0.1% lotion</p> <p>LOCOID LIPOCREAM (hydrocortisone butyrate-emollient) 0.1% cream</p> <p>LUXIQ (betamethasone valerate) 0.12% foam</p> <p>PANDEL (hydrocortisone probutate) 0.1% cream</p> <p>Prednicarbate 0.1% cream, ointment</p> <p>PSORCON (diflorasone) 0.05% cream</p> <p>SYNALAR (fluocinolone) 0.025% cream/kit, ointment/kit</p> <p>Triamcinolone 0.147 mg/gm spray</p>	
High potency		
<p style="text-align: center;">No PA Required (*unless exceeds duration of therapy)</p> <p>*Betamethasone dipropionate/propylene glycol (augmented) 0.05% cream</p>	<p style="text-align: center;">PA Required</p> <p>Amcinonide 0.1% cream, lotion</p> <p>APEXICON-E (diflorasone/emollient) 0.05% cream</p>	<p>Non-preferred High Potency topical corticosteroids may be approved following adequate trial and failure of two preferred agents in the High Potency class (failure is defined as lack of efficacy with 4-week trial, allergy, intolerable side effects or significant drug-drug interactions).</p>

<p>*Fluocinonide 0.05% cream, 0.05% gel, 0.05% solution, 0.05% ointment</p> <p>*Triamcinolone acetonide 0.5% cream, 0.5% ointment</p>	<p>Betamethasone dipropionate 0.05% ointment</p> <p>Desoximetasone 0.05%, 0.25% cream, 0.05% gel, 0.05%, 0.25% ointment</p> <p>Diflorasone 0.05% ointment</p> <p>Halcinonide 0.1% cream</p> <p>HALOG (halcinonide) 0.1% cream, ointment, solution</p> <p>TOPICORT (desoximetasone) 0.05%, 0.25% cream, 0.05% gel, 0.05%, 0.25% ointment</p>	<p>*All High Potency topical corticosteroids will require prior authorization beyond 4 weeks of therapy. The provider will be encouraged to transition to a medium or low potency topical steroid after this time has elapsed.</p> <p>Claims for compounded products containing high-potency topical steroids will be limited to a maximum of 60 grams or 60 mL of a high-potency ingredient per 4-week treatment period. Claims exceeding this quantity limit will require prior authorization with prescriber's justification for use of the product at the prescribed dose.</p>
---	---	--

Very high potency

No PA Required (Unless exceeds duration of therapy*)	PA Required	
<p>*Betamethasone dipropionate/propylene glycol (augmented) 0.05% ointment</p> <p>*Clobetasol 0.05% cream, 0.05% gel, 0.05% ointment, 0.05% solution</p> <p>*Fluocinonide 0.1% cream</p>	<p>Betamethasone dipropionate/propylene glycol (augmented) 0.05% gel, 0.05% lotion</p> <p>BRYHALI (halobetasol) 0.01% lotion</p> <p>Clobetasol emollient/emulsion 0.05% cream, foam</p> <p>Clobetasol 0.05% lotion, foam, spray, shampoo</p> <p>CLOBEX (clobetasol) 0.05% spray, 0.05% shampoo</p> <p>CLODAN (clobetasol) 0.05% cleanser kit</p> <p>Desoximetasone 0.25% spray</p> <p>DIPROLENE (betamethasone dipropionate/propylene glycol, augmented) 0.05% ointment</p> <p>Halobetasol 0.05% cream, foam, ointment</p> <p>IMPEKLO (clobetasol) 0.05% lotion</p> <p>LEXETTE (halobetasol) 0.05% foam</p> <p>OLUX (clobetasol) 0.05% foam</p> <p>OLUX-E (clobetasol) 0.05% foam</p>	<p>Non-preferred Very High Potency topical corticosteroids may be approved following adequate trial and failure of clobetasol propionate in the same formulation as the product being requested (if the formulation of the requested non-preferred product is not available in preferred clobetasol product options, then trial and failure of any preferred clobetasol product formulation will be required). Failure is defined as lack of efficacy with 2-week trial, allergy, intolerable side effects or significant drug-drug interactions.</p> <p>*All Very High Potency topical corticosteroids will require prior authorization beyond 2 weeks of therapy. If clobetasol propionate shampoo is being used to treat plaque psoriasis, then prior authorization will be required beyond 4 weeks of therapy. The provider will be encouraged to transition to a medium or low potency topical steroid after this time has elapsed.</p>

	TEMOVATE (clobetasol) 0.05% cream, ointment TOPICORT (desoximetasone) 0.25% spray TOVET EMOLLIENT (clobetasol) 0.05% foam ULTRAVATE (halobetasol) 0.05% lotion VANOS (fluocinonide) 0.1% cream	
--	--	--

VI. Endocrine

Therapeutic Drug Class: **ANDROGENIC AGENTS, Topical, Injectable, Oral** -Effective 10/1/2023

PA Required for all agents in this class

Preferred	Non-Preferred	
ANDRODERM (testosterone) patch Testosterone cypionate IM injection Testosterone gel packet Testosterone 1.62% gel pump <i>Injectable testosterone cypionate is a pharmacy benefit when self-administered. Administration in an office setting is a medical benefit.</i>	ANDROGEL (testosterone) gel packet ANDROGEL (testosterone) gel 1.62% pump ANDROID (methyltestosterone) capsule DEPO-TESTOSTERONE (testosterone cypionate) IM injection FORTESTA (testosterone) gel pump METHITEST (methyltestosterone) tablet Methyltestosterone capsule NATESTO (testosterone) nasal spray TESTIM (testosterone) gel Testosterone 1% gel tube, 30 mg/1.5 ml pump Testosterone enanthate IM injection TLANDO (testosterone undecanoate) capsules VOGELXO (testosterone) packet, pump	<p><u>Hypogonadotropic or Primary Hypogonadism (may be secondary to Klinefelter Syndrome):</u></p> <p>Preferred products may be approved for members meeting the following:</p> <ul style="list-style-type: none"> Member is a male patient ≥ 16 years of age with a documented diagnosis of hypogonadotropic or primary hypogonadism OR ≥ 12 years of age with a diagnosis of hypogonadotropic or hypogonadism secondary to Klinefelter Syndrome (all other diagnoses will require manual review) AND Member has two documented low serum testosterone levels below the lower limit of normal range for testing laboratory prior to initiation of therapy AND Member does not have a diagnosis of breast or prostate cancer AND If the member is > 40 years of age, has prostate-specific antigen (PSA) < 4 ng/mL or has no palpable prostate nodule AND Member has baseline hematocrit $< 50\%$ <p>Reauthorization Criteria (requests for renewal of a currently expiring prior authorization for a preferred product may be approved for members meeting the following criteria):</p> <ul style="list-style-type: none"> Member is a male patient ≥ 16 years of age with a documented diagnosis of hypogonadotropic or primary hypogonadism OR ≥ 12 years of age with a diagnosis of hypogonadotropic or hypogonadism secondary to Klinefelter Syndrome AND Serum testosterone is being regularly monitored (at least annually) to achieve total testosterone level in the middle tertile of the normal reference range AND Member does not have a diagnosis of breast or prostate cancer AND Member has a hematocrit $< 54\%$

	<p>XYOSTED (testosterone enanthate) SC injection</p>	<p><u>Gender Transition/Affirming Hormone Therapy:</u></p> <p>Preferred androgenic drugs may be approved for members meeting the following:</p> <ol style="list-style-type: none"> 1. Female sex assigned at birth and has reached Tanner stage 2 of puberty AND 2. Is undergoing female to male transition AND 3. Has a negative pregnancy test prior to initiation AND 4. Hematocrit (or hemoglobin) is being monitored. <p>Non-Preferred Products:</p> <p>Non-preferred topical androgenic agents may be approved for patients meeting the above criteria with trial and failed‡ therapy with two preferred topical androgen formulations.</p> <p>Non-preferred injectable androgenic agents may be approved for patients meeting the above criteria with trial and failed‡ therapy with a preferred injectable androgenic drug.</p> <p>Prior authorization for oral androgen agents (tablet, capsule, buccal) may be approved if member has trialed and failed‡ therapy with a preferred topical agent AND testosterone cypionate injection.</p> <p>‡Failure is defined as lack of efficacy with 8 week trial, allergy, intolerable side effects, contraindication to, or significant drug-drug interaction.</p> <p>For all agents and diagnoses, members < 16 years of age will require a manual prior authorization review by a pharmacist (with exception of members ≥ 12 years of age with a diagnosis of hypogonadotropic or hypogonadism secondary to Klinefelter Syndrome).</p>
--	--	---

Therapeutic Drug Class: **BONE RESORPTION SUPPRESSION AND RELATED AGENTS** -Effective 10/1/2023

Bisphosphonates

No PA Required	PA Required	
<p>Alendronate tablet, solution</p> <p>Ibandronate tablet</p> <p>Risedronate tablet</p>	<p>ACTONEL (risedronate) tablet</p> <p>ATELVIA (risedronate) tablet</p> <p>BONIVA (ibandronate) tablet</p> <p>FOSAMAX (alendronate) tablet</p> <p>FOSAMAX plus D (alendronate/vit D) tablet\</p>	<p>Non-preferred bisphosphonates may be approved for members who have failed treatment with one preferred product at treatment dose. Failure is defined as lack of efficacy with a 12-month trial, allergy, intolerable side effects, or significant drug-drug interaction.</p> <p>For members who have a low risk of fracture, discontinuation of bisphosphonate therapy and drug holiday should be considered following 5 years of treatment. Low risk is defined as having a bone mineral density, based on the most recent T-score, of greater than (better than) -2.5 AND no history of low trauma or fragility fracture.</p>

Non-Bisphosphonates

PA Required

Calcitonin salmon nasal spray
 FORTEO (teriparatide) SC pen
 Raloxifene tablet
 Teriparatide SC pen
 TYMLOS (abaloparatide) SC pen

CALCITONIN SALMON (nasal) may be approved if the member meets the following criteria:

- Member has a diagnosis of post-menopausal osteoporosis (BMD T-scores of -2.5 or less)

AND

- Has trial and failure of preferred bisphosphonate for 12 months (failure is defined as: lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction) **OR**
- Member cannot swallow solid oral dosage forms or has a feeding tube.

Quantity limit: One spray daily

RALOXIFENE may be approved if the member meets the following criteria:

- Diagnosis of postmenopausal osteoporosis (BMD T-scores of -2.5 or less) **AND**
- Has trial and failure of preferred bisphosphonate for one year (Failure is defined as: lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction)

Maximum dose: 60mg daily

FORTEO (teriparatide) or generic teriparatide may be approved if the member meets the following criteria:

- Member has one of the following diagnoses:
 - Male primary or hypogonadal osteoporosis (BMD T-scores of -2.5 or less).
 - Osteoporosis due to corticosteroid use
 - Postmenopausal osteoporosis

AND

- Member is at very high risk for fracture* **OR** member has history of trial and failure of a preferred bisphosphonate for one year. Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction **AND**
- For brand FORTEO, member has trialed and failed generic teriparatide. Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction **AND**
- Prior authorization will be given for one year and total exposure of parathyroid hormone analogs (Forteo and Tymlos) shall not exceed two years

Maximum dose: 20mcg daily

TYMLOS (abaloparatide) may be approved if the member meets the following criteria:

- Member has a diagnosis of postmenopausal osteoporosis (BMD T-scores of -2.5 or less)

AND

- Member is post-menopausal with very high risk for fracture* **OR** member has history of trial and failure of a preferred bisphosphonate for one year (Failure is defined as: lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction) **AND**
- Prior authorization will be given for one year and total exposure of parathyroid hormone analogs (Forteo and Tymlos) shall not exceed two years.

Maximum dose: 80 mcg daily

All other non-preferred non-bisphosphonates may be approved for members who have failed treatment with one preferred bisphosphonate product at treatment dose. Failure is defined as lack of

		<p>efficacy with a 12-month trial, allergy, unable to use oral therapy, intolerable side effects, or significant drug-drug interaction.</p> <p>*Members at very high risk for fracture: Members will be considered at very high risk for fracture if they meet <u>one</u> of the following:</p> <ul style="list-style-type: none"> • A history of fracture within the past 12 months OR • Fractures experienced while receiving guideline-supported osteoporosis therapy OR • A history of multiple fractures OR • A history of fractures experienced while receiving medications that cause skeletal harm (such as long-term glucocorticoids) OR • A very low T-score (less than -3.0) OR • A high risk for falls or a history of injurious falls OR • A very high fracture probability by FRAX (> 30% for a major osteoporosis fracture or > 4.5% for hip fracture) <p><i>Note: Prior authorization criteria for Prolia (denosumab) and other injectable bone resorption and related agents are listed on Appendix P.</i></p>
--	--	--

Therapeutic Drug Class: CONTRACEPTIVES - Topical Effective 10/1/2023

Effective 01/14/22, topical contraceptive patch products are eligible for coverage with a written prescription by an enrolled pharmacist. Additional information regarding pharmacist enrollment can be found at <https://hcpf.colorado.gov/pharm-serv>.

No PA Required	PA Required	
<p>ANNOVERA (segesterone acetate/EE) vaginal ring</p> <p>NUVARING^{BNR} (etonogestrel/EE) vaginal ring</p> <p>PHEXXI (lactic acid/citric/potassium) vaginal gel</p> <p>TWIRLA (levonorgestrel/EE) TD patch</p> <p>XULANE (norelgestromin/EE) TD patch</p> <p>*EE – Ethinyl Estradiol</p>	<p>ELURYNG (Etonogestrel/EE) vaginal ring</p> <p>Etonogestrel/EE vaginal ring</p> <p>ZAFEMY (norelgestromin/EE) TD patch</p> <p>*EE – Ethinyl Estradiol</p> <p>Haloette vaginal ring</p>	<p>Non-preferred topical contraceptive products may be approved following a trial and failure of one preferred topical contraceptive product. Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction.</p> <p>Effective 7/1/2022: Prescriptions are eligible to be filled for up to a twelve-month supply.</p> <p><i>Note: IUD and select depot product formulations are billed through the medical benefit</i></p>

Therapeutic Drug Class: **DIABETES MANAGEMENT CLASSES, INSULINS**- *Effective 10/1/2023*

Rapid-Acting

No PA Required	PA Required	
<p>HUMALOG (insulin lispro) 100U/mL, vial, pen</p> <p>HUMALOG (insulin lispro) KwikPen, cartridge</p> <p>HUMALOG Jr. (insulin lispro) KwikPen^{BNR}</p> <p>Insulin aspart cartridge, pen, vial</p> <p>Insulin lispro vial</p> <p>NOVOLOG (insulin aspart) cartridge, vial, FlexTouch pen</p>	<p>ADMELOG (insulin lispro) Solostar pen, vial</p> <p>AFREZZA (regular insulin) cartridge, unit</p> <p>APIDRA (insulin glulisine) Solostar pen, vial</p> <p>FIASP (insulin aspart) FlexTouch pen, PenFill, vial</p> <p>HUMALOG (insulin lispro) 200 U/mL pen</p> <p>LYUMJEV (insulin lispro-aabc) Kwikpen, vial, Tempo pen</p> <p>Insulin lispro pen</p> <p>Insulin lispro, Jr. Kwikpen</p>	<p>Non-preferred products may be approved following trial and failure of treatment with two preferred products, one of which is the same rapid-acting insulin analog (lispro or aspart) as the non-preferred product being requested. (Failure is defined as allergy [hives, maculopapular rash, erythema multiforme, pustular rash, severe hypotension, bronchospasm, and angioedema] or intolerable side effects).</p> <p>Afrezza (human insulin) may be approved if meeting the following criteria:</p> <ul style="list-style-type: none"> • Member is 18 years or older AND • Member has trialed and failed treatment with two preferred products (failure is defined as allergy [hives, maculopapular rash, erythema multiforme, pustular rash, severe hypotension, bronchospasm, or angioedema] or intolerable side effects) AND • Member must not have chronic lung disease such as COPD or asthma AND • If member has type 1 diabetes, must use in conjunction with long-acting insulin AND • Prescriber acknowledges that Afrezza is not recommended in patients who smoke or have recently stopped smoking.

Short-Acting

No PA Required	PA Required	
<p>HUMULIN R U-100 (insulin regular) vial (OTC)</p> <p>NOVOLIN R U-100 (insulin regular) FlexPen (OTC)</p>	<p>NOVOLIN R U-100 (insulin regular) vial (OTC)</p>	<p>Non-preferred products may be approved following trial and failure of treatment with one preferred product (failure is defined as allergy or intolerable side effects).</p>

Intermediate-Acting

No PA Required	PA Required	
<p>HUMULIN N U-100 (insulin NPH) vial (OTC)</p> <p>NOVOLIN N U-100 (insulin NPH) FlexPen (OTC)</p>	<p>HUMULIN N U-100 (insulin NPH) KwikPen (OTC)</p> <p>NOVOLIN N U-100 (insulin NPH) vial (OTC)</p>	<p>Non-preferred products may be approved following trial and failure of treatment with one preferred product (failure is defined as allergy or intolerable side effects).</p>

Long Acting

No PA Required	PA Required	
<p>LANTUS (insulin glargine) vial, Solostar</p> <p>LEVEMIR (insulin detemir) vial, FlexTouch</p>	<p>BASAGLAR (insulin glargine) KwikPen, Tempo pen</p> <p>Insulin degludec FlexTouch, vial</p> <p>Insulin glargine vial, solostar</p>	<p>Non-preferred products may be approved if the member has failed treatment with Levemir AND Lantus (failure is defined as lack of efficacy, allergy or intolerable side effects).</p>

	REZOGLAR (insulin glargine-aglr) Kwikpen SEMGLEE (insulin glargine-yfgn) pen, vial TOUJEO (insulin glargine) Solostar TOUJEO MAX (insulin glargine) Solostar TRESIBA (insulin degludec) FlexTouch, vial	
Concentrated		
No PA Required	PA Required	
HUMULIN R U-500 (insulin regular) concentrated vial, Kwikpen		Non-preferred products may be approved following trial and failure of treatment with one preferred product (failure is defined as allergy or intolerable side effects).
Mixtures		
No PA Required	PA Required	
HUMALOG MIX 50/50 Kwikpen, vial HUMALOG MIX 75/25 Kwikpen ^{BNR} , vial HUMULIN 70/30 (OTC) Kwikpen, vial Insulin aspart protamine/insulin aspart 70/30 FlexPen, vial (generic Novolog Mix) NOVOLOG MIX 70/30 FlexPen, vial	NOVOLIN 70/30 FlexPen, vial (OTC) Insulin lispro protamine/insulin lispro 75/25 Kwikpen (generic Humalog Mix)	Non-preferred products may be approved if the member has failed treatment with two of the preferred products (failure is defined as: allergy or intolerable side effects).
Therapeutic Drug Class: DIABETES MANAGEMENT CLASSES, NON- INSULINS- 10/1/2023		
Amylin		
	PA Required	
	SYMLIN (pramlintide) pen	SYMLIN (pramlintide) may be approved following trial and failure of metformin AND trial and failure of a DPP4-inhibitor or GLP-1 analogue. Failure is defined as lack of efficacy (such as not meeting hemoglobin A1C goal despite adherence to regimen) following 3-month trial, allergy, intolerable side effects, or a significant drug-drug interaction. Prior authorization may be approved for Symlin (pramlintide) products for members with a diagnosis of Type 1 diabetes without requiring trial and failure of other products. Maximum Dose: Prior authorization will be required for doses exceeding FDA-approved dosing listed in product package labeling.

Biguanides

No PA Required	PA Required	
Metformin IR tablets Metformin ER 500mg, 750mg tablets (generic Glucophage XR)	FORTAMET ER (metformin) tablet GLUMETZA ER (metformin) tablet Metformin ER (generic Fortamet, Glumetza) RIOMET (metformin) solution RIOMET ER (metformin) suspension	Non-preferred products may be approved for members who have failed treatment with two preferred products. Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction. Liquid metformin may be approved for members who meet one of the following: <ul style="list-style-type: none"> • Member is under the age of 12 with a feeding tube OR Prescriber confirms that member has difficulty swallowing

Dipeptidyl Peptidase-4 Enzyme inhibitors (DPP-4is)

Preferred	Non-Preferred PA Required													
JANUVIA (sitagliptin) tablet TRADJENTA (linagliptin) tablet	Alogliptin tablet NESINA (alogliptin) tablet ONGLYZA (saxagliptin) tablet Saxagliptin tablet	Non-preferred DPP-4 inhibitors may be approved after a member has failed a 3-month trial of two preferred products. Failure is defined as lack of efficacy (such as not meeting hemoglobin A1C goal despite adherence to regimen), allergy, intolerable side effects, or a significant drug-drug interaction. <u>Maximum Dose:</u> Prior authorization will be required for doses exceeding the FDA-approved maximum dosing listed in the following table: <table border="1" style="margin-left: auto; margin-right: auto; border-collapse: collapse; width: 80%;"> <thead> <tr> <th style="text-align: center;">DPP-4 Inhibitor</th> <th style="text-align: center;">FDA-Approved Maximum Daily Dose</th> </tr> </thead> <tbody> <tr> <td>Alogliptin (generic Nesina)</td> <td style="text-align: center;">25 mg/day</td> </tr> <tr> <td>Januvia (sitagliptin)</td> <td style="text-align: center;">100 mg/day</td> </tr> <tr> <td>Nesina (alogliptin)</td> <td style="text-align: center;">25 mg/day</td> </tr> <tr> <td>Onglyza (saxagliptin)</td> <td style="text-align: center;">5 mg/day</td> </tr> <tr> <td>Tradjenta (linagliptin)</td> <td style="text-align: center;">5 mg/day</td> </tr> </tbody> </table>	DPP-4 Inhibitor	FDA-Approved Maximum Daily Dose	Alogliptin (generic Nesina)	25 mg/day	Januvia (sitagliptin)	100 mg/day	Nesina (alogliptin)	25 mg/day	Onglyza (saxagliptin)	5 mg/day	Tradjenta (linagliptin)	5 mg/day
DPP-4 Inhibitor	FDA-Approved Maximum Daily Dose													
Alogliptin (generic Nesina)	25 mg/day													
Januvia (sitagliptin)	100 mg/day													
Nesina (alogliptin)	25 mg/day													
Onglyza (saxagliptin)	5 mg/day													
Tradjenta (linagliptin)	5 mg/day													

DPP-4 Inhibitors – Combination with Metformin

Preferred	Non-Preferred PA Required	
JANUMET (sitagliptin/metformin) tablet JANUMET XR (sitagliptin/metformin) tablet JENTADUETO (linagliptin/metformin) tablet JENTADUETO XR (linagliptin/metformin) tablet	Alogliptin/metformin tablet KAZANO (alogliptin/metformin) tablet KOMBIGLYZE XR (saxagliptin/metformin) Saxagliptin/metformin tablet	Non-preferred combination products may be approved for members who have been stable on the two individual ingredients of the requested combination for three months AND have had adequate three-month trial and failure of a preferred combination agent. Failure is defined as lack of efficacy (such as not meeting hemoglobin A1C goal despite adherence to regimen), allergy, intolerable side effects, or a significant drug-drug interaction.

Maximum Dose:

Prior authorization will be required for doses exceeding the FDA-approved maximum dosing listed in the following table:

DPP-4 Inhibitor Combination	FDA Approved Maximum Daily Dose
Alogliptin/metformin tablet	25 mg alogliptin/2,000 mg metformin
Janumet and Janumet XR (sitagliptin/metformin)	100 mg sitagliptin/2,000 mg of metformin
Jentadueto and Jentadueto XR(linagliptin/metformin)	5 mg linagliptin/2,000 mg metformin
Kazano (alogliptin/metformin)	25 mg alogliptin/ 2,000 mg metformin
Kombiglyze XR (saxagliptin ER/metformin ER) tablet	5 mg saxagliptin/2,000 mg metformin

Glucagon-like Peptide-1 Receptor Agonists (GLP-1 Analogues)

Preferred
***Must meet eligibility criteria**

*BYETTA (exenatide) pen
 *TRULICITY (dulaglutide) pen
 *VICTOZA (liraglutide) pen

Non-Preferred PA Required

ADLYXIN (lixisenatide)
 BYDUREON BCISE (exenatide ER) autoinjector
 MOUNJARO (tirzepatide) pen
 OZEMPIC (semaglutide) pen
 RYBELSUS (semaglutide) oral tablet

*Preferred products may be approved for members with a diagnosis of type 2 diabetes.

Non-preferred products may be approved for members with a diagnosis of type 2 diabetes following a 3-month trial of two preferred products. Failure is defined as lack of efficacy (such as not meeting hemoglobin A1C goal despite adherence to regimen), allergy, intolerable side effects, limited dexterity resulting in the inability to administer doses of a preferred product, or a significant drug-drug interaction.

Maximum Dose:
 Prior authorization is required for all products exceeding maximum dose listed in product package labeling.

Adlyxin (lixisenatide)	20 mcg per day
Bydureon Bcise (exenatide)	2 mg weekly
Byetta (exenatide)	20 mcg per day
Mounjaro (tirzepatide)	15 mg weekly
Ozempic (semaglutide)	2 mg weekly
Rybelsus (semaglutide)	14 mg daily
Trulicity (dulaglutide)	4.5 mg weekly
Victoza (liraglutide)	1.8 mg per day

Note: Prior Authorization for GLP-1 analogues prescribed solely for weight loss will not be approved.

Other Hypoglycemic Combinations

	PA Required	
	<p>Alogliptin/pioglitazone tablet</p> <p>DUETACT (pioglitazone/glimepiride) tablet</p> <p>Glipizide/metformin tablet</p> <p>Glyburide/metformin tablet</p> <p>GLYXAMBI (empagliflozin/linagliptin) tablet</p> <p>OSENI (alogliptin/pioglitazone) tablet</p> <p>Pioglitazone/glimepiride tablet</p> <p>QTERN (dapagliflozin/saxagliptin) tablet</p> <p>SOLIQUA (insulin glargine/lixisenatide) pen</p> <p>STEGLUJAN (ertugliflozin/sitagliptin) tablet</p> <p>TRIJARDY XR tablet(empagliflozin/linagliptin/metformin)</p> <p>XULTOPHY (insulin degludec/liraglutide) pen</p>	<p>Non-preferred products may be approved for members who have been stable on each of the individual ingredients in the requested combination for 3 months (including cases where the ingredients are taken as two separate 3-month trials or when taken in combination for at least 3 months).</p>

Meglitinides

	PA Required	
	<p>Nateglinide tablet</p> <p>Repaglinide tablet</p>	<p>Non-preferred products may be approved for members who have failed treatment with one sulfonylurea. Failure is defined as: lack of efficacy (such as not meeting hemoglobin A1C goal despite adherence to regimen), allergy, intolerable side effects, or significant drug-drug interaction.</p>

Meglitinides Combination with Metformin

	PA Required	
	<p>Repaglinide/metformin</p>	<p>Non-preferred products may be approved for members who have been stable on the two individual ingredients of the requested combination for 3 months.</p>

Sodium-Glucose Cotransporter Inhibitors (SGLT inhibitors)

No PA Required	PA Required	
<p>FARXIGA (dapagliflozin) tablet</p> <p>INVOKANA (canagliflozin) tablet</p>	<p>INPEFA (sotagliflozin) tablet</p> <p>STEGLATRO (ertugliflozin) tablet</p>	<p>Non-preferred products may receive approval following trial and failure with two preferred products. Failure is defined as lack of efficacy with 3-month trial (such as not meeting hemoglobin A1C goal despite adherence to regimen), allergy, intolerable side effects, or a significant drug-drug interaction.</p>

JARDIANCE (empagliflozin) tablet	SGLT Inhibitor Renal Dosing Recommendations		
	SGLT Inhibitor	Clinical Setting	
	Renal Dosing Recommendations (FDA labeling)		
	FARXIGA (dapagliflozin)	Glycemic control in patients without established CV disease or CV risk factors	Not recommended when eGFR is <45 mL/min/1.73 m ²
		Chronic kidney disease (CKD) or heart failure (HF)	Initiation of therapy not recommended when eGFR is <25 mL/min/1.73 m ² (safety and efficacy in members on dialysis has not been established)
	INPEFA (sotagliflozin)	Reduce risk of CV death, HF hospitalization and urgent HF visit in adults with HF or Type 2 DM, CKD and other CV risk factors	Safety and efficacy in members with eGFR less than 25 mL/min/1.73 m ² or on dialysis has not been established
	INVOKANA (canagliflozin)	Glycemic control in patients without established CV disease or CV risk factors	Initiation of therapy not recommended when eGFR is <30 mL/min/1.73 m ²
	JARDIANCE (empagliflozin)	Glycemic control in patients without established CV disease or CV risk factors	Not recommended when eGFR is <30 mL/min/1.73 m ² (contraindicated in members on dialysis)
Chronic kidney disease (CKD) or heart failure (HF)		Not recommended when eGFR is < 20 mL/min/1.73 m ² (Contraindicated in members on dialysis)	
STEGLATRO (ertugliflozin)	Adjunct to diet and exercise in members with Type 2 DM	Not recommended when eGFR is <45 mL/min/1.73 m ² (contraindicated in members on dialysis)	
<p><u>Maximum Dose:</u> Prior authorization is required for all products exceeding maximum dose listed in product package labeling.</p>			
SGLT Inhibitor Combinations with Metformin			
No PA Required	PA Required		
INVOKAMET (canagliflozin/metformin) tablet INVOKAMET XR (canagliflozin/metformin) tablet	SEGLUOMET (ertugliflozin/metformin) tablet	Non-preferred products may be approved for members who have been stable on the two individual ingredients of the requested combination for 3 months. INVOKAMET, INVOKAMET XR, SEGLUOMET, SYNJARDY, SYNJARDY XR and XIGDUO XR are contraindicated in patients with an eGFR less than 30 mL/min/1.73 m ² or on dialysis.	

SYNJARDY (empagliflozin/metformin) tablet SYNJARDY XR (empagliflozin/metformin) tablet XIGDUO XR (dapagliflozin/metformin) tablet																		
Thiazolidinediones (TZDs)																		
No PA Required Pioglitazone tablet	PA Required ACTOS (pioglitazone) tablet	Non-preferred agents may be approved following trial and failure of one preferred product. Failure is defined as lack of efficacy (such as not meeting hemoglobin A1C goal despite adherence to regimen) with a 3-month trial, allergy, intolerable side effects, or a significant drug-drug interaction.																
Thiazolidinediones Combination with Metformin																		
	PA Required ACTOPLUS MET (pioglitazone/metformin) TABLET Pioglitazone/metformin tablet	Non-preferred products may be approved for members who have been stable on the two individual ingredients of the requested combination for 3 months.																
Therapeutic Drug Class: ESTROGEN AGENTS -Effective 10/1/2023																		
No PA Required	PA Required	Non-preferred parenteral estrogen agents may be approved with trial and failure of one preferred parenteral agent. Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction.																
Parenteral																		
DELESTROGEN ^{BNR} (estradiol valerate) vial DEPO-ESTRODIOL (estradiol cypionate) vial	Estradiol valerate vial	Non-preferred oral estrogen agents may be approved with trial and failure of one preferred oral agent. Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction.																
Oral/Transdermal																		
CLIMARA ^{BNR} (estradiol) patch Estradiol oral tablet MINIVELLE ^{BNR} (estradiol) patch VIVELLE-DOT ^{BNR} (estradiol) patch	ALORA (estradiol) patch DOTTI (estradiol) patch ESTRACE (estradiol) oral tablet Estradiol daily patch Estradiol bi-weekly patch LYLLANA (estradiol) patch	Non-preferred transdermal estrogen agents may be approved with trial and failure of two preferred transdermal agents. Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction. <table border="1" data-bbox="1146 1187 1980 1515" style="margin-top: 20px;"> <thead> <tr> <th colspan="2" data-bbox="1146 1187 1980 1224" style="text-align: center;">Table 1: Transdermal Estrogen FDA-Labeled Dosing</th> </tr> </thead> <tbody> <tr> <td data-bbox="1146 1224 1766 1268">ALORA (estradiol) patch</td> <td data-bbox="1766 1224 1980 1268" style="text-align: center;">2/week</td> </tr> <tr> <td data-bbox="1146 1268 1766 1312">CLIMARA (estradiol) patch</td> <td data-bbox="1766 1268 1980 1312" style="text-align: center;">1/week</td> </tr> <tr> <td data-bbox="1146 1312 1766 1356">DOTTI (estradiol) patch</td> <td data-bbox="1766 1312 1980 1356" style="text-align: center;">2/week</td> </tr> <tr> <td data-bbox="1146 1356 1766 1399">Estradiol patch (once weekly)</td> <td data-bbox="1766 1356 1980 1399" style="text-align: center;">1/week</td> </tr> <tr> <td data-bbox="1146 1399 1766 1443">Estradiol patch (twice weekly)</td> <td data-bbox="1766 1399 1980 1443" style="text-align: center;">2/week</td> </tr> <tr> <td data-bbox="1146 1443 1766 1487">LYLLANA (estradiol) patch</td> <td data-bbox="1766 1443 1980 1487" style="text-align: center;">2/week</td> </tr> <tr> <td data-bbox="1146 1487 1766 1515">MENOSTAR (estradiol) patch</td> <td data-bbox="1766 1487 1980 1515" style="text-align: center;">1/week</td> </tr> </tbody> </table>	Table 1: Transdermal Estrogen FDA-Labeled Dosing		ALORA (estradiol) patch	2/week	CLIMARA (estradiol) patch	1/week	DOTTI (estradiol) patch	2/week	Estradiol patch (once weekly)	1/week	Estradiol patch (twice weekly)	2/week	LYLLANA (estradiol) patch	2/week	MENOSTAR (estradiol) patch	1/week
Table 1: Transdermal Estrogen FDA-Labeled Dosing																		
ALORA (estradiol) patch	2/week																	
CLIMARA (estradiol) patch	1/week																	
DOTTI (estradiol) patch	2/week																	
Estradiol patch (once weekly)	1/week																	
Estradiol patch (twice weekly)	2/week																	
LYLLANA (estradiol) patch	2/week																	
MENOSTAR (estradiol) patch	1/week																	

	MENOSTAR (estradiol) patch	MINIVELLE (estradiol) patch	2/week
		VIVELLE-DOT (estradiol) patch	2/week

Note: Estrogen agents are a covered benefit for gender affirming hormone therapy and treating clinicians and mental health providers should be knowledgeable about the diagnostic criteria for gender-affirming hormone treatment and have sufficient training and experience in assessing related mental health conditions.

Therapeutic Drug Class: GLUCAGON, SELF-ADMINISTERED -Effective 10/1/2023

Preferred No PA Required	Non-Preferred PA Required	<p>Non-preferred products may be approved if the member has failed treatment with two preferred products (failure is defined as allergy to ingredients in product, intolerable side effects, contraindication, or inability to administer dosage form).</p> <p>Quantity limit for all products: 2 doses per year unless used/ damaged/ lost</p>
<p>BAQSIMI (glucagon) nasal spray</p> <p>GLUCAGEN HYPOKIT (glucagon)</p> <p>Glucagon Emergency Kit (<i>Eli Lilly</i>)</p> <p>Glucagon Emergency Kit (<i>Amphastar</i>)</p> <p>ZEGALOGUE (dasiglucagon) autoinjector</p>	<p>Glucagon Emergency Kit (<i>Fresenius</i>)</p> <p>GVOKE (glucagon) Hypopen, Syringe, vial</p> <p>ZEGALOGUE (dasiglucagon) syringe</p>	

Therapeutic Drug Class: GROWTH HORMONES -Effective 10/1/2023

Preferred No PA Required (If diagnosis and dose met)	Non-Preferred PA Required	<p>All preferred products may be approved if the member has one of the qualifying diagnoses listed below (diagnosis may be verified through AutoPA) AND if prescription does not exceed limitations for maximum dosing (Table 1).</p> <p>Non-preferred Growth Hormone products may be approved if the following criteria are met:</p> <ul style="list-style-type: none"> • Member failed treatment with one preferred growth hormone product (failure is defined as lack of efficacy, allergy, intolerable side effects or significant drug-drug interactions) AND • Member has a qualifying diagnosis that includes at least one of the following conditions: <ul style="list-style-type: none"> ▪ Prader-Willi Syndrome (PWS) ▪ Chronic renal insufficiency/failure requiring transplantation (defined as Creatinine Clearance < 30mL/min) ▪ Turner's Syndrome ▪ Hypopituitarism: as a result of pituitary disease, hypothalamic disease, surgery, radiation therapy or trauma verified by one of the following: <ul style="list-style-type: none"> ○ Has failed at least one GH stimulation test (peak GH level < 10 ng/mL) ○ Has at least one documented low IGF-1 level (below normal range for patient's age – refer to range on submitted lab document) ○ Has deficiencies in ≥ 3 pituitary axes (such as TSH, LH, FSH, ACTH, ADH)
<p>GENOTROPIN (somatropin) cartridge, Miniquick pen</p> <p>NORDITROPIN (somatropin) Flexpro pen</p>	<p>HUMATROPE (somatropin) cartridge</p> <p>NUTROPIN AQ (somatropin) Nuspin injector</p> <p>OMNITROPE (somatropin) cartridge, vial</p> <p>SAIZEN (somatropin) cartridge, vial</p> <p>SEROSTIM (somatropin) vial</p> <p>SKYTROFA (lonapegsomatropin-tcgd) cartridge</p> <p>SOGROYA (somapacitan-beco) pen</p> <p>ZOMACTON (somatropin) vial</p> <p>ZORBTIVE (somatropin) vial</p>	

- Cachexia associated with AIDS
- Noonan Syndrome
- Short bowel syndrome
- Neonatal symptomatic growth hormone deficiency (limited to 3-month PA approval)

AND

- Prescription does not exceed limitations for FDA-labeled maximum dosing for prescribed indication (Table 1) based on prescriber submission/verification of patient weight from most recent clinical documentation

Table 1: Growth Hormone Product Maximum Dosing*		
Medication	Pediatric Maximum Dosing (age < 18 years)	Adult Maximum Dosing (age ≥ 18 years)
Genotropin	0.48 mg/kg/week	0.08 mg/kg/week
Humatrope	0.47 mg/kg/week	0.0875 mg/kg/week
Norditropin Flexpro	0.47 mg/kg/week	0.112 mg/kg/week
Nutropin AQ Nuspin	0.375 mg/kg/week	0.175 mg/kg/week for ≤35 years of age 0.0875 mg/kg/week for >35 years of age
Omnitrope	0.48 mg/kg/week	0.08 mg/kg/week
Saizen	0.18 mg/kg/week	0.01 mg/kg/day
Serostim	Not Indicated	42 mg/week for cachexia with HIV only (in combination with antiretroviral therapy)
Skytrofa	0.2625 mg/kg/week	N/A
Zomacton	0.47 mg/kg/week	0.0125 mg/kg/day
Zorbitive	Not Indicated	8 mg/28 days for short bowel syndrome only

*Based on FDA labeled indications and dosing

VII. Gastrointestinal

Therapeutic Drug Class: **BILE SALTS** -Effective 7/1/2023

No PA Required	PA Required	
<p>Ursodiol capsule</p> <p>Ursodiol tablet</p>	<p>BYLVAY (odevixibat) capsule, pellet</p> <p>CHENODAL (chenodiol) tablet</p> <p>CHOLBAM (cholic acid) capsule</p> <p>LIVMARLI (maralixibat) solution</p> <p>OCALIVA (obeticholic acid) tablet</p> <p>RELTONE (ursodiol) capsule</p> <p>URSO (ursodiol) tablet</p> <p>URSO FORTE (ursodiol) tablet</p>	<p>Chenodal (chenodiol) and Actigall (ursodiol) may be approved for members who meet the following criteria:</p> <ul style="list-style-type: none"> • Member is \geq 18 years of age AND • Member has tried and failed therapy with a 12-month trial of a preferred ursodiol product (failure is defined as lack of efficacy, allergy, intolerable side effects or significant drug-drug interactions). <p>Cholbam (cholic acid) may be approved for members who meet the following criteria:</p> <ul style="list-style-type: none"> • Bile acid synthesis disorders: <ul style="list-style-type: none"> ○ Member age must be greater than 3 weeks old AND ○ Member has a diagnosis for bile acid synthesis disorder due to single enzyme defect (Single Enzyme-Defect Disorders: Defective sterol nucleus synthesis, 3β-hydroxy-Δ-c27-steroid oxidoreductase deficiency, AKR1D1 deficiency, CYP7A1 deficiency, Defective side-chain synthesis, CYP27A1 deficiency (cerebrotendinous xanthomatosis), 2-methylacyl-CoA racemase deficiency (AMACR), 25-hydroxylation pathway (Smith–Lemli–Opitz). • Peroxisomal disorder including Zellweger spectrum disorders: <ul style="list-style-type: none"> ○ Member age must be greater than 3 weeks old AND ○ Member has diagnosis of peroxisomal disorders (PDs) including Zellweger spectrum disorders AND ○ Member has manifestations of liver disease, steatorrhea or complications from decreased fat-soluble vitamin absorption. <p>Ocaliva (obeticholic acid) may be approved for members meeting the following criteria:</p> <ul style="list-style-type: none"> • Member is \geq 18 years of age AND • Medication is prescribed by or in consultation with a gastroenterologist, hepatologist, or liver transplant provider AND • Member has the diagnosis of primary biliary cholangitis without cirrhosis OR a diagnosis of primary biliary cholangitis with compensated cirrhosis with no evidence of portal hypertension AND • Member has failed treatment with a preferred ursodiol product for at least 6 months due to an inadequate response, intolerable side effects, drug-drug interaction, or allergy to preferred ursodiol formulations. <p>Reltone (ursodiol) may be approved for members meeting the following criteria:</p> <ul style="list-style-type: none"> • Member is \geq 18 years of age AND • The requested medication is prescribed by or in consultation with a gastroenterologist, hepatologist, or liver transplant provider AND • The requested medication is being prescribed for one of the following: <ul style="list-style-type: none"> ○ Treatment of radiolucent, noncalcified gallbladder stones < 20 mm in greatest diameter AND elective cholecystectomy would be undertaken

except for the presence of increased surgical risk due to systemic disease, advanced age, idiosyncratic reaction to general anesthesia, or for those patients who refuse surgery OR

- Prevention of gallstone formation in obese patients experiencing rapid weight loss

AND

- No compelling reasons for the member to undergo cholecystectomy exist, including unremitting acute cholecystitis, cholangitis, biliary obstruction, gallstone pancreatitis, or biliary-gastrointestinal fistula, **AND**
- Member has trialed and failed treatment with a preferred ursodiol product for at least 6 months due to an inadequate response, intolerable side effects, drug-drug interaction, or allergy to inactive ingredients contained in the preferred ursodiol formulations.

Initial approval: 1 year

Reauthorization: May be reauthorized for 1 additional year with provider attestation that partial or complete stone dissolution was observed after completion of the initial year of Reltone therapy. Maximum cumulative approval per member is 24 months.

Urso (ursodiol) and Urso Forte (ursodiol) may be approved for members meeting the following criteria:

- Member is ≥ 18 years of age AND
- Medication is prescribed by or in consultation with a gastroenterologist, hepatologist, or liver transplant provider AND
- Member has the diagnosis of Primary Biliary Cholangitis as evidenced by two of the following at the time of diagnosis:
 - Evidence of cholestasis with an alkaline phosphatase elevation of at least 1.5 times the upper limit of normal
 - Presence of antimitochondrial antibody with titer of 1:40 or higher
 - Histologic evidence of nonsuppurative destruction cholangitis and destruction of interlobular bile ducts AND
- Member has failed treatment with a preferred ursodiol product for at least 6 months due to an inadequate response, intolerable side effects, drug-drug interaction, or allergy to inactive ingredients contained in the preferred ursodiol formulations.

Requests for drug products that are FDA-indicated for the treatment of nonalcoholic steatohepatitis (NASH) may be approved if meeting the following:

- A diagnosis of NASH has been confirmed through liver biopsy AND
- Member meets the FDA-labeled minimum age requirement for the prescribed product AND
- Member does not have significant liver disease other than NASH, AND
- The requested medication is being prescribed for use for the FDA-labeled

		<p>indication and as outlined in product package labeling AND</p> <ul style="list-style-type: none"> Medication is prescribed by or in consultation with a gastroenterologist, hepatologist, or liver transplant provider. <p>Non-preferred products prescribed for FDA-labeled indications not identified above may receive approval for use as outlined in product package labeling.</p>
Therapeutic Drug Class: ANTI-EMETICS, Oral -Effective 7/1/2023		
No PA Required	PA Required	
DICLEGIS DR ^{BNR} tablet (doxylamine/pyridoxine)	AKYNZEO (netupitant/palonosetron) capsule	<p>Emend (aprepitant) TriPack or Emend (aprepitant) powder kit may be approved following trial and failure of two preferred products AND Emend (aprepitant) capsule. Failure is defined as lack of efficacy with 14-day trial, allergy, intolerable side effects, or significant drug-drug interaction.</p> <p>Doxylamine/pyridoxine tablet (generic) or Bonjesta (doxylamine/pyridoxine) may be approved for 9 months if meeting the following criteria:</p> <ul style="list-style-type: none"> Member has nausea and vomiting associated with pregnancy AND Member has trialed and failed DICLEGIS DR tablet AND one of the following (failure is defined as lack of efficacy with a 7-day trial, allergy, intolerable side effects, or significant drug-drug interaction): <ul style="list-style-type: none"> Antihistamine (such as diphenhydramine, dimenhydrinate, meclizine) OR Dopamine antagonist (such as metoclopramide, prochlorperazine, promethazine) OR Serotonin antagonist (ondansetron, granisetron) <p>All other non-preferred products may be approved for members who have trialed and failed treatment with two preferred products. Failure is defined as lack of efficacy with 14-day trial, allergy, intolerable side effects, or significant drug-drug interaction.</p> <p>Dronabinol prior authorization may be approved for members meeting above non-preferred criteria OR via AutoPA for members with documented HIV diagnosis.</p> <p>Promethazine product formulations require prior authorization for members < 2 years of age due to risk of fatal respiratory depression.</p>
Meclizine (Rx) 12.5 mg, 25 mg tablet	ANTIVERT (meclizine) 50 mg tablet	
Metoclopramide solution, tablet	Aprepitant capsule, tripack	
Ondansetron ODT, tablet	BONJESTA ER (doxylamine/pyridoxine) tablet	
Ondansetron oral suspension/ solution	Doxylamine/pyridoxine tablet (generic Diclegis)	
Prochlorperazine tablet	Dronabinol capsule	
Promethazine syrup, tablet	EMEND (aprepitant) capsule, powder for suspension, dose/tri pack	
Trimethobenzamide capsule	Granisetron tablet	
	MARINOL (dronabinol) capsule	
	Metoclopramide ODT	
	REGLAN (metoclopramide) tablet	
	TIGAN (trimethobenzamide) capsule	
	ZOFRAN (ondansetron) tablet	

Therapeutic Drug Class: ANTI-EMETICS, Non-Oral -Effective 7/1/2023		
No PA Required	PA Required	Non-preferred products may be approved for members who have trialed and failed treatment with two preferred products. Failure is defined as lack of efficacy with 14-day trial, allergy, intolerable side effects, or significant drug-drug interaction.
Prochlorperazine 25 mg suppository	COMPRO (Prochlorperazine) suppository	
Promethazine 12.5 mg, 25 mg suppository	PROMETHEGAN 50 mg (Promethazine) suppository	
Scopolamine patch	SANCUSO (granisetron) patch	
	TRANSDERM-SCOP (scopolamine) patch	
Therapeutic Drug Class: GI MOTILITY, CHRONIC -Effective 7/1/2023		
PA Required for all agents in this class		All agents will only be approved for FDA labeled indications and up to FDA approved maximum doses listed below.
Preferred	Non-Preferred	<p>Preferred agents may be approved if the member meets the following criteria:</p> <ul style="list-style-type: none"> • Has diagnosis of Irritable Bowel Syndrome – Constipation (IBS-C), Chronic Idiopathic Constipation (CIC), or Opioid Induced Constipation (OIC) in patients with opioids prescribed for noncancer pain AND • Member does not have a diagnosis of GI obstruction AND • For indication of OIC, member opioid use must exceed 4 weeks of treatment • For indications of CIC, OIC, IBS-C; member must have documentation of adequate trial of two or more over-the-counter motility agents (polyethylene glycol, docusate or bisacodyl, for example). OR If the member cannot take oral medications, then the member must fail a 7-day trial with a nonphosphate enema (docusate or bisacodyl enema). Failure is defined as a lack of efficacy for a 7-day trial, allergy, intolerable side effects, contraindication to, or significant drug-drug interaction AND • For indication of IBS-D, must have documentation of adequate trial and failure with loperamide and trial and failure with dicyclomine or hyoscyamine. Failure is defined as a lack of efficacy for a 7-day trial, allergy, intolerable side effects, contraindication to, or significant drug-drug interaction. <p>Non-preferred agents may be approved if the member meets the following criteria:</p> <ul style="list-style-type: none"> • Member meets all listed criteria for preferred agents AND • Member has trialed and failed two preferred agents OR if the indication is OIC caused by methadone, then a non-preferred agent may be approved after an adequate trial of MOVANTIK (naloxegol). Failure is defined as a lack of efficacy for a 7-day trial, allergy, intolerable side effects, contraindication to, or significant drug-drug interaction AND • If prescribed Viberzi (eluxadoline) or Lotronex (alosetron), member meets the additional criteria for those agents listed below.
AMITIZA ^{BNR} (lubiprostone) capsule	Alosetron tablet	
LINZESS (linaclotide) capsule	LOTRONEX (alosetron) tablet	
MOVANTIK (naloxegol) tablet	Lubiprostone capsule	
	MOTEGRITY (prucalopride) tablet	
	RELISTOR (methylnaltrexone) tablet, syringe	
	SYMPROIC (naldemedine) tablet	
	TRULANCE (plecanatide) tablet	
	VIBERZI (eluxadoline) tablet	

VIBERZI (eluxadoline) may be approved for members who meet the following additional criteria:

- Diagnosis of Irritable Bowel Syndrome – Diarrhea (IBS-D) **AND**
- Member has a gallbladder **AND**
- Member does not have severe hepatic impairment (Child-Pugh C), history of severe constipation, known mechanical gastrointestinal obstruction, biliary duct obstruction, history of pancreatitis or structural disease of the pancreas **AND**
- Member does not drink more than 3 alcoholic drinks per day

LOTROXEX (alosetron) and generic alosetron may be approved for members who meet the following additional criteria:

- Member is a female with Irritable Bowel Syndrome – Diarrhea (IBS-D) with symptoms lasting 6 months or longer **AND**
- Member does not have severe hepatic impairment (Child-Pugh C), history of severe constipation or ischemic colitis, hypercoagulable state, Crohn’s disease or ulcerative colitis, or known mechanical gastrointestinal obstruction.

Medication	FDA approved indication	FDA Max Dose
Amitiza (lubiprostone)	IBS-C (females only), CIC, OIC (not caused by methadone)	48mcg/day
Linzess (linaclotide)	IBS-C, CIC	290mcg/day
Movantik (naloxegol)	OIC	25mg/day
Viberzi (eluxadoline)	IBS-D	200mg/day
Relistor subcutaneous injection (methylnaltrexone)	OIC	12mg/day
Relistor oral (methylnaltrexone)	OIC	450mg/day
Lotronex (alosetron)	IBS-D (females only)	2mg/day (females only)
Symproic (Naldemedine)	OIC	0.2mg/day
Trulance (plecanatide)	CIC, IBS-C	3mg/day
Motegrity (prucalopride)	CIC	2mg/day

CIC – chronic idiopathic constipation, OIC – opioid induced constipation, IBS – irritable bowel syndrome, D – diarrhea predominant, C – constipation predominant

Therapeutic Drug Class: H. PYLORI TREATMENTS -Effective 7/1/2023

No PA Required	PA Required	
PYLERA ^{BNR} capsule (bismuth subcitrate/metronidazole tetracycline)	Amoxicillin/lansoprazole/clarithromycin pack OMECLAMOX-PAK (amoxicillin/omeprazole/clarithromycin) TALICIA (omeprazole/amoxicillin/rifabutin) tablet	Non-preferred <i>H. pylori</i> treatments should be used as individual product ingredients unless one of the individual products is not commercially available, then a PA for the combination product may be given.

	Bismuth subcitrate/metronidazole tetracycline capsule	
Therapeutic Drug Class: HEMORRHOIDAL, ANORECTAL, AND RELATED TOPICAL ANESTHETIC AGENTS - Effective 7/1/2023		
Hydrocortisone single agent		Non-preferred products may be approved following trial and failure of therapy with 3 preferred products (failure is defined as lack of efficacy with 4-week trial, allergy, intolerable side effects or significant drug-drug interactions).
No PA Required	PA Required	
ANUSOL-HC (hydrocortisone) 2.5% cream with applicator	COLOCORT (hydrocortisone) enema	
CORTIFOAM (hydrocortisone) 10% aerosol	CORTENEMA (hydrocortisone) enema	
Hydrocortisone 1% cream with applicator	MICORT-HC (hydrocortisone) cream	
Hydrocortisone 2.5% cream with applicator		
Hydrocortisone enema		
PROCTO-MED HC (hydrocortisone) 2.5% cream		
PROCTO-PAK (hydrocortisone) 1% cream		
PROCTOSOL-HC 2.5% (hydrocortisone) cream		
PROCTOZONE-HC 2.5% (hydrocortisone) cream		
Lidocaine single agent		
No PA Required	PA Required	
Lidocaine 5% ointment	Lidocaine 3% cream	
Other and Combinations		
No PA Required	PA Required	
Hydrocortisone-Pramoxine 1%-1% cream	EPIFOAM (Hydrocortisone-Pramoxine) 1%-1% foam	

Hydrocortisone-Pramoxine 2.5%-1% cream	Lidocaine-Hydrocortisone in Coleus 2%-2% cream kit	
Lidocaine-Hydrocortisone 3-0.5% cream with applicator	Lidocaine-Hydrocortisone 2.8%-0.55% gel	
Lidocaine-Prilocaine Cream (<i>all other manufacturers</i>)	Lidocaine-Hydrocortisone 3%-0.5% cream w/o applicator, cream kit	
PROCTOFOAM-HC (hydrocortisone-pramoxine) 1%-1% foam	Lidocaine-Hydrocortisone 3%-1% cream kit	
	Lidocaine-Hydrocortisone 3%-2.5% gel kit	
	Lidocaine-Prilocaine Cream (<i>Fougera only</i>)	
	PLIAGIS (lidocaine-tetracaine) 7%-7% cream	
	RECTIV (nitroglycerin) 0.4% ointment	
Therapeutic Drug Class: PANCREATIC ENZYMES -Effective 7/1/2023		
No PA Required	PA Required	Non-preferred products may be approved for members who have failed an adequate trial (4 weeks) with at least two preferred products. (Failure is defined as lack of efficacy, allergy, intolerable side effects or significant drug-drug interaction.)
CREON (pancrelipase) capsule	PERTZYE (pancrelipase) capsule	
ZENPEP (pancrelipase) capsule	VIOKACE (pancrelipase) tablet	
Therapeutic Drug Class: PROTON PUMP INHIBITORS -Effective 7/1/2023		
No PA Required	PA Required	<p>For members treating GERD symptoms that are controlled on PPI therapy, it is recommended that the dose of the PPI be re-evaluated or step-down with an H2 blocker (such as famotidine or ranitidine) be trialed in order to reduce long-term PPI use. Prior authorization for non-preferred proton pump inhibitors may be approved if all of the following criteria are met:</p> <ul style="list-style-type: none"> ● Member has a qualifying diagnosis (below) AND ● Member has trialed and failed therapy with three preferred agents within the last 24 months. (Failure is defined as: lack of efficacy following 4-week trial, allergy, intolerable side effects, or significant drug-drug interaction) AND ● Member has been diagnosed using one of the following diagnostic methods: <ul style="list-style-type: none"> ○ Diagnosis made by GI specialist ○ Endoscopy ○ X-ray ○ Biopsy ○ Blood test ○ Breath Test <p>Qualifying Diagnoses: Barrett's esophagus, duodenal ulcer, erosive esophagitis, gastric ulcer, GERD, GI Bleed, H. pylori infection, hypersecretory conditions (Zollinger-Ellison), NSAID-induced ulcer, pediatric esophagitis, requiring mechanical ventilation, requiring a feeding tube</p>
DEXILANT (dexlansoprazole) capsule ^{BNR}	ACIPHEX (rabeprazole) tablet, sprinkle capsule	
Esomeprazole DR capsule (RX)	Dexlansoprazole capsule	
Lansoprazole DR capsules (RX)	Esomeprazole DR 49.3 capsule (RX), (OTC) capsule, packet for oral suspension	
Lansoprazole ODT (lansoprazole) (<i>for members under 2 years</i>)	Lansoprazole DR capsule OTC	
NEXIUM ^{BNR} (esomeprazole) oral suspension packet	NEXIUM (esomeprazole) capsule (RX), 24HR (OTC)	
Omeprazole DR capsule (RX)	Omeprazole/Na Bicarbonate capsule, packet for oral suspension	
Pantoprazole tablet	Omeprazole DR tablet (OTC), ODT (OTC)	
PROTONIX (pantoprazole DR) packet for oral suspension ^{BNR}	Pantoprazole packet for oral suspension	

	<p>PREVACID (lansoprazole) capsule, Solutab, suspension</p> <p>PRIOLOSEC (omeprazole) suspension</p> <p>PROTONIX (pantoprazole DR) tablet</p> <p>Rabeprazole tablet</p> <p>ZEGERID (omeprazole/Na bicarbonate) capsule, packet for oral suspension</p>	<p>Quantity Limits: All agents will be limited to once daily dosing except when used for the following diagnoses: Barrett’s esophagus, GI Bleed, H. pylori infection, hypersecretory conditions (Zollinger-Ellison), or members who have spinal cord injury with associated acid reflux.</p> <p>Adult members with GERD on once daily, high-dose PPI therapy who continue to experience symptoms may receive initial prior authorization approval for a 4-week trial of twice daily, high-dose PPI therapy. Continuation of the twice daily dosing regimen for GERD beyond 4 weeks will require additional prior authorization approval verifying adequate member response to the dosing regimen and approval may be placed for one year. If a member with symptomatic GERD does not respond to twice daily, high-dose PPI therapy, this should be considered a treatment failure.</p> <p>Pediatric members (< 18 years of age) on once daily dosing of a PPI who continue to experience symptoms may receive one-year prior authorization approval for twice daily PPI therapy.</p> <p>Age Limits: Nexium 24H and Zegerid will not be approved for members less than 18 years of age.</p> <p>Prevacid Solutab may be approved for members < 2 years of age OR for members ≥ 2 years of age with a feeding tube.</p>
--	--	---

Therapeutic Drug Class: NON-BIOLOGIC ULCERATIVE COLITIS AGENTS- Oral -Effective 7/1/2023

No PA Required	PA Required	
<p>APRISO^{BNR} (mesalamine ER) capsule</p> <p>LIALDA^{BNR} (mesalamine DR) tablet</p> <p>PENTASA^{BNR} (mesalamine) capsule</p> <p>Sulfasalazine IR and DR tablet</p>	<p>ASACOL HD (mesalamine DR) tablet</p> <p>AZULFIDINE (sulfasalazine) Entab, tablet</p> <p>Balsalazide capsule</p> <p>Budesonide DR tablet</p> <p>COLAZAL (balsalazide) capsule</p> <p>DELZICOL (mesalamine DR) capsule</p> <p>DIPENTUM (olsalazine) capsule</p> <p>Mesalamine DR tablet (generic Asacol HD, Lialda)</p> <p>Mesalamine DR/ER capsule (generic Apriso, Delzicol, Pentasa)</p> <p>UCERIS (budesonide) tablet</p>	<p>Prior authorization for non-preferred oral formulations will require trial and failure of two preferred oral products with different active ingredients AND one preferred rectal product. If inflammation is not within reach of topical therapy, trial of preferred rectal product is not required. Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction.</p> <p>Uceris (budesonide) tablet: Prior authorization may be approved following trial and failure of one preferred oral product AND one preferred rectal product. If inflammation is not within reach of topical therapy, trial of preferred rectal product is not required. Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction. Approval will be placed for 8 weeks. Further prior authorization may be approved if 7 days of steroid-free time has elapsed and member continues to meet the above criteria.</p>

Therapeutic Drug Class: NON-BIOLOGIC ULCERATIVE COLITIS AGENTS- Rectal -Effective 7/1/2023

No PA Required	PA Required	
<p>Mesalamine suppository</p> <p>Mesalamine 4gm/60 ml enema (generic SF ROWASA)</p>	<p>CANASA (mesalamine) suppository</p> <p>Mesalamine enema, kit</p> <p>ROWASA/SF ROWASA enema, kit (mesalamine)</p> <p>UCERIS (budesonide) foam</p>	<p>Prior authorization for non-preferred rectal formulations will require trial and failure of one preferred rectal formulation and one preferred oral formulation (Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction).</p> <p>Uceris (budesonide) foam: If the above criteria are met, Uceris (budesonide) foam prior authorization may be approved for 6 weeks. Further prior authorization may be approved if 7 days of steroid-free time has elapsed, and member continues to meet the above criteria.</p>

VIII. Hematological

Therapeutic Drug Class: ANTICOAGULANTS- Oral -Effective 7/1/2023

No PA Required	PA Required	
<p>ELIQUIS (apixaban) tablet</p> <p>PRADAXA^{BNR} (dabigatran) capsule</p> <p>Warfarin tablet</p> <p>XARELTO (rivaroxaban) 10 mg, 15 mg, 20 mg tablet, dose pack</p>	<p>Dabigatran capsule</p> <p>SAVAYSA (edoxaban) tablet</p> <p>PRADAXA (dabigatran) pelletXARELTO (rivaroxaban) 2.5 mg tablet</p> <p>XARELTO (rivaroxaban) oral suspension</p> <p>SAVAYSA (edoxaban) tablet</p>	<p>SAVAYSA (edoxaban) may be approved if all the following criteria have been met:</p> <ul style="list-style-type: none"> ● The member has failed therapy with two preferred agents. (Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction) AND ● Member is not on dialysis AND ● Member does not have CrCl > 95 mL/min AND ● The member has a diagnosis of deep vein thrombosis (DVT), pulmonary embolism (PE) OR ● The member has a diagnosis of non-valvular atrial fibrillation AND ● The member does not have a mechanical prosthetic heart valve <p>XARELTO 2.5mg (rivaroxaban) may be approved for members meeting all of the following criteria:</p> <ul style="list-style-type: none"> ● Xarelto 2.5mg is being prescribed to reduce major CV events in members diagnosis of chronic coronary artery disease (CAD) or peripheral artery disease AND ● Xarelto 2.5mg is being taken twice daily and in combination with aspirin 75-100mg daily AND ● Member must not be receiving dual antiplatelet therapy, other non-aspirin antiplatelet therapy, or other oral anticoagulant AND ● Member must not have had an ischemic, non-lacunar stroke within the past month AND ● Member must not have had a hemorrhagic or lacunar stroke at any time <p>XARELTO (rivaroxaban) oral suspension may be approved without prior authorization for members <18 years of age who require a rivaroxaban dose of less than 10 mg OR with prior authorization verifying the member is unable to use the solid oral dosage form.</p>

		<p>All other non-preferred oral agents require trial and failure of two preferred oral agents. Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction.</p> <p>Continuation of Care: Members with current prior authorization approval on file for a non-preferred <u>oral</u> anticoagulant medication may continue to receive approval for that medication</p>
Therapeutic Drug Class: ANTICOAGULANTS- Parenteral -Effective 7/1/2023		
No PA Required	PA Required	<p>Non-preferred parenteral anticoagulants may be approved if member has trial and failure of one preferred parenteral agent. Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction</p> <p>ARIXTRA (fondaparinux) may be approved if the following criteria have been met:</p> <ul style="list-style-type: none"> ● Member is 18 years of age or older AND ● Member has a CrCl > 30 ml/min AND ● Member weighs > 50 kg AND ● Member has a documented history of heparin induced-thrombocytopenia OR ● Member has a contraindication to enoxaparin <p>Members currently stabilized on fondaparinux (Arixtra) or dalteparin (Fragmin) may receive prior authorization approval to continue receiving that medication.</p>
Enoxaparin syringe	ARIXTRA (fondaparinux) syringe	
Enoxaparin vial	Fondaparinux syringe	
	FRAGMIN (dalteparin) vial, syringe	
	LOVENOX (enoxaparin) syringe, vial	
Therapeutic Drug Class: ANTI-PLATELETS -Effective 7/1/2023		
No PA Required	PA Required	<p>Zontivity (vorapaxar) may be approved for patients with a diagnosis of myocardial infarction or peripheral artery disease without a history of stroke, transient ischemic attack, intracranial bleeding, or active pathological bleeding. Patients must also be taking aspirin and/or clopidogrel concomitantly.</p> <p>Non-preferred products without criteria will be reviewed on a case-by-case basis.</p>
Aspirin/dipyridamole ER capsule	EFFIENT (prasugrel) tablet	
BRILINTA (tigacrelor) tablet	PLAVIX (clopidogrel) tablet	
Cilostazol tablet	ZONTIVITY (vorapaxar) tablet	
Clopidogrel tablet		
Dipyridamole tablet		
Pentoxifylline ER tablet		
Prasugrel tablet		

Therapeutic Drug Class: COLONY STIMULATING FACTORS -Effective 7/1/2023

PA Required for all agents in this class*

Preferred	Non-Preferred
NEUPOGEN (filgrastim) vial, syringe	FULPHILA (pegfilgrastim-jmdb) syringe
NYVEPRIA (pegfilgrastim-apgf) syringe	GRANIX (tbo-filgrastim) syringe, vial
	LEUKINE (sargramostim) vial
	NEULASTA (pegfilgrastim) syringe, kit
	NIVESYM (filgrastim-aafi) syringe, vial
	RELEUKO (filgrastim-ayow) syringe, vial
	UDENYCA (pegfilgrastim-cbqv) syringe
	ZARXIO (filgrastim-sndz) syringe
	ZIEXTENZO (pegfilgrastim-bmez) syringe

*Prior authorization for preferred agents may be approved if meeting the following criteria:

- Medication is being used for one of the following indications:
 - Patient with cancer receiving myelosuppressive chemotherapy –to reduce incidence of infection (febrile neutropenia) (Either the post nadir ANC is less than 10,000 cells/mm3 or the risk of neutropenia for the member is calculated to be greater than 20%)
 - Acute Myeloid Leukemia (AML) patients receiving chemotherapy
 - Bone Marrow Transplant (BMT)
 - Peripheral Blood Progenitor Cell Collection and Therapy
 - Hematopoietic Syndrome of Acute Radiation Syndrome
 - Severe Chronic Neutropenia (Evidence of neutropenia infection exists or ANC is below 750 cells/mm3)

AND

- For Nyvepria (pegfilgrastim-apgf), the member meets the following criteria:
 - Member has trial and failure of Neupogen. Failure is defined as lack of efficacy, intolerable side effects, drug-drug interaction, or contraindication to Neupogen therapy. Trial and failure of Neupogen will not be required if meeting one of the following:
 - Member has limited access to caregiver or support system for assistance with medication administration **OR**
 - Member has inadequate access to healthcare facility or home care interventions.
 -

Prior authorization for non-preferred agents may be approved if meeting the following criteria:

- Medication is being used for one of the following indications:
 - Patient with cancer receiving myelosuppressive chemotherapy –to reduce incidence of infection (febrile neutropenia) (Either the post nadir ANC is less than 10,000 cells/mm3 or the risk of neutropenia for the member is calculated to be greater than 20%)
 - Acute Myeloid Leukemia (AML) patients receiving chemotherapy
 - Bone Marrow Transplant (BMT)
 - Peripheral Blood Progenitor Cell Collection and Therapy
 - Hematopoietic Syndrome of Acute Radiation Syndrome
 - Severe Chronic Neutropenia (Evidence of neutropenia infection exists or ANC is below 750 cells/mm3)

AND

- Member has history of trial and failure of Neupogen AND one other preferred agent. Failure is defined as a lack of efficacy with a 3-month trial, allergy, intolerable side effects, significant drug-drug interactions, or contraindication to therapy. Trial and failure of Neupogen will not be required if meeting one of the following:

		<ul style="list-style-type: none"> ○ Member has limited access to caregiver or support system for assistance with medication administration OR ○ Member has inadequate access to healthcare facility or home care interventions.
--	--	---

Therapeutic Drug Class: ERYTHROPOIESIS STIMULATING AGENTS *Effective 7/1/2023*

PA Required for all agents in this class*		<p>*Prior Authorization is required for all products and may be approved if meeting the following:</p> <ul style="list-style-type: none"> ● Medication is being administered in the member’s home or in a long-term care facility AND ● Member meets <u>one</u> of the following: <ul style="list-style-type: none"> ○ A diagnosis of cancer, currently receiving chemotherapy, with chemotherapy-induced anemia, and hemoglobin[†] of 10g/dL or lower OR ○ A diagnosis of chronic renal failure, and hemoglobin[†] below 10g/dL OR ○ A diagnosis of hepatitis C, currently taking ribavirin and failed response to a reduction of ribavirin dose, and hemoglobin[†] less than 10g/dL (or less than 11g/dL if symptomatic) OR ○ A diagnosis of HIV, currently taking zidovudine, hemoglobin[†] less than 10g/dL, and serum erythropoietin level of 500 mU/mL or less OR ○ Member is undergoing elective, noncardiac, nonvascular surgery and medication is given to reduce receipt of allogenic red blood cell transfusions, hemoglobin[†] is greater than 10g/dL, but less than or equal to 13g/dL and high risk for perioperative blood loss. Member is not willing or unable to donate autologous blood pre-operatively <p>AND</p> <ul style="list-style-type: none"> ● For any non-preferred product, member has trialed and failed treatment with one preferred product. Failure is defined as lack of efficacy with a 6-week trial, allergy, intolerable side effects, or significant drug-drug interaction. <p>[†]Hemoglobin results must be from the last 30 days.</p>
Preferred	Non-Preferred	
EPOGEN (epoetin alfa) vial	ARANESP (darbepoetin alfa) syringe, vial	
RETACRIT (epoetin alfa-epbx) (<i>Pfizer only</i>)	MIRCERA (methoxy peg-epoetin beta) syringe	
	PROCRIT (epoetin alfa) vial	

IX. Immunological

Therapeutic Drug Class: IMMUNE GLOBULINS *-Effective 1/1/2023*

PA Required for all agents in this class*		<p>Preferred agents may be approved for members meeting at least one of the approved conditions listed below for prescribed doses not exceeding maximum (Table 1).</p> <p>Non-preferred agents may be approved for members meeting the following:</p> <ul style="list-style-type: none"> ● Member meets at least one of the approved conditions listed below AND ● Member has history of trial and failure of two preferred agents (failure is defined as lack of efficacy with 4-week trial, allergy, intolerable side effects or significant drug-drug interactions) AND ● Prescribed dose does not exceed listed maximum (Table 1) <p>Approved Conditions for Immune Globulin Use:</p>
Preferred	Non-Preferred	
CUVITRU 20% SQ liquid	BIVIGAM 10% IV liquid	
GAMMAGARD 10% IV/SQ liquid	CUTAQUIG 16.5% SQ liquid	
GAMMAKED 10% IV/SQ liquid	FLEBOGAMMA DIF 5%, 10% IV liquid	

GAMMAPLEX 5%, 10% IV liquid

GAMUNEX-C 10% IV/SQ liquid

HIZENTRA 20% SQ liquid

PRIVIGEN 10% IV liquid

If immune globulin is being administered in a long-term care facility or in a member's home by a home healthcare provider, it should be billed as a pharmacy claim. All other claims must be submitted through the medical benefit.

GAMMAGARD S/D vial

HYQVIA 10% SQ liquid

OCTAGAM 5%, 10% IV liquid

PANZYGA 10% IV liquid

XEMBIFY 20% IV liquid

- Primary Humoral Immunodeficiency disorders including:
 - Common Variable Immunodeficiency (CVID)
 - Severe Combined Immunodeficiency (SCID)
 - X-Linked Agammaglobulinemia
 - X-Linked with Hyperimmunoglobulin M (IgM) Immunodeficiency
 - Wiskott-Aldrich Syndrome
 - Members < 13 years of age with pediatric Human Immunodeficiency Virus (HIV) and CD-4 count > 200/mm³
- Neurological disorders including:
 - Guillain-Barré Syndrome
 - Relapsing-Remitting Multiple Sclerosis
 - Chronic Inflammatory Demyelinating Polyneuropathy
 - Myasthenia Gravis
 - Polymyositis and Dermatomyositis
 - Multifocal Motor Neuropathy
- Kawasaki Syndrome
- Chronic Lymphocytic Leukemia (CLL)
- Autoimmune Neutropenia (AN) with absolute neutrophil count < 800 mm and history of recurrent bacterial infections
- Autoimmune Hemolytic Anemia (AHA)
- Liver or Intestinal Transplant
- Immune Thrombocytopenia Purpura (ITP) including:
 - Requiring preoperative therapy for undergoing elective splenectomy with platelet count < 20,000/mcL
 - Members with active bleeding & platelet count <30,000/mcL
 - Pregnant members with platelet counts <10,000/mcL in the third trimester
 - Pregnant members with platelet count 10,000 to 30,000/mcL who are bleeding
- Multisystem Inflammatory Syndrome in Children (MIS-C)

Table 1: FDA-Approved Maximum Immune Globulin Dosing	
Asceniv – IV admin	800 mg/kg every 3 to 4 weeks
Bivigam – IV admin	800 mg/kg every 3 to 4 weeks
Cuvitru – SQ admin	12.6 grams every 2 weeks
Flebogamma DIF – IV admin	600 mg/kg every 3 weeks
Gammaplex 5% – IV Infusion	800mg/kg every 3 weeks
Gammagard liquid – SQ or IV admin	2.4 grams/kg/month
Gammaked – SQ or IV admin	600 mg/kg every 3 weeks
Gamunex-C – SQ or IV admin	600 mg/kg every 3 weeks
Hizentra – SQ admin	0.4g/kg per week
Octagam – IV admin	600 mg/kg every 3 to 4 weeks
Panzyga – IV admin	2 g/kg every 3 weeks
Privigen – IV admin	2 g/kg

		Members currently receiving a preferred or non-preferred immunoglobulin product may receive approval to continue therapy with that product at prescribed doses not exceeding maximum (Table 1).
Therapeutic Drug Class: NEWER GENERATION ANTIHISTAMINES -Effective 1/1/2023		
No PA Required	PA Required	
Cetirizine (OTC) tablet, syrup/solution (OTC/RX) Desloratadine tablet (RX) Levocetirizine tablet (RX/OTC) Loratadine tablet (OTC), syrup/solution (OTC)	Cetirizine (OTC) chewable tablet, softgel CLARINEX (desloratadine) tablet Desloratadine ODT (RX) Fexofenadine tablet (OTC), suspension (OTC) Levocetirizine solution (RX) Loratadine chewable (OTC), ODT (OTC)	Non-preferred single agent antihistamine products may be approved for members who have failed treatment with two preferred products in the last 6 months. For members with respiratory allergies, an additional trial of an intranasal corticosteroid will be required in the last 6 months. Failure is defined as lack of efficacy with a 14-day trial, allergy, intolerable side effects, or significant drug-drug interaction.
Therapeutic Drug Class: ANTIHISTAMINE/DECONGESTANT COMBINATIONS - Effective 1/1/2023		
No PA Required	PA Required	
Loratadine-D (OTC) tablet	Cetirizine-PSE (OTC) CLARINEX-D (desloratadine-D) Fexofenadine/PSE (OTC)	Non-preferred antihistamine/decongestant combinations may be approved for members who have failed treatment with the preferred product in the last 6 months. For members with respiratory allergies, an additional trial of an intranasal corticosteroid will be required in the last 6 months. Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction.
Therapeutic Drug Class: INTRANASAL RHINITIS AGENTS -Effective 1/1/2023		
No PA Required	PA Required	
Azelastine 0.15%, 137 mcg Budesonide (OTC) Fluticasone (RX) Ipratropium Olopatadine Triamcinolone acetonide (OTC)	Azelastine/Fluticasone BECONASE AQ (beclomethasone dipropionate) DYMISTA (azelastine/ fluticasone) Flunisolide 0.025% Fluticasone (OTC) Mometasone	Non-preferred products may be approved following trial and failure of treatment with three preferred products (failure is defined as lack of efficacy with a 2-week trial, allergy, intolerable side effects or significant drug-drug interactions). Non-preferred combination agents may be approved following trial of individual products with same active ingredients AND trial and failure of one additional preferred agent (failure is defined as lack of efficacy with 2-week trial, allergy, intolerable side effects or significant drug-drug interactions).

	<p>NASONEX (mometasone)</p> <p>OMNARIS (ciclesonide)</p> <p>QNASL (beclomethasone)</p> <p>RYALTRIS (olopatadine/mometasone)</p> <p>XHANCE (fluticasone)</p> <p>ZETONNA (ciclesonide)</p>	
--	--	--

Therapeutic Drug Class: LEUKOTRIENE MODIFIERS -Effective 1/1/2023

No PA Required	PA Required	
Montelukast tablet, chewable	<p>ACCOLATE (zafirlukast) tablet</p> <p>Montelukast granules</p> <p>SINGULAIR (montelukast) tablet, chewable, granules</p> <p>Zafirlukast tablet</p> <p>Zileuton ER tablet</p> <p>ZYFLO (zileuton) tablet</p>	<p>Non-preferred products may be approved if meeting the following criteria:</p> <ul style="list-style-type: none"> Member has trialed and failed treatment with one preferred product (failure is defined as lack of efficacy, allergy, intolerable side effects or significant drug-drug interactions) AND Member has a diagnosis of asthma. <p>Montelukast granules may be approved if a member has tried and failed montelukast chewable tablets AND has difficulty swallowing.</p>

Therapeutic Drug Class: METHOTREXATE PRODUCTS -Effective 1/1/2023

No PA Required	PA Required	
Methotrexate oral tablet, vial	<p>OTREXUP (methotrexate) auto-injector</p> <p>RASUVO (methotrexate) auto-injector</p> <p>REDITREX (methotrexate) syringe</p> <p>TREXALL (methotrexate) oral tablet</p> <p>XATMEP (methotrexate) oral solution</p>	<p>OTREXUP, REDITREX or RASUVO may be approved if meeting the following criteria:</p> <ul style="list-style-type: none"> Member has diagnosis of severe, active rheumatoid arthritis OR active polyarticular juvenile idiopathic arthritis (pJIA) OR inflammatory bowel disease (IBD) AND Member has trialed and failed preferred methotrexate tablet formulation (failure is defined as lack of efficacy, allergy, intolerable side effects, inability to take oral product formulation, or member has a diagnosis of pJIA and provider has determined that the subcutaneous formulation is necessary to optimize methotrexate therapy) AND Member (or parent/caregiver) is unable to administer preferred methotrexate vial formulation due to limited functional ability (such as vision impairment, limited manual dexterity and/or limited hand strength). <p>TREXALL may be approved if meeting the following criteria:</p> <ul style="list-style-type: none"> Member has trialed and failed preferred methotrexate tablet formulation. Failure is defined as allergy or intolerable side effects.

XATMEP may be approved for members who meet the following criteria:

- Member is < 18 years of age
- Member has a diagnosis of acute lymphoblastic leukemia **OR**
- Member has a diagnosis of active polyarticular juvenile idiopathic arthritis (pJIA) and has had an insufficient therapeutic response to, or is intolerant to, an adequate trial of first-line therapy including full dose non-steroidal anti-inflammatory agents (NSAIDs) **AND**
- Member has a documented swallowing difficulty due to young age and/or a medical condition and is unable to use the preferred methotrexate tablet formulation

Methotrexate can cause serious embryo-fetal harm when administered during pregnancy and it is contraindicated for use during pregnancy for the treatment of non-malignant diseases. Advise members of reproductive potential to use effective contraception during and after treatment with methotrexate, according to FDA product labeling.

Members currently stabilized on a non-preferred methotrexate product may receive approval to continue that agent.

Therapeutic Drug Class: **MULTIPLE SCLEROSIS AGENTS** -Effective 4/1/2023

Disease Modifying Therapies

<p>Preferred No PA Required (Unless indicated*)</p>	<p>Non-Preferred PA Required</p>	
<p><i>Brand/generic changes effective 4/10/23</i></p> <p>AVONEX (interferon beta 1a) injection</p> <p>BETASERON (interferon beta 1b) injection</p> <p>COPAXONE^{BNR} (glatiramer) injection</p> <p>Dimethyl fumarate tablet, starter pack</p> <p>*KESIMPTA (ofatumumab) pen**2nd Line**</p> <p>Teriflunomide tablet</p> <p>Fingolimod 0.5mg capsule</p>	<p>AUBAGIO (teriflunomide) tablet</p> <p>BAFIERTAM (monomethyl fumarate DR) capsule</p> <p>EXTAVIA (interferon beta 1b) kit, vial</p> <p>GLATOPA (glatiramer) injection</p> <p>Glatiramer 20mg, 40mg injection</p> <p>GILENYA (fingolimod) 0.5 mg capsule</p> <p>MAVENCLAD (cladribine) tablet</p> <p>MAYZENT (siponimod) tablet, pack</p> <p>PLEGRIDY (peg-interferon beta 1a) syringe, pen</p> <p>PONVORY (ponesimod) tablet, pack</p>	<p>*Kesimpta (ofatumumab) may be approved if member has trialed and failed treatment with one preferred agent (failure is defined as intolerable side effects, contraindication to therapy, drug-drug interaction, or lack of efficacy).</p> <p><u>Non-Preferred Products:</u> Non-preferred products may be approved if meeting the following:</p> <ul style="list-style-type: none"> • Member has a diagnosis of a relapsing form of multiple sclerosis AND • Member has previous trial and failure with three preferred agents. Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction AND • Prescribed dose does not exceed the maximum FDA-approved dose for the medication being ordered AND • If indicated in the product labeling, a negative pre-treatment pregnancy test has been documented, AND • If indicated in the product labeling, an ophthalmologic examination has been performed and documented prior to medication initiation, AND • The request meets additional criteria listed for any of the following: <p>Mayzent (siponimod):</p> <ul style="list-style-type: none"> • Member has no evidence of relapse in the 3 months preceding initiation of therapy AND • Member has previous trial and failure of three preferred agents, one of which must be Gilenya (fingolimod). Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction.

	<p>REBIF (interferon beta 1a) syringe</p> <p>TECFIDERA (dimethyl fumarate) tablet, pack</p> <p>VUMERITY (diroximel DR) capsule</p> <p>ZEPOSIA (ozanimod) capsule, kit</p>	<p>Mavenclad (cladribine):</p> <ul style="list-style-type: none"> Member has history of ≥ 1 relapse in the 12 months preceding initiation of therapy AND Member has previous trial and failure of three other therapies for relapsing forms of multiple sclerosis (failure is defined as lack of efficacy with 3-month trial, allergy, intolerable side effects, or significant drug-drug interactions) <p>Vumerity (diroximel fumarate) or Bafiertam (monomethyl fumarate DR):</p> <ul style="list-style-type: none"> Member has previous trial and failure of three preferred agents, one of which must be Tecfidera (dimethyl fumarate). Failure is defined as lack of efficacy, allergy, significant drug-drug interactions, intolerable side effects (if GI adverse events, must meet additional criteria below) AND If the requested medication is being prescribed due to GI adverse events with Tecfidera therapy (and no other reason for failure of Tecfidera is given), then the following additional criteria must be met: <ul style="list-style-type: none"> Member has trialed a temporary dose reduction of Tecfidera (with maintenance dose being resumed within 4 weeks) AND Member has trialed taking Tecfidera with food AND GI adverse events remain significant despite maximized use of gastrointestinal symptomatic therapies (such as calcium carbonate, bismuth subsalicylate, PPIs, H2 blockers, anti-bloating/anti-constipation agents, anti-diarrheal, and centrally acting anti-emetics) AND Initial authorization will be limited to 3 months. Continuation (12-month authorization) will require documentation of clinically significant reduction in GI adverse events. <p>Members currently stabilized on a preferred second line (Kesimpta) or non-preferred product (may receive approval to continue therapy with that agent).</p>
--	---	---

Symptom Management Therapies

<p align="center">No PA Required</p> <p>Dalfampridine ER tablet</p>	<p align="center">PA Required</p> <p>AMPYRA ER (dalfampridine) tablet</p>	<p>Non-preferred products may be approved with prescriber attestation that there is clinical rationale supporting why the preferred brand/generic equivalent product formulation is unable to be used.</p> <p><u>Maximum Dose:</u> Ampyra (dalfampridine) 10mg twice daily</p>
--	--	--

Therapeutic Drug Class: **TARGETED IMMUNE MODULATORS** -Effective 1/1/2023

Preferred agents: ENBREL (etanercept); FASENRA (benralizumab) pen; HUMIRA (adalimumab); OTEZLA (apremilast) tablet; KEVZARA (sarilumab); TALTZ (ixekizumab); XELJANZ IR (tofacitinib) tablet; XOLAIR (omalizumab) syringe

Rheumatoid Arthritis, all other Arthritis (except psoriatic arthritis, see below), and Ankylosing Spondylitis

<p>Preferred No PA Required (If diagnosis met) (*Must meet eligibility criteria)</p>	<p>Non-Preferred PA Required</p>	<p>First line preferred agents (HUMIRA, ENBREL, and XELJANZ IR) may receive approval for use for FDA-labeled indications.</p> <p>Quantity Limit: XELJANZ IR is limited to 2 tablets per day or 60 tablets for a 30-day supply</p> <p>*TALTZ (ixekizumab) may receive approval for use for FDA-labeled indications following trial and failure[‡] of HUMIRA or ENBREL.</p> <p>*KEVZARA (sarilumab) may receive approval for use for FDA-labeled indications following trial and failure[‡] of HUMIRA or ENBREL AND XELJANZ IR.</p> <p>COSENTYX (secukinumab) may receive approval for:</p> <ul style="list-style-type: none"> • FDA-labeled indications following trial and failure[‡] of all indicated preferred agents OR • Treatment of enthesitis-related arthritis if meeting the following: <ul style="list-style-type: none"> ○ Member is ≥ 4 years of age and weighs ≥ 15 kg AND ○ Member has had trialed and failed[‡] NSAID therapy AND ENBREL AND HUMIRA <p>KINERET (anakinra) may receive approval for:</p> <ul style="list-style-type: none"> • FDA-labeled indications following trial and failure[‡] of HUMIRA or ENBREL AND XELJANZ IR OR • Treatment of systemic juvenile idiopathic arthritis (sJIA) or Adult-Onset Still’s Disease (AOSD) <p>ILARIS (canakinumab) may receive approval if meeting the following:</p> <ul style="list-style-type: none"> • Medication is being prescribed for systemic juvenile idiopathic arthritis (sJIA) or Adult-Onset Still’s Disease (AOSD), AND • Member has trialed and failed[‡] ACTEMRA (tocilizumab) <p>XELJANZ (tofacitinib) XR approval will require verification of the clinically relevant reason for use of the XELJANZ XR formulation versus the XELJANZ IR formulation, in addition to meeting non-preferred criteria listed below.</p> <p>XELJANZ (tofacitinib) oral solution may be approved for members with a diagnosis of polyarticular course juvenile idiopathic arthritis (pJIA) who require a weight-based dose for <40 kg following trial and failure[‡] of HUMIRA or ENBREL.</p>
<p>ENBREL (etanercept)</p> <p>HUMIRA (adalimumab)</p> <p>*KEVZARA (sarilumab) pen, syringe</p> <p>*TALTZ (ixekizumab)</p> <p>XELJANZ IR (tofacitinib) tablet</p>	<p>ACTEMRA (tocilizumab) syringe, Actpen</p> <p>CIMZIA (certolizumab pegol) syringe</p> <p>COSENTYX (secukinumab) syringe, pen-injector</p> <p>ILARIS (canakinumab) vial</p> <p>KINERET (anakinra) syringe</p> <p>OLUMIANT (baricitinib) tablet</p> <p>ORENCIA (abatacept) syringe, clickject</p> <p>RINVOQ (upadacitinib) tablet</p> <p>SIMPONI (golimumab) pen, syringe</p> <p>XELJANZ (tofacitinib) solution</p> <p>XELJANZ XR (tofacitinib ER) tablet</p> <p>*For information on IV-infused Targeted Immune Modulators please see Appendix P</p>	

		<p>All other non-preferred agents may receive approval for FDA-labeled indications following trial and failure[‡] of all indicated preferred agents. Non-preferred agents that are being prescribed per FDA-label to treat non-radiographic axial spondyloarthritis (nr-axSpA) will require trial and failure[‡] of preferred agents that are FDA-labeled for treating an axial spondyloarthritis condition, including ankylosing spondylitis (AS) or nr-axSpA.</p> <p>Members currently taking COSENTYX or XELJANZ oral solution may receive approval to continue on that agent.</p> <p>[‡]Failure is defined as lack of efficacy with a three-month trial, contraindication to therapy, allergy, intolerable side effects, or significant drug-drug interaction. Note that trial and failure of preferred TNF inhibitors will not be required when prescribed to treat polyarticular juvenile idiopathic arthritis (pJIA) in members with documented clinical features of lupus.</p> <p><i>The Department would like to remind providers that many products are associated with patient-centered programs that are available to assist with drug administration, education, and emotional support related to our members' various disease states.</i></p>
--	--	--

Psoriatic Arthritis

<p style="text-align: center;">Preferred No PA Required (If diagnosis met) (*Must meet eligibility criteria)</p>	<p style="text-align: center;">Non-Preferred PA Required</p>	<p>First line preferred agents (HUMIRA, ENBREL, XELJANZ IR) may receive approval for psoriatic arthritis indication.</p> <p>Quantity Limit: XELJANZ IR is limited to 2 tablets per day or 60 tablets for a 30-day supply</p>
<p>ENBREL (etanercept)</p> <p>HUMIRA (adalimumab)</p> <p>*OTEZLA (apremilast) tablet</p> <p>*TALTZ (ixekizumab)</p> <p>XELJANZ IR (tofacitinib) tablet</p>	<p>CIMZIA (certolizumab pegol) syringe</p> <p>COSENTYX (secukinumab) syringe, pen-injector</p> <p>ORENCIA (abatacept) syringe, clickject</p> <p>RINVOQ (upadacitinib) tablet</p> <p>SIMPONI (golimumab) pen, syringe</p> <p>SKYRIZI (risankizumab-rzaa) pen, syringe</p> <p>STELARA (ustekinumab) syringe</p> <p>TREMFYA (guselkumab) injector, syringe</p> <p>XELJANZ (tofacitinib) solution</p> <p>XELJANZ XR (tofacitinib ER) tablet</p>	<p>*OTEZLA (apremilast) may receive approval for psoriatic arthritis indication following trial and failure[‡] of HUMIRA or ENBREL AND XELJANZ IR or TALTZ.</p> <p>*TALTZ (ixekizumab) may receive approval for psoriatic arthritis indication following trial and failure[‡] of HUMIRA or ENBREL AND XELJANZ IR or OTEZLA.</p> <p>COSENTYX (secukinumab) may receive approval for psoriatic arthritis indication for members ≥ 2 years of age and weighing ≥ 15 kg following trial and failure[‡] of HUMIRA (adalimumab) or ENBREL AND XELJANZ IR AND TALTZ or OTEZLA.</p> <p>STELARA (ustekinumab) syringe for subcutaneous use may receive approval if meeting the following:</p> <ul style="list-style-type: none"> ▪ Member has trial and failure[‡] of HUMIRA or ENBREL AND XELJANZ IR AND TALTZ or OTEZLA AND ▪ Prior authorization approval may be given for an initial 16-week supply and authorization approval for continuation may be provided based on clinical response.

	<p>*For information on IV-infused Targeted Immune Modulators please see Appendix-P</p>	<p>XELJANZ (tofacitinib) XR approval will require verification of the clinically relevant reason for use of the XELJANZ XR formulation versus the XELJANZ IR formulation, in addition to meeting non-preferred criteria listed below.</p> <p>All other non-preferred agents may receive approval for psoriatic arthritis following trial and failure[‡] of HUMIRA or ENBREL AND XELJANZ IR AND TALTZ or OTEZLA.</p> <p>[‡]Failure is defined as lack of efficacy with a three-month trial, contraindication to therapy, allergy, intolerable side effects, or significant drug-drug interaction.</p> <p>Members currently taking COSENTYX may receive approval to continue on that agent.</p> <p><i>The Department would like to remind providers that many products are associated with patient-centered programs that are available to assist with drug administration, education, and emotional support related to our members' various disease states.</i></p>
--	---	---

Plaque Psoriasis

<p style="text-align: center;">Preferred No PA Required (If diagnosis met) (*Must meet eligibility criteria)</p>	<p style="text-align: center;">Non-Preferred PA Required</p>	
<p>ENBREL (etanercept)</p> <p>HUMIRA (adalimumab)</p> <p>*OTEZLA (apremilast) tablet</p> <p>*TALTZ (ixekizumab)</p>	<p>CIMZIA (certolizumab pegol) syringe</p> <p>COSENTYX (secukinumab) syringe, pen-injector</p> <p>SILIQ (brodalumab) syringe</p> <p>SKYRIZI (risankizumab-rzaa) pen, syringe</p> <p>STELARA (ustekinumab) syringe</p> <p>TREMFYA (guselkumab) injector, syringe</p> <p>*For information on IV infused Targeted Immune Modulators please see Appendix-P</p>	<p>First line preferred agents (HUMIRA, ENBREL) may receive approval for plaque psoriasis indication.</p> <p>*Second line preferred agents (TALTZ, OTEZLA) may receive approval for plaque psoriasis indication following trial and failure[‡] of HUMIRA OR ENBREL.</p> <p>STELARA (ustekinumab) syringe for subcutaneous use may receive approval if meeting the following:</p> <ul style="list-style-type: none"> ▪ Member has trial and failure[‡] of one indicated first line agent (HUMIRA, ENBREL) AND two indicated second line agents (TALTZ, OTEZLA), AND ▪ Prior authorization approval may be given for an initial 16-week supply and authorization approval for continuation may be provided based on clinical response. <p>All other non-preferred agents may receive approval for plaque psoriasis indication following trial and failure[‡] of one indicated first line agent (HUMIRA, ENBREL) AND two second line agents (TALTZ, OTEZLA).</p> <p>[‡]Failure is defined as lack of efficacy with a three-month trial, contraindication to therapy, allergy, intolerable side effects, or significant drug-drug interaction.</p> <p>Members currently taking COSENTYX may receive approval to continue on that agent.</p> <p><i>The Department would like to remind providers that many products are associated with patient-centered programs that are available to assist with drug administration, education, and emotional support related to our members' various disease states.</i></p>

Crohn's Disease and Ulcerative Colitis

Preferred No PA Required (If diagnosis met) (*Must meet eligibility criteria)	Non-Preferred PA Required	
<p>HUMIRA (adalimumab)</p> <p>*XELJANZ IR (tofacitinib) tablet</p>	<p>CIMZIA (certolizumab pegol) syringe</p> <p>COSENTYX (secukinumab) syringe, pen-injector</p> <p>OLUMIANT (baricitinib) tablet</p> <p>RINVOQ (upadacitinib) tablet</p> <p>SIMPONI (golimumab) pen, syringe</p> <p>SKYRIZI (risankizumab-rzaa) pen, syringe, OnBody</p> <p>STELARA (ustekinumab) syringe</p> <p>XELJANZ (tofacitinib) solution</p> <p>XELJANZ XR (tofacitinib ER) tablet</p> <p>*For information on IV infused Targeted Immune Modulators please see Appendix-P</p>	<p>First line preferred agents (HUMIRA) may receive approval for Crohn's disease and ulcerative colitis indications.</p> <p>*XELJANZ IR may receive approval for ulcerative colitis indication following trial and failure[‡] of HUMIRA.</p> <p>Quantity Limit: XELJANZ IR is limited to 2 tablets per day or 60 tablets for a 30-day supply</p> <p>SIMPONI (golimumab) may receive approval if meeting the following:</p> <ul style="list-style-type: none"> • Member is ≥ 18 years of age AND • Member has a diagnosis of moderately to severely active ulcerative colitis and meets the following: <ul style="list-style-type: none"> ○ Member has trialed and failed[‡] all preferred agents in the “Targeted Immune Modulators” PDL drug class that are FDA-labeled for use for the prescribed indication AND ○ Member has demonstrated corticosteroid dependence or has had an inadequate response to (or failed to tolerate) oral aminosalicylates, oral corticosteroids, azathioprine, or 6-mercaptopurine for inducing and maintaining clinical response, improving endoscopic appearance of the mucosa during induction, inducing clinical remission, or achieving and sustaining clinical remission in induction responders. <p>SKYRIZI (risankizumab) syringe for subcutaneous use and on-body injector formulations may receive approval if meeting the following:</p> <ul style="list-style-type: none"> • The requested medication is being prescribed for use for treating moderately-to-severely active Crohn's disease AND • Member is ≥ 18 years of age AND • Member has trial and failure[‡] of all indicated preferred agents AND • Prescriber acknowledges that administration of IV induction therapy prior to approval of SKYRIZI prefilled syringe or on-body injector formulation using the above criteria should be avoided and will not result in an automatic approval of requests for these formulations. <p>Dosing Limit: SKYRIZI on-body formulation maintenance dosing is limited to one 360 mg/2.4 mL single-dose prefilled cartridge or one 180mg/1.2mL prefilled cartridge every 8 weeks.</p> <p>STELARA (ustekinumab) syringe for subcutaneous use may receive approval if meeting the following:</p> <ul style="list-style-type: none"> ▪ For treatment of moderately-to-severely active Crohn's disease, member has trial and failure[‡] of all indicated preferred agents (HUMIRA) OR for treatment of moderately-to-severely active ulcerative colitis, member has trial and failure of all indicated preferred agents (HUMIRA and XELJANZ IR) AND

		<ul style="list-style-type: none"> ▪ The member is ≥ 18 years of age AND ▪ Prescriber acknowledges that loading dose administration prior to approval of STELARA for maintenance therapy using the above criteria should be avoided and will not result in an automatic approval of STELARA for maintenance therapy AND ▪ Prior authorization approval may be given for an initial 16-week supply and authorization approval for continuation may be provided based on clinical response. <p>XELJANZ (tofacitinib) XR approval will require verification of the clinically relevant reason for use of the XELJANZ XR formulation versus the XELJANZ IR formulation, in addition to meeting non-preferred criteria listed below.</p> <p>All other non-preferred agents may receive approval for FDA-labeled indications following trial and failure[‡] of all indicated preferred agents.</p> <p>Members currently taking COSENTYX may receive approval to continue on that agent.</p> <p>[‡]Failure is defined as lack of efficacy with a three-month trial, contraindication to therapy, allergy, intolerable side effects, or significant drug-drug interaction. Note that trial and failure of Xeljanz IR will not be required when prescribed for ulcerative colitis for members ≥ 50 years of age that have an additional CV risk factor.</p> <p><i>The Department would like to remind providers that many products are associated with patient-centered programs that are available to assist with drug administration, education, and emotional support related to our members' various disease states.</i></p>
--	--	---

Asthma

<p style="text-align: center;">Preferred PA Required (*Must meet eligibility criteria)</p> <p>*FASENRA (benralizumab) pen</p> <p>*XOLAIR (omalizumab) syringe</p>	<p style="text-align: center;">Non-Preferred PA Required</p> <p>DUPIXENT (dupilumab) pen, syringe</p> <p>NUCALA (mepolizumab) auto-injector, syringe</p> <p>*For information on IV infused or health care professional administered (Fasenra syringe) Targeted Immune Modulators please see Appendix-P</p>	<p>*Preferred products (Fasenra, Xolair) may receive approval if meeting the following:</p> <p>FASENRA (benralizumab) pen:</p> <ul style="list-style-type: none"> • Member is ≥ 12 years of age AND • Member has an FDA-labeled indicated use for treating asthma with an eosinophilic phenotype based on a blood eosinophil level of ≥ 150/mcL AND • Member's asthma has been refractory to recommended evidence-based, guideline-supported pharmacologic therapies AND • The requested medication is being prescribed as add-on therapy to existing asthma regimen AND • The requested medication will not be used concomitantly with other biologic products indicated for asthma. <p>XOLAIR (omalizumab) syringe:</p> <ul style="list-style-type: none"> • Member is ≥ 6 years of age AND • Member has an FDA-labeled indicated use for treating asthma AND • Member has a positive skin test or in vitro reactivity to a perennial inhaled allergen or has a pre-treatment IgE serum concentration ≥ 30 IU/mL AND
--	--	---

- Member's asthma has been refractory to recommended evidence-based, guideline-supported pharmacologic therapies **AND**
- The requested medication is being prescribed as add-on therapy to existing asthma regimen **AND**
- The requested medication will not be used concomitantly with other biologic products indicated for asthma.

DUPIXENT (dupilumab) may receive approval if meeting the following:

- Member is 6 years of age or older **AND**
- Member has a diagnosis of moderate to severe asthma (on medium to high dose inhaled corticosteroid and a long-acting beta agonist) with eosinophilic phenotype **OR** oral corticosteroid dependent asthma **AND**
- Member has had at least one asthma exacerbation in the past year requiring systemic corticosteroids or emergency department visit or hospitalization **OR** dependence on daily oral corticosteroid therapy **PLUS** regular use of high dose inhaled corticosteroid **PLUS** an additional controller medication **AND**
- Member has trialed and failed[‡] both preferred agents (FASENRA and XOLAIR) **AND**
- Medication is being prescribed as add-on therapy to existing regimen **AND**
- Medication is being prescribed by or in consultation with a rheumatologist, allergist, or pulmonologist **AND**
- For indication of moderate to severe asthma with eosinophilic phenotype:
 - baseline lung function (FEV1) is provided, and baseline eosinophils are greater than 300 cells/mcL **AND**
 - Initial authorization will be for 12 weeks. Continued authorization will require prescriber attestation to improvement in FEV1 of 25% from baseline and will be for 12 months.
- For indication of oral corticosteroid dependent asthma:
 - Dosing of the oral corticosteroid is provided **AND**
 - Initial authorization will be 24 weeks. Continued authorization will require prescriber attestation of a reduction of oral corticosteroid by at least 50% and will be for 12 months.

Quantity Limit: 2 syringes every 28 days after initial 14 days of therapy (first dose is twice the regular scheduled dose)

NUCALA (mepolizumab) may receive approval if meeting the following:

- For billing under the pharmacy benefit, the request meets one of the following:
 - The medication is being administered by a healthcare professional in the member's home or in a long-term care facility **OR**
 - The prescriber verifies that the member has been properly trained in subcutaneous injection technique and on the preparation and administration of Nucala (mepolizumab) per information contained in product package labeling

AND

- Member is 6 years of age or older **AND**

		<ul style="list-style-type: none"> • Member has diagnosis of severe asthma with an eosinophilic phenotype AND • Member has a blood eosinophil count of greater than or equal to 150 cells/mcL within 6 weeks of dosing or greater than or equal to 300 cells/mcL in the previous 12 months AND • Member has had 2 or more asthma exacerbations requiring use of oral or systemic corticosteroids and/or hospitalizations and/or ER visits OR member requires daily use of oral corticosteroids AND • Baseline FEV1 and frequency of asthma exacerbations per month are provided AND • Member has trialed and failed[‡] two preferred agents (FASENRA and XOLAIR). <p><u>Initial approval:</u> 1 year</p> <p><u>Reauthorization:</u></p> <ul style="list-style-type: none"> • May be approved if member has shown clinical improvement as documented by <u>one</u> of the following: <ul style="list-style-type: none"> ○ Improvement in lung function, measured in FEV1 OR ○ Reduction in the number of asthma exacerbations, defined as a decrease in use of oral or systemic corticosteroids and/or reduced asthma related hospitalizations and/or ER visits. <p><u>Dosing Limits:</u> 100mg every 4 weeks (members ≥ 12 years of age); 40mg every 4 weeks (members 6-11 years of age)</p> <p>All other non-preferred FDA-indicated biologic agents for asthma may receive approval following trial and failure[‡] of two preferred agents (FASENRA, XOLAIR).</p> <p>[‡]Failure is defined as a lack of efficacy with a three-month trial, allergy, intolerable side effects, contraindication to, or significant drug-drug interactions.</p> <p>Members currently taking a preferred agent may receive approval to continue therapy with that agent. Members with current prior authorization approval on file for a non-preferred agent:</p> <ul style="list-style-type: none"> • Will be subject to meeting reauthorization criteria listed above for the prescribed agent OR • If reauthorization criteria is not listed above, may receive approval for continuation of therapy with the prescribed agent.
Atopic Dermatitis		
	<p style="text-align: center;">Non-Preferred PA Required</p> <p>ADBRY (tralokinumab-ldrm) syringe</p> <p>CIBINQO (abrocitinib) tablet</p>	<p>ADBRY (tralokinumab-ldrm) may be approved if the following criteria are met:</p> <ul style="list-style-type: none"> • Member is ≥ 18 years of age AND • The requested drug is being prescribed for moderate-to-severe atopic dermatitis AND

DUPIXENT (dupilumab) pen, syringe

RINVOQ (upadacitinib) tablet

***For information on IV infused Targeted Immune Modulators please see Appendix-P**

- Member has baseline Investigator Global Assessment (IGA) score for atopic dermatitis severity of at least 3 (Scored 0-4, 4 being most severe) OR moderate erythema and moderate papulation/infiltration **AND**
- Member has been educated by provider regarding the elimination of exacerbating factors including aeroallergens, food allergens, and contact allergens **AND**
- Member has been educated by provider regarding the appropriate use of emollients and moisturizers for promotion of skin hydration **AND**
- Member has trialed and failed[‡] the following agents:
 - Two medium potency to very-high potency topical corticosteroids (such as mometasone furoate, betamethasone dipropionate) **AND**
 - Two topical calcineurin inhibitors (such as pimecrolimus and tacrolimus)**AND**
- The requested drug is being prescribed by, or in consultation with, a dermatologist, allergist/immunologist, or rheumatologist.

Maximum Dose: 600 mg/2 weeks

Quantity Limit: Four 150 mg/mL prefilled syringes/2 weeks

Initial approval: 18 weeks

Reauthorization:

- Additional one year approval for continuation may be granted with prescriber attestation that member has a 16-week IGA score showing improvement by at least 2 points from baseline OR has demonstrated clinically significant improvement due to treatment with the requested medication **AND**
- If clear or almost clear skin has been achieved after 16 weeks of treatment with, provider attests to considering a dose reduction to 300 mg every 4 weeks.

DUPIXENT (dupilumab) may be approved for members meeting the following criteria:

- Member is 6 years of age or older **AND**
- Member has a diagnosis of moderate to severe chronic atopic dermatitis **AND**
- Member has baseline Investigator Global Assessment (IGA) score for atopic dermatitis severity of at least 3 (Scored 0-4, 4 being most severe) OR moderate erythema and moderate papulation/infiltration **AND**
- Member has been educated by provider regarding the elimination of exacerbating factors including aeroallergens, food allergens, and contact allergens **AND**
- Member has been educated by provider regarding the appropriate use of emollients and moisturizers for promotion of skin hydration **AND**
- Member has trialed and failed[‡] the following agents:

- Two medium potency to very-high potency topical corticosteroids [such as mometasone furoate, betamethasone dipropionate, or fluocinonide (see PDL for list of preferred products) **AND**
- Two topical calcineurin inhibitors (see PDL for list of preferred products) **AND**
- Must be prescribed by or in conjunction consultation with a dermatologist, allergist/immunologist, or rheumatologist **AND**

Initial approval: 18 weeks

Reauthorization: Dupixent may be authorized for 12 months with prescriber attestation to 16-week IGA score showing improvement by at least 2 points from baseline **OR** clinically significant improvement with Dupixent regimen.

Quantity Limit: 2 syringes every 28 days after initial 14 days of therapy (first dose is twice the regular scheduled dose)

All other non-preferred agents indicated for the treatment of atopic dermatitis may receive approval if meeting the following:

- Member has a diagnosis of moderate to severe chronic atopic dermatitis **AND**
- Member has trialed and failed[‡] the following agents:
 - Two medium potency to very-high potency topical corticosteroids (such as mometasone furoate, betamethasone dipropionate, or fluocinonide)
 - Two topical calcineurin inhibitors (such as pimecrolimus and tacrolimus)**AND**
- The medication is being prescribed by or in consultation with a dermatologist, allergist, immunologist, or rheumatologist.

Initial authorization: 18 weeks

Reauthorization: may be approved for 12 months with prescriber attestation to 16-week IGA score showing improvement by at least 2 points from baseline **OR** clinically significant improvement with regimen.

[‡]Failure is defined as a lack of efficacy with a three-month trial, allergy, intolerable side effects, contraindication to, or significant drug-drug interactions.

Members with current prior authorization approval on file for a non-preferred agent:

- Will be subject to meeting reauthorization criteria listed above for the prescribed agent **OR**

If reauthorization criteria is not listed above, may receive approval for continuation of therapy with the prescribed agent.

Other indications

<p align="center">Preferred (If diagnosis met, No PA required) (Must meet eligibility criteria*)</p>	<p align="center">Non-Preferred PA Required</p>	<p>HUMIRA, ENBREL, OTEZLA and XELJANZ IR may receive approval for use for FDA-labeled indications.</p>
<p>ENBREL (etanercept)</p> <p>HUMIRA (adalimumab)</p> <p>OTEZLA (apremilast) tablet</p> <p>XELJANZ IR (tofacitinib) tablet</p> <p>*XOLAIR (omalizumab) syringe</p>	<p>ACTEMRA (tocilizumab) syringe, Actpen</p> <p>ARCALYST (rilonacept) injection</p> <p>CIMZIA (certolizumab pegol) syringe</p> <p>COSENTYX (secukinumab) syringe, pen-injector</p> <p>DUPIXENT (dupilumab) pen, syringe</p> <p>ILARIS (canakinumab) vial</p> <p>KINERET (anakinra) syringe</p> <p>NUCALA (mepolizumab) auto-injector, syringe</p> <p>OLUMIANT (baricitinib) tablet</p> <p>*For information on IV infused Targeted Immune Modulators please see Appendix-P</p>	<p>Quantity Limit: XELJANZ IR is limited to 2 tablets per day or 60 tablets for a 30-day supply</p> <p>*Xolair (omalizumab) may receive approval if meeting the following based on prescribed indication:</p> <p><u>Chronic Rhinosinusitis with Nasal Polyps:</u></p> <ul style="list-style-type: none"> • If the member has a concomitant diagnosis of asthma or chronic idiopathic urticaria, then criteria listed for the respective diagnosis are met AND • Member is 18 years of age or older AND • Member has a pre-treatment IgE level greater than or equal to 30 IU per mL AND • Member has tried and failed[‡] at least two intranasal corticosteroids (see Intranasal Rhinitis Agents PDL class). Failure is defined as lack of efficacy with a 2-week trial, contraindication to therapy, allergy, intolerable side effects, or significant drug-drug interaction AND • Member is currently adherent to intranasal corticosteroid therapy AND • Member has a baseline bilateral endoscopic nasal polyps score indicating the need for treatment AND • The requested medication is being prescribed by or in consultation with a qualified subspecialist such as an allergist, ear/nose/throat specialist, immunologist, rheumatologist, or pulmonologist AND • Maximum dose for nasal polyps is 600 mg subcutaneously every 2 weeks <p><u>Chronic Idiopathic Urticaria (CIU):</u></p> <ul style="list-style-type: none"> • Member is 12 years of age or older AND • Member is diagnosed with chronic idiopathic urticaria AND • Member is symptomatic despite H1 antihistamine treatment AND • Member has tried and failed[‡] <u>at least three</u> of the following: <ul style="list-style-type: none"> ○ High-dose second generation H1 antihistamine ○ H2 antihistamine ○ First-generation antihistamine ○ Leukotriene receptor antagonist ○ Hydroxyzine or doxepin (must include) <p>AND</p> <ul style="list-style-type: none"> • Prescriber attests that the need for continued therapy will be periodically reassessed (as the appropriate duration of Xolair therapy for CIU has currently not been evaluated).

ARCALYST (rilonacept) may receive approval if meeting the following:

- Medication is being prescribed for one of the following autoinflammatory periodic fever syndromes (approval for all other indications is subject to meeting non-preferred criteria listed below):
 - Cryopyrin-associated Autoinflammatory Syndrome (CAPS), including:
 - Familial Cold Autoinflammatory Syndrome (FCAS)
 - Muckle-Wells Syndrome (MWS)
 - Maintenance of remission of Deficiency of Interleukin-1 Receptor Antagonist (DIRA) in adults and pediatric patients weighing at least 10 kg
 - Treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children ≥ 12 years of age

AND

- Member has trialed and failed[‡] colchicine **AND**
- Initial approval will be given for 12 weeks and authorization approval for continuation will be provided based on clinical response.

DUPIXENT (dupilumab) may receive approval if meeting the following criteria:

- For members that have a diagnosis of asthma and/or atopic dermatitis in addition to another indicated diagnosis for Dupixent (dupilumab), the member must meet criteria listed for the respective diagnosis **AND**
- Request meets the following based on prescribed indication:

Eosinophilic Esophagitis (EoE):

- Member is ≥ 12 years of age **AND**
- Member weighs at least 40 kg **AND**
- Member has a diagnosis of eosinophilic esophagitis (EoE) with ≥ 15 intraepithelial eosinophils per high-power field (eos/hpf), with or without a history of esophageal dilations **AND**
- Member is following appropriate dietary therapy interventions **AND**
- Medication is being prescribed by or in consultation with a gastroenterologist, allergist or immunologist **AND**
- Member has trialed and failed[†] other treatment options for EoE including:
 - Proton pump inhibitor trial of at least eight weeks in duration if reflux is a contributing factor **AND/OR**
 - Minimum four-week trial of local therapy with fluticasone (using a metered dose inhaler) sprayed into the mouth and then swallowed or budesonide slurry.

Chronic Rhinosinusitis with Nasal Polyposis:

- Member is ≥ 18 years of age **AND**
- Medication is being prescribed as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP) **AND**

- Member has a baseline bilateral endoscopic nasal polyps score (NPS; scale 0-8) AND nasal congestion/obstruction score (NC; scale 0-3) averaged over 28-day period **AND**
- Member has trialed and failed‡ therapy with three intranasal corticosteroids (see PDL Class) **AND**
- Medication is being prescribed by or in consultation with a rheumatologist, allergist, ear/nose/throat specialist or pulmonologist **AND**
- Dose of 300mg every 2 weeks is used **AND**
- Initial authorization will be for 24 weeks, for additional 12-month approval member must meet the following criteria:
 - NC and NPS scores are provided and show a 20% reduction in symptoms **AND**
 - Member continues to use primary therapies such as intranasal corticosteroids.

Other Indications:

- Approval for other indications is subject to meeting non-preferred criteria listed below.

ILARIS (canakinumab) may receive approval if meeting the following:

- Medication is being prescribed for one of the following autoinflammatory periodic fever syndromes (approval for all other indications is subject to meeting non-preferred criteria listed below):
 - Familial Mediterranean Fever (FMF)
 - Hyperimmunoglobulinemia D syndrome (HIDS)
 - Mevalonate Kinase Deficiency (MKD)
 - Neonatal onset multisystem inflammatory disease (NOMID)
 - TNF Receptor Associated Periodic Syndrome (TRAPS)
 - Cryopyrin-associated Autoinflammatory Syndrome (including Familial Cold Autoinflammatory Syndrome and Muckle-Wells Syndrome)

AND

- Member has trialed and failed‡ colchicine.

KINERET (anakinra) may receive approval if meeting the following:

- Medication is being prescribed for one of the following indications (approval for all other indications is subject to meeting non-preferred criteria below):
 - Neonatal onset multisystem inflammatory disease (NOMID).
 - Familial Mediterranean Fever (FMF)

AND

- Member has trialed and failed‡ colchicine.

NUCALA (mepolizumab) may receive approval if meeting the following based on prescribed indication:

Chronic Rhinosinusitis with Nasal Polyps:

- Member is 18 years of age or older **AND**
- Medication is being prescribed as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP) **AND**
- Member has a baseline bilateral endoscopic nasal polyps score (NPS; scale 0-8) **AND** nasal congestion/obstruction score (NC; scale 0-3) averaged over 28-day period **AND**
- Member has trialed and failed[‡] therapy with three intranasal corticosteroids (see PDL Class) **AND**
- Medication is being prescribed by or in consultation with a rheumatologist, allergist, ear/nose/throat specialist or pulmonologist **AND**
- Initial authorization will be for 24 weeks, for additional 12-month approval member must meet the following criteria:
 - NC and NPS scores are provided and show a 20% reduction in symptoms from baseline **AND**
 - Member continues to use primary therapies such as intranasal corticosteroids.

Eosinophilic Granulomatosis with polyangiitis (EGPA):

- Member is 18 years of age or older **AND**
- Member has been diagnosed with relapsing or refractory EGPA at least 6 months prior to request as demonstrated by ALL the following:
 - Member has a diagnosis of asthma **AND**
 - Member has a blood eosinophil count of greater than or equal to 1000 cells/mcL or a blood eosinophil level of 10%

AND

- Member has the presence of two of the following EGPA characteristics:
 - Histopathological evidence of eosinophilic vasculitis, perivascular eosinophilic infiltration, or eosinophil-rich granulomatous inflammation
 - Neuropathy
 - Pulmonary infiltrates
 - Sinonasal abnormality
 - Cardiomyopathy
 - Glomerulonephritis
 - Alveolar hemorrhage
 - Palpable purpura
 - Antineutrophil cytoplasmic antibody (ANCA) positive

AND

- Member is on a stable dose of corticosteroids for at least 4 weeks prior to request **AND**
- Dose of 300 mg once every 4 week is being prescribed.

Hypereosinophilic Syndrome (HES):

- Member is 12 years of age or older **AND**
- Member has a diagnosis for HES for at least 6 months that is nonhematologic secondary HES **AND**
- Member has a blood eosinophil count of greater than or equal to 1000 cells/mcL **AND**
- Member has a history of two or more HES flares (defined as worsening clinical symptoms or blood eosinophil counts requiring an increase in therapy) **AND**
- Member has been on stable dose of HES therapy for at least 4 weeks, at time of request, including at least one of the following:
 - Oral corticosteroids
 - Immunosuppressive therapy
 - Cytotoxic therapy**AND**
- Dose of 300 mg once every 4 weeks is being prescribed.

All other non-preferred agents may receive approval for FDA-labeled indications following trial and failure[‡] of all indicated preferred agents (Enbrel, Humira, Xeljanz IR, Taltz, Otezla, Xolair).

[‡]Failure is defined as lack of efficacy with a three-month trial, contraindication to therapy, allergy, intolerable side effects, or significant drug-drug interaction.

Members currently taking Cosentyx may receive approval to continue on that agent. Members with current prior authorization approval on file for Xolair, Dupixent, or Nucala will be subject to meeting reauthorization criteria above when listed for the prescribed indication OR if reauthorization criteria is not listed for the prescribed indication, may receive approval for continuation of therapy.

Note: Prior authorization requests for OLUMIANT (baricitinib) prescribed solely for treating alopecia areata will not be approved.

The Department would like to remind providers that many products are associated with patient-centered programs that are available to assist with drug administration, education, and emotional support related to our members' various disease states.

X. Miscellaneous

Therapeutic Drug Class: **EPINEPHRINE PRODUCTS** -Effective 1/1/2023

No PA Required	PA Required	
EPIPEN ^{BNR} 0.3 mg/0.3 ml (epinephrine) auto-injector	Epinephrine 0.15mg/0.15ml, 0.3mg/0.3ml auto-injector (generic Adrenaclick, Epipen)	Non-preferred products may be approved if the member has failed treatment with one of the preferred products. Failure is defined as allergy to ingredients in product or intolerable side effects. Quantity limit: 4 auto injectors per year unless used / damaged / lost
EPIPEN JR ^{BNR} 0.15 mg/0.15 ml, (epinephrine) auto-injector	SYMJEPI 0.15mg/0.3ml, 0.3mg/0.3ml (epinephrine) syringe	

Therapeutic Drug Class: **NEWER HEREDITARY ANGIOEDEMA PRODUCTS** -Effective 1/1/2023

PA Required for all agents in this class		Medications Indicated for Routine Prophylaxis:
<p style="text-align: center;">Preferred</p> <p><u>Prophylaxis:</u></p> <p>HAEGARDA (C1 esterase inhibitor) vial</p> <p><u>Treatment:</u></p> <p>BERINERT (C1 esterase inhibitor) kit</p> <p>Icatibant syringe (generic FIRAZYR)</p>	<p style="text-align: center;">Non-Preferred</p> <p><u>Prophylaxis:</u></p> <p>CINRYZE (C1 esterase inhibitor) kit</p> <p>ORLADEYO (berotralstat) oral capsule</p> <p>TAKHZYRO (lanadelumab-flyo) vial</p> <p><u>Treatment:</u></p> <p>FIRAZYR (icatibant acetate) syringe</p> <p>RUCONEST (C1 esterase inhibitor, recomb) vial</p>	<p>Members are restricted to coverage of one medication for <u>routine prophylaxis</u> at one time. Prior authorization approval will be for one year.</p> <p>HAEGARDA (C1 esterase inhibitor - human) may be approved for members meeting the following criteria:</p> <ul style="list-style-type: none"> ○ Member has a diagnosis of HAE confirmed by laboratory tests obtained on two separate instances at least one month apart (C4 level, C1-INH level) AND ○ Member has a documented history of at least one symptom of a moderate to severe HAE attack (moderate to severe abdominal pain, facial swelling, airway swelling) in the absence of hives or a medication known to cause angioedema AND ○ Member meets at least one of the following: <ul style="list-style-type: none"> ▪ Haegarda is being used for short-term prophylaxis to undergo a surgical procedure or major dental work OR ▪ Haegarda is being used for long-term prophylaxis and member meets one of the following: <ul style="list-style-type: none"> ○ History of ≥ 1 attack per month resulting in documented ED admission or hospitalization OR ○ History of laryngeal attacks OR ○ History of ≥ 2 attacks per month involving the face, throat, or abdomen AND ○ Member is not taking medications that may exacerbate HAE including ACE inhibitors and estrogen-containing medications AND ○ Member has received hepatitis A and hepatitis B vaccination AND ○ Provider attests to performing annual testing or screening (as appropriate) for HBV, HCV, and HIV <p>Maximum Dose: 60 IU/kg Minimum Age: 6 years</p>

CINRYZE (C1 esterase inhibitor - human) may be approved for members meeting the following criteria:

- Member has history of trial and failure of Haegarda. Failure is defined as lack of efficacy allergy, intolerable side effects, or a significant drug-drug interaction **AND**
- Member has a diagnosis of HAE confirmed by laboratory tests obtained on two separate instances at least one month apart (C4 level, C1-INH level) **AND**
- Member has a documented history of at least one symptom of a moderate to severe HAE attack (moderate to severe abdominal pain, facial swelling, airway swelling) in the absence of hives or a medication known to cause angioedema **AND**
- Member meets at least one of the following:
 - Cinryze is being used for short-term prophylaxis to undergo a surgical procedure or major dental work **OR**
 - Cinryze is being used for long-term prophylaxis and member meets one of the following:
 - History of ≥ 1 attack per month resulting in documented ED admission or hospitalization **OR**
 - History of laryngeal attacks **OR**
 - History of ≥ 2 attacks per month involving the face, throat, or abdomen **AND**
- Member is not taking medications that may exacerbate HAE including ACE inhibitors and estrogen-containing medications **AND**
- Member has received hepatitis A and hepatitis B vaccination **AND**
- Provider attests to performing annual testing or screening (as appropriate) for HBV, HCV, and HIV.

Minimum age: 6 years

Maximum dose: 100 Units/kg

ORLADEYO (berotralstat) may be approved for members meeting the following criteria:

- Member has history of trial and failure of HAEGARDA. Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction **AND**
- Member has a diagnosis of HAE confirmed by laboratory tests obtained on two separate instances at least one month apart (C4 level, C1-INH level) **AND**
- Member has a documented history of at least one symptom of a moderate to severe HAE attack (moderate to severe abdominal pain, facial swelling, airway swelling) in the absence of hives or a medication known to cause angioedema **AND**
- ORLADEYO is prescribed by or in consultation with an allergist or immunologist **AND**
- Appropriate drug interaction interventions will be made for members using concomitant medications that may require dose adjustments (such as cyclosporine, fentanyl, pimozide, digoxin) **AND**

- Member meets at least one of the following:
 - ORLADEYO is being used for short-term prophylaxis to undergo a surgical procedure or major dental work
 - ORLADEYO is being used for long-term prophylaxis and member meets one of the following:
 - History of ≥ 1 attack per month resulting in documented ED admission or hospitalization **OR**
 - History of laryngeal attacks **OR**
 - History of ≥ 2 attacks per month involving the face, throat, or abdomen **AND**
 - Member is not taking medications that may exacerbate HAE, including ACE inhibitors and estrogen-containing medications

Minimum age: 12 years

Maximum dose: 150 mg once daily

TAKHZYRO (lanadelumab-flyo) may be approved for members meeting the following criteria:

- Member has history of trial and failure of Haegarda. Failure is defined as: lack of efficacy, allergy, intolerable side effects, or a significant drug-drug interaction **AND**
- Member has a diagnosis of HAE confirmed by laboratory tests obtained on two separate instances at least one month apart (C4 level, C1-INH level) **AND**
- Member has a documented history of at least one symptom of a moderate to severe HAE attack (moderate to severe abdominal pain, facial swelling, airway swelling) in the absence of hives or a medication known to cause angioedema **AND**
- Member is not taking medications that may exacerbate HAE including ACE inhibitors and estrogen-containing medications **AND**
- Member has received hepatitis A and hepatitis B vaccination.

Minimum age: 2 years

Maximum dose: The recommended starting dose is 300mg every 2 weeks. A dosing interval of 300 mg every 4 weeks is also effective and may be considered if the patient is well-controlled (attack free) for more than 6 months

Medications Indicated for Treatment of Acute Attacks:

Members are restricted to coverage of one medication for treatment of acute attacks at one time. Prior authorization approval will be for one year.

FIRAZYR (icatibant acetate) may be approved for members meeting the following criteria:

- Member has a diagnosis of HAE confirmed by laboratory tests obtained on two separate instances at least one month apart (C4 level, C1-INH level) **AND**

- Member has a documented history of at least one symptom of a moderate to severe HAE attack (moderate to severe abdominal pain, facial swelling, airway swelling) in the absence of hives or a medication known to cause angioedema AND
- Member is not taking medications that may exacerbate HAE including ACE inhibitors and estrogen-containing medications

Minimum age: 18 years

Maximum dose: 30mg

BERINERT (C1 esterase inhibitor - human) may be approved for members meeting the following criteria:

- Member has a diagnosis of HAE confirmed by laboratory tests obtained on two separate instances at least one month apart (C4 level, C1-INH level) **AND**
- Member has a documented history of at least one symptom of a moderate to severe HAE attack (moderate to severe abdominal pain, facial swelling, airway swelling) in the absence of hives or a medication known to cause angioedema AND
- Member is not taking medications that may exacerbate HAE including ACE inhibitors and estrogen-containing medications **AND**
- Member has received hepatitis A and hepatitis B vaccination **AND**
- Provider attests to performing annual testing or screening (as appropriate) for HBV, HCV, and HIV

Minimum age: 6 years

Max dose: 20 IU/kg

RUCONEST (C1 esterase inhibitor - recombinant) may be approved for members meeting the following criteria:

- Member has a history of trial and failure of Firazyr OR Berinert. Failure is defined as lack of efficacy, allergy, intolerable side effects, or a significant drug-drug interaction **AND**
- Member has a diagnosis of HAE confirmed by laboratory tests obtained on two separate instances at least one month apart (C4 level, C1-INH level) **AND**
- Member has a documented history of at least one symptom of a moderate to severe HAE attack (moderate to severe abdominal pain, facial swelling, airway swelling) in the absence of hives or a medication known to cause angioedema AND
- Member is not taking medications that may exacerbate HAE including ACE inhibitors and estrogen-containing medications **AND**
- Member has received hepatitis A and hepatitis B vaccination **AND**
- Provider attests to performing annual testing or screening (as appropriate) for HBV, HCV, and HIV.

Minimum age: 13 years

Maximum dose: 4,200 Units/dose

		<p>All other non-preferred agents may be approved if the member has trialed and failed at least two preferred agents with the same indicated role in therapy as the prescribed medication (prophylaxis or treatment). Failure is defined as lack of efficacy, allergy, intolerable side effects, or a significant drug-drug interaction.</p>
Therapeutic Drug Class: PHOSPHATE BINDERS -Effective 10/1/2023		
<p style="text-align: center;">No PA Required</p> <p>Calcium acetate capsule</p> <p>PHOSLYRA (calcium acetate) solution</p> <p>RENAGEL (sevelamer HCl) 800mg tablet</p> <p>RENVELA^{BNR} (sevelamer carbonate) tablet, powder pack</p> <p>Sevelamer HCl 800mg tablet</p>	<p style="text-align: center;">PA Required</p> <p>AURYXIA (ferric citrate) tablet</p> <p>Calcium acetate tablet</p> <p>CALPHRON (calcium acetate) tablet</p> <p>FOSRENOL (lanthanum carbonate) chewable tablet, powder pack</p> <p>Lanthanum carbonate chewable tablet</p> <p>Sevelamer carbonate tablet, powder pack</p> <p>Sevelamer HCl 400mg tablet</p> <p>VELPHORO (sucroferric oxide) chewable tablet</p>	<p>Prior authorization for non-preferred products in this class may be approved if member meets all the following criteria:</p> <ul style="list-style-type: none"> ● Member has diagnosis of end stage renal disease AND ● Member has elevated serum phosphorus [> 4.5 mg/dL or > 1.46 mmol/L] AND ● Provider attests to member avoidance of high phosphate containing foods from diet AND ● Member has trialed and failed‡ one preferred agent (lanthanum products require trial and failure‡ of a preferred sevelamer product). <p>Auryxia (ferric citrate) may be approved if the member meets all the following criteria:</p> <ul style="list-style-type: none"> ● Member is diagnosed with end-stage renal disease, receiving dialysis, and has elevated serum phosphate (> 4.5 mg/dL or > 1.46 mmol/L). AND ● Provider attests to counseling member regarding avoiding high phosphate containing foods from diet AND ● Member has trialed and failed‡ three preferred agents with different mechanisms of action prescribed for hyperphosphatemia in end stage renal disease <p>OR</p> <ul style="list-style-type: none"> ● Member is diagnosed with chronic kidney disease with iron deficiency anemia and is not receiving dialysis AND ● Member has tried and failed‡ at least two different iron supplement product formulations (OTC or RX) <p>Velphoro (sucroferric oxyhydroxide tablet, chewable) may be approved if the member meets all of the following criteria:</p> <ul style="list-style-type: none"> ● Member is diagnosed with chronic kidney disease and receiving dialysis and has elevated serum phosphate (> 4.5 mg/dL or > 1.46 mmol/L). AND ● Provider attests to counseling member regarding avoiding high phosphate containing foods from diet AND ● Member has trialed and failed‡ two preferred agents, one of which must be a preferred sevelamer product Maximum Dose: Velphoro 3000mg daily <p>Members currently stabilized on a non-preferred lanthanum product may receive approval to continue therapy with that product.</p> <p>‡Failure is defined as lack of efficacy with 6-week trial, allergy, intolerable side effects, or significant drug-drug interaction.</p>

Note: Medications administered in a dialysis unit or clinic are billed through the Health First Colorado medical benefit or Medicare with members with dual eligibility.

Therapeutic Drug Class: PRENATAL VITAMINS / MINERALS -Effective 10/1/2023

<p>Preferred *Must meet eligibility criteria</p>	<p>Non-Preferred PA Required</p>	
<p>COMPLETE NATAL DHA tablet</p> <p>M-NATAL PLUS tablet</p> <p>NESTABS tablets</p> <p>PNV 29-1 tablet</p> <p>PRENATAL VITAMIN PLUS LOW IRON tablet <i>(Patrin Pharma only)</i></p> <p>PREPLUS CA-FE 27 mg – FA 1 mg tablet</p> <p>SE-NATAL 19 chewable tablet</p> <p>TARON-C DHA capsule</p> <p>THRIVITE RX tablet</p> <p>TRINATAL RX 1 tablet</p> <p>Virt C DHA softgel</p> <p>VITAFOL gummies</p> <p>VP-PNV-DHA softgel</p> <p>WESTAB PLUS tablet</p>	<p>All other rebateable prescription products are non-preferred</p>	<p>*Preferred and non-preferred prenatal vitamin products are a benefit for members from 11-60 years of age who are pregnant, lactating, or trying to become pregnant.</p> <p>Prior authorization for non-preferred agents may be approved if member fails 7-day trial with four preferred agents. Failure is defined as: allergy, intolerable side effects, or significant drug-drug interaction.</p>

XI. Ophthalmic

Therapeutic Drug Class: **OPHTHALMIC, ALLERGY** -Effective 4/1/2023

No PA Required	PA Required	
<p>ALREX (loteprednol) 2%</p> <p>Cromolyn 4%</p> <p>Ketotifen 0.025% (OTC)</p> <p>LASTACAFT (alcaftadine) 0.25% (OTC)</p> <p>Olopatadine 0.1%, 0.2% (OTC) (generic Pataday Once Daily)</p>	<p>ALOCRIIL (nedocromil) 2%</p> <p>ALOMIDE (lodoxamide) 0.1%</p> <p>Azelastine 0.05%</p> <p>Bepotastine 1.5%</p> <p>BEPREVE (bepotastine) 1.5%</p> <p>Epinastine 0.05%</p> <p>LASTACAFT (alcaftadine) 0.25% (Rx) Olopatadine 0.1%, 0.2% (RX)</p> <p>PATADAY ONCE DAILY (olopatadine) 0.2% (OTC)</p> <p>PATADAY TWICE DAILY (olopatadine) 0.1% (OTC)</p> <p>PATADAY XS ONCE DAILY (olopatadine) 0.7% (OTC)</p> <p>ZADITOR (ketotifen) 0.025% (OTC)</p> <p>ZERVIAATE (cetirizine) 0.24%</p>	<p>Non-preferred products may be approved following trial and failure of therapy with two preferred products (failure is defined as lack of efficacy, allergy, intolerable side effects or significant drug-drug interactions).</p>

Therapeutic Drug Class: **OPHTHALMIC, IMMUNOMODULATORS** -Effective 4/1/2023

No PA Required	PA Required	
<p>RESTASIS^{BNR} (cyclosporine 0.05%) vials</p>	<p>CEQUA (cyclosporine) 0.09% solution</p> <p>Cyclosporine 0.05% vials</p> <p>RESTASIS MULTIDOSE (cyclosporine) 0.05%</p>	<p>Non-preferred products may be approved for members meeting all of the following criteria:</p> <ul style="list-style-type: none"> ● Member is 18 years and older AND ● Member has a diagnosis of chronic dry eye AND ● Member has failed a 3-month trial of one preferred product. Failure is defined as a lack of efficacy, allergy, intolerable side effects, contraindication to, or significant drug-drug interactions AND

	TYRVAYA (varenicline) nasal spray XIIDRA (lifitegrast) 5% solution	<ul style="list-style-type: none"> Prescriber is an ophthalmologist, optometrist or rheumatologist <u>Maximum Dose/Quantity:</u> 60 single use containers for 30 days 5.5 mL/20 days for Restasis Multi-Dose
Therapeutic Drug Class: OPTHALMIC, ANTI-INFLAMMATORIES -Effective 4/1/2023		
NSAIDs		Durezol (difluprednate) may be approved if meeting the following criteria: <ul style="list-style-type: none"> Member has a diagnosis of severe intermediate uveitis, severe panuveitis, or severe uveitis with the complication of uveitic macular edema AND has trialed and failed prednisolone acetate 1% (failure is defined as lack of efficacy, allergy, contraindication to therapy, intolerable side effects, or significant drug-drug interaction) OR Members with a diagnosis other than those listed above require trial and failure of three preferred agents (failure is defined as lack of efficacy, contraindication to therapy, allergy, intolerable side effects, or significant drug-drug interaction). Eysuvis (loteprednol etabonate) may be approved if meeting all of the following: <ul style="list-style-type: none"> Member is \geq 18 years of age AND Eysuvis (loteprednol etabonate) is being used for short-term treatment (up to two weeks) of the signs and symptoms of dry eye disease AND Member has failed treatment with one preferred product in the Ophthalmic Immunomodulator therapeutic class. Failure is defined as lack of efficacy with a 3-month trial, contraindication to therapy, allergy, intolerable side effects, or significant drug-drug interaction) AND Member does not have any of the following conditions: Viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella OR Mycobacterial infection of the eye and fungal diseases of ocular structures <u>Quantity limit:</u> one bottle/15 days Lotemax SM (loteprednol etabonate) or Inveltys (loteprednol etabonate) may be approved if meeting all of the following: <ul style="list-style-type: none"> Member is \geq 18 years of age AND Lotemax SM or Inveltys (loteprednol etabonate) is being used for the treatment of post-operative inflammation and pain following ocular surgery AND Member has trialed and failed therapy with two preferred loteprednol formulations (failure is defined as lack of efficacy with 2-week trial, allergy,
No PA Required	PA Required	
Diclofenac 0.1% Flurbiprofen 0.03% Ketorolac 0.5%, Ketorolac LS 0.4% NEVANAC (nepafenac) 0.1%	ACULAR (ketorolac) 0.5%, LS 0.4% ACUVAIL (ketorolac/PF) 0.45% Bromfenac 0.09% BROMSITE (bromfenac) 0.075% ILEVRO (nepafenac) 0.03% PROLENSA (bromfenac) 0.07%	
Corticosteroids		
No PA Required	PA Required	
FLAREX (fluorometholone) 0.1% Fluorometholone 0.1% drops FML FORTE (fluorometholone) 0.25% drops LOTEMAX ^{BNR} (loteprednol) 0.5% drops LOTEMAX (loteprednol) 0.5% ointment MAXIDEX (dexamethasone) 0.1% PRED MILD (prednisolone) 0.12% Prednisolone acetate 1%	Dexamethasone 0.1% Difluprednate 0.05% DUREZOL (difluprednate) 0.05% EYSUVIS (loteprednol) 0.25% FML LIQUIFILM (fluorometholone) 0.1% drop FML S.O.P (fluorometholone) 0.1% ointment INVELTYS (loteprednol) 1% LOTEMAX (loteprednol) 0.5% gel	

	<p>LOTEMAX SM (loteprednol) 0.38% gel</p> <p>Loteprednol 0.5% drops, 0.5% gel</p> <p>PRED FORTE (prednisolone) 1%</p> <p>Prednisolone sodium phosphate 1%</p> <p>Verkazia (cyclosporine) 0.1% emulsion</p>	<p>contraindication to therapy, intolerable side effects, or significant drug-drug interaction) AND</p> <ul style="list-style-type: none"> Member has trialed and failed therapy with two preferred agents that do not contain loteprednol (failure is defined as lack of efficacy with 2-week trial, contraindication to therapy, allergy, intolerable side effects, or significant drug-drug interaction) AND Member does not have any of the following conditions: <ul style="list-style-type: none"> Viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella OR Mycobacterial infection of the eye and fungal diseases of ocular structures <p>Verkazia (cyclosporine ophthalmic emulsion) may be approved if the following criteria are met:</p> <ul style="list-style-type: none"> Member is ≥ 4 years of age AND Verkazia is being used for the treatment of vernal keratoconjunctivitis (VKC) AND Member has trialed and failed therapy with three agents from the following pharmacologic categories: preferred dual-acting mast cell stabilizer/antihistamine from the Ophthalmics-Allergy PDL class, oral antihistamine, preferred topical ophthalmic corticosteroid from the Ophthalmics-Anti-inflammatories PDL class. Failure is defined as lack of efficacy with 2-week trial, allergy, contraindication to therapy, intolerable side effects, or significant drug-drug interaction <u>Quantity limit</u>: 120 single-dose 0.3 mL vials/15 days <p>All other non-preferred products may be approved with trial and failure of three preferred agents (failure is defined as lack of efficacy with 2-week trial, allergy, contraindication, intolerable side effects, or significant drug-drug interaction).</p>
Therapeutic Drug Class: OPHTHALMIC, GLAUCOMA -Effective 4/1/2023		
Beta-blockers		
No PA Required	PA Required	<p>Non-preferred products may be approved following trial and failure of therapy with three preferred products, including one trial with a preferred product having the same general mechanism (such as prostaglandin analogue, alpha2-adrenergic agonist, beta-blocking agent, or carbonic anhydrase inhibitor). Failure is defined as lack of efficacy with 4-week trial, allergy, intolerable side effects or significant drug-drug interactions.</p> <p>Non-preferred combination products may be approved following trial and failure of therapy with one preferred combination product AND trial and failure of individual products with the same active ingredients as the combination product being requested (if available) to establish tolerance. Failure is defined as lack of efficacy with 4-week trial, allergy, intolerable side effects or significant drug-drug interactions.</p> <p>Preservative free products may be approved with provider documentation of adverse effect to preservative-containing product.</p>
Levobunolol 0.5% Timolol (generic Timoptic) 0.25%, 0.5%	Betaxolol 0.5% BETIMOL (timolol) 0.25%, 0.5% BETOPIC-S (betaxolol) 0.25% Carteolol 1% ISTALOL (timolol) 0.5% Timolol (generic Istalol) 0.5% drops	

	<p>Timolol GFS 0.25%, 0.5%</p> <p>TIMOPTIC, TIMOPTIC OCUDOSE (timolol) 0.25%, 0.5%</p> <p>TIMOPTIC-XE (timolol GFS) 0.25%, 0.5%</p>	
Carbonic anhydrase inhibitors		
No PA Required	PA Required	
<p>AZOPT^{BNR} (brinzolamide) 1%</p> <p>Dorzolamide 2%</p>	<p>Brinzolamide 1%</p> <p>TRUSOPT (dorzolamide) 2%</p>	
Prostaglandin analogue		
No PA Required	PA Required	
<p>Latanoprost 0.005%</p> <p>LUMIGAN (bimatoprost) 0.01%</p> <p>TRAVATAN Z^{BNR} (travoprost) 0.004%</p>	<p>Bimatoprost 0.03%</p> <p>Tafluprost 0.0015%</p> <p>Travoprost 0.004%</p> <p>VYZULTA (latanoprostene) 0.024%</p> <p>XALATAN (latanoprost) 0.005%</p> <p>XELPROS (latanoprost) 0.005%</p> <p>ZIOPTAN (tafluprost PF) 0.0015%</p>	
Alpha-2 adrenergic agonists		
No PA Required	PA Required	
<p>ALPHAGAN P^{BNR} 0.1% (brimonidine)</p> <p>ALPHAGAN P^{BNR} 0.15% (brimonidine)</p> <p>Brimonidine 0.2%</p>	<p>Apraclonidine 0.5%</p> <p>Brimonidine 0.1%</p> <p>Brimonidine 0.15%</p> <p>IOPIDINE (apraclonidine) 0.5%, 1%</p>	

Other ophthalmic, glaucoma and combinations	
No PA Required	PA Required
COMBIGAN ^{BNR} 0.2%-0.5% (brimonidine/timolol)	Brimonidine/Timolol 0.2%-0.5%
Dorzolamide/Timolol 2%-0.5%	COSOPT/COSOPT PF (dorzolamide/timolol) 2%-0.5%
	Dorzolamide/Timolol PF 2%-0.5%
	PHOSPHOLINE IODIDE (echothiophate) 0.125%
	Pilocarpine 1%, 2%, 4%
	RHOPRESSA (netarsudil) 0.02%
	ROCKLATAN (netarsudil/latanoprost) 0.02%-0.005%
	SIMBRINZA (brinzolamide/brimonidine) 1%-0.2%
	VUITY (pilocarpine) 1.25%

XII. Renal/Genitourinary

Therapeutic Drug Class: **BENIGN PROSTATIC HYPERPLASIA (BPH) AGENTS** -Effective 10/1/2023

No PA Required	PA Required	
Alfuzosin ER tablet	AVODART (dutasteride) softgel	<p>Prior authorization for non-preferred products in this class may be approved if member meets all of the following criteria:</p> <ul style="list-style-type: none"> • Member has tried and failed‡ three preferred agents AND • For combinations agents, member has tried and failed‡ each of the individual agents within the combination agent and one other preferred agent. <p>‡Failure is defined as lack of efficacy with 8-week trial, allergy, intolerable side effects, contraindication to, or significant drug-drug interaction.</p> <p>*CIALIS (tadalafil) may be approved for members with a documented diagnosis of BPH who have failed a trial of finasteride (at least 3 months in duration) AND either a trial of a nonselective alpha blocker (therapeutic dose for at least two months) OR a trial of tamsulosin (therapeutic dose for at least one month). Documentation of BPH diagnosis will require BOTH of the following:</p>
Doxazosin tablet	CARDURA (doxazosin) tablet	
Dutasteride capsule	CARDURA XL (doxazosin ER) tablet	
Finasteride tablet	*CIALIS (tadalafil) 2.5 mg, 5 mg tablet	
Tamsulosin capsule	Dutasteride/tamsulosin capsule	
Terazosin capsule	ENTADFI (finasteride/tadalafil) capsule	
	FLOMAX (tamsulosin) capsule	

	<p>JALYN (dutasteride/tamsulosin) capsule</p> <p>PROSCAR (finasteride) tablet</p> <p>RAPAFLO (silodosin) capsule</p> <p>Silodosin capsule</p> <p>*Tadalafil 2.5 mg, 5 mg tablet</p>	<ul style="list-style-type: none"> • AUA Prostate Symptom Score ≥ 8 AND • Results of a digital rectal exam. <p>Cialis (tadalafil) will not be approved for any patient continuing alpha-blocker therapy as this combination is contraindicated in this population.</p> <p>Doses exceeding 5mg per day of Cialis (tadalafil) will not be approved.</p>
--	---	---

Therapeutic Drug Class: ANTI-HYPERURICEMICS -Effective 10/1/2023

No PA Required	PA Required	
<p>Allopurinol 100 mg, 300 mg tablets</p> <p>Colchicine tablet</p> <p>Febuxostat tablet</p> <p>Probenecid tablet</p> <p>Probenecid/Colchicine tablet</p>	<p>Allopurinol 200 mg tablets</p> <p>Colchicine capsule</p> <p>COLCRYS (colchicine) tablet</p> <p>GLOPERBA (colchicine) oral solution</p> <p>MITIGARE (colchicine) capsule</p> <p>ULORIC (febuxostat) tablet</p> <p>ZYLOPRIM (allopurinol) tablet</p>	<p>Non-preferred xanthine oxidase inhibitor products (allopurinol or febuxostat formulations) may be approved following trial and failure of preferred allopurinol. Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction. If member has tested positive for the HLA-B*58:01 allele, it is not recommended that they trial allopurinol. A positive result on this genetic test will count as a failure of allopurinol.</p> <p>Prior authorization for all other non-preferred agents (non-xanthine oxidase inhibitors) may be approved after trial and failure of two preferred products. Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction.</p> <p>GLOPERBA (colchicine) oral solution may be approved for members who require individual doses <0.6 mg OR for members who have documented swallowing difficulty due to young age and/or a medical condition (preventing use of solid oral dosage form).</p> <p>Colchicine tablet quantity limits:</p> <ul style="list-style-type: none"> • Chronic hyperuricemia/gout prophylaxis: 60 tablets per 30 days • Familial Mediterranean Fever: 120 tablets per 30 days

Therapeutic Drug Class: OVERACTIVE BLADDER AGENTS -Effective 10/1/2023

No PA Required	PA Required	
<p>GELNIQUE (oxybutynin) gel</p> <p>MYRBETRIQ (mirabegron) tablet</p> <p>Oxybutynin IR, ER tablets, syrup</p> <p>Solifenacin tablet</p> <p>TOVIAZ^{BNR} (Fesoterodine ER) tablet</p>	<p>Darifenacin ER tablet</p> <p>DETROL (tolterodine) tablet</p> <p>DETROL LA (tolterodine ER) ER capsule</p> <p>DITROPAN (Oxybutynin) tablet</p> <p>DITROPAN XL (Oxybutynin ER) tablet</p> <p>Fesoterodine ER tablet</p> <p>Flavoxate tablet</p>	<p>Non-preferred products may be approved for members who have failed treatment with two preferred products. Failure is defined as: lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction.</p> <p>Members with hepatic failure can receive approval for trospium (Sanctura) or trospium extended release (Sanctura XR) products without a trial on a Preferred product.</p>

	<p>GELNIQUE (oxybutynin) gel pump</p> <p>GEMTESA (vibegron) tablet</p> <p>MYRBETRIQ (mirabegron) suspension</p> <p>OXYTROL (oxybutynin patch)</p> <p>SANCTURA (trospium)</p> <p>SANCTURA XL (trospium ER)</p> <p>Tolterodine tablet, ER capsule</p> <p>Trospium ER capsule, tablet</p> <p>VESICARE (solifenacin) tablet</p> <p>VESICARE LS (solifenacin) suspension</p>	
--	---	--

XIII. RESPIRATORY

Therapeutic Drug Class: **RESPIRATORY AGENTS** -Effective 1/1/2023

Inhaled Anticholinergics

Preferred No PA Required (Unless indicated*)	Non-Preferred PA Required	
<p><u>Solutions</u> Ipratropium solution</p> <p><u>Short-Acting Inhalation Devices</u> ATROVENT HFA (ipratropium)</p> <p><u>Long-Acting Inhalation Devices</u> SPIRIVA Handihaler^{BNR} (tiotropium) *SPIRIVA RESPIMAT (tiotropium)</p>	<p><u>Solutions</u> LONHALA MAGNAIR (glycopyrrolate) solution</p> <p>YUPELRI (revefenacin) solution</p> <p><u>Short-Acting Inhalation Devices</u></p> <p><u>Long-Acting Inhalation Devices</u> INCRUSE ELLIPTA (umeclidinium) TUDORZA PRESSAIR (aclidinium)</p>	<p>*SPIRIVA RESPIMAT (tiotropium) 1.25 mcg may be approved for members \geq 6 years of age with a diagnosis of asthma (qualifying diagnosis verified by AutoPA). SPIRIVA RESPIMAT is intended to be used by members whose asthma is not controlled with regular use of a combination medium-dose inhaled corticosteroid and long-acting beta agonist (LABA).</p> <p>*SPIRIVA RESPIMAT (tiotropium) 2.5 mcg may be approved for members with a diagnosis of COPD who have trialed and failed SPIRIVA HANDIHALER. Failure is defined as intolerable side effects or inability to use dry powder inhaler (DPI) formulation.</p> <p>LONHALA MAGNAIR (glycopyrrolate) may be approved for members \geq 18 years of age with a diagnosis of COPD including chronic bronchitis and emphysema who have trialed and failed[‡] treatment with two preferred anticholinergic agents.</p> <p>Non-preferred single agent anticholinergic agents may be approved for members with a diagnosis of COPD including chronic bronchitis and/or emphysema who have trialed and failed[‡] treatment with two preferred agents, one of which must be SPIRIVA HANDIHALER.</p>

		‡Failure is defined as lack of efficacy with 6-week trial, allergy, intolerable side effects, or significant drug-drug interaction.
Inhaled Anticholinergic Combinations		
<p style="text-align: center;">No PA Required</p> <p><u>Solutions</u> Albuterol/ipratropium solution</p> <p><u>Short-Acting Inhalation Devices</u> COMBIVENT RESPIMAT (albuterol/ipratropium)</p> <p><u>Long-Acting Inhalation Devices</u> ANORO ELLIPTA (umeclidinium/vilanterol)</p>	<p style="text-align: center;">PA Required</p> <p><u>Solutions</u></p> <p><u>Short-Acting Inhalation Devices</u></p> <p><u>Long-Acting Inhalation Devices</u> BEVESPI AEROSPHERE (glycopyrrolate /formoterol fumarate)</p> <p>BREZTRI AEROSPHERE (budesonide/glycopyrrolate/ formoterol)</p> <p>DUAKLIR PRESSAIR (aclidinium/formoterol)</p> <p>STIOLTO RESPIMAT (tiotropium/olodaterol)</p>	<p>BREZTRI AEROSPHERE (budesonide/glycopyrrolate/formoterol) may be approved for members ≥ 18 years of age with a diagnosis of COPD who have trialed and failed‡ treatment with two preferred anticholinergic-containing agents.</p> <p>DUAKLIR PRESSAIR (aclidinium/formoterol) may be approved for members ≥ 18 years of age with a diagnosis of COPD who have trialed and failed‡ treatment with two preferred anticholinergic-containing agents.</p> <p>All other non-preferred inhaled anticholinergic combination agents may be approved for members with a diagnosis of COPD including chronic bronchitis and/or emphysema who have trialed and failed‡ treatment with two preferred inhaled anticholinergic combination agents OR three preferred inhaled anticholinergic-containing agents (single ingredient or combination).</p> <p>Members who are currently stabilized on Bevespi Aerosphere may receive approval to continue therapy with that product.</p> <p>‡Failure is defined as lack of efficacy with 6-week trial, allergy, intolerable side effects, or significant drug-drug interaction.</p>
Inhaled Beta2 Agonists (short acting)		
<p style="text-align: center;">No PA Required</p> <p><u>Solutions</u> Albuterol solution, for nebulizer</p> <p><u>Inhalers</u> PROAIR^{BNR} HFA (albuterol)</p> <p>PROVENTIL^{BNR} HFA (albuterol)</p> <p>VENTOLIN^{BNR} HFA (albuterol)</p>	<p style="text-align: center;">PA Required</p> <p><u>Solutions</u> Levalbuterol solution</p> <p>XOPENEX (levalbuterol) solution</p> <p><u>Inhalers</u> Albuterol HFA</p> <p>Levalbuterol HFA</p> <p>PROAIR DIGIHALER, RESPICLICK (albuterol)</p> <p>XOPENEX (levalbuterol) Inhaler</p>	<p>Non-preferred short acting beta-2 agonists may be approved for members who have failed treatment with one preferred agent. Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction.</p> <p>MDI formulation quantity limits: 2 inhalers / 30 days</p>

Inhaled Beta2 Agonists (long acting)

<p style="text-align: center;">Preferred</p> <p>*Must meet eligibility criteria</p> <p><u>Solutions</u></p> <p><u>Inhalers</u></p> <p>*SEREVENT DISKUS (salmeterol) inhaler</p>	<p style="text-align: center;">Non-Preferred PA Required</p> <p><u>Solutions</u></p> <p>Arformoterol solution</p> <p>BROVANA (arformoterol) solution</p> <p>Formoterol solution</p> <p>PERFOROMIST (formoterol) solution</p> <p><u>Inhalers</u></p> <p>STRIVERDI RESPIMAT (olodaterol)</p>	<p>*SEREVENT (salmeterol) may be approved for members with moderate to very severe COPD. Serevent will not be approved for treatment of asthma in members needing add-on therapy due to safety risks associated with monotherapy.</p> <p>Non-preferred agents may be approved for members with moderate to severe COPD, AND members must have failed a trial of Serevent. Failure is defined as lack of efficacy with a 6-week trial, allergy, intolerable side effects, or significant drug-drug interaction.</p> <p>For treatment of members with diagnosis of asthma needing add-on therapy, please refer to preferred agents in combination Long-Acting Beta Agonist/Inhaled Corticosteroid therapeutic class.</p>
---	---	--

Inhaled Corticosteroids

<p style="text-align: center;">No PA Required</p> <p><u>Solutions</u></p> <p>Budesonide nebulas</p> <p><u>Inhalers</u></p> <p>ASMANEX Twisthaler (mometasone)</p> <p>FLOVENT DISKUS (fluticasone)</p> <p>FLOVENT HFA^{BNR} (fluticasone)</p> <p>PULMICORT FLEXHALER (budesonide)</p>	<p style="text-align: center;">PA Required</p> <p><u>Solutions</u></p> <p>PULMICORT (budesonide) nebulas</p> <p><u>Inhalers</u></p> <p>ALVESCO (ciclesonide) inhaler</p> <p>ARMONAIR DIGIHALER (fluticasone propionate)</p> <p>ARNUITY ELLIPTA (fluticasone furoate)</p> <p>ASMANEX HFA (mometasone furoate) inhaler</p> <p>Fluticasone propionate HFA</p> <p>QVAR REDIHALER (beclomethasone)</p>	<p>Non-preferred inhaled corticosteroids may be approved in members with asthma who have failed an adequate trial of two preferred agents. An adequate trial is defined as at least 6 weeks. (Failure is defined as: lack of efficacy with a 6-week trial, allergy, contraindication to, intolerable side effects, or significant drug-drug interactions.)</p> <p><u>Maximum Dose:</u></p> <p>Pulmicort (budesonide) nebulizer suspension: 2mg/day</p>
---	--	--

Inhaled Corticosteroid Combinations

<p style="text-align: center;">No PA Required</p> <p>ADVAIR DISKUS^{BNR} (fluticasone/salmeterol)</p> <p>ADVAIR HFA^{BNR} (fluticasone/salmeterol)</p> <p>DULERA (mometasone/formoterol)</p>	<p style="text-align: center;">PA Required</p> <p>AIRDUO DIGIHALER, RESPICLICK (fluticasone/salmeterol)</p> <p>BREO ELLIPTA (vilanterol/fluticasone furoate)</p> <p>Budesonide/formoterol (generic Symbicort)</p>	<p>Non-preferred inhaled corticosteroid combinations may be approved for members meeting both of the following criteria:</p> <ul style="list-style-type: none"> • Member has a qualifying diagnosis of asthma or severe COPD; AND • Member has failed two preferred agents (Failure is defined as lack of efficacy with a 6-week trial, allergy, intolerable side effects, significant drug-drug interactions, or dexterity/coordination limitations (per provider notes) that significantly impact appropriate use of a specific dosage form.)
---	--	---

<p>SYMBICORT^{BNR} (budesonide/formoterol) inhaler</p>	<p>Fluticasone/salmeterol (generic Airduo)</p> <p>Fluticasone/salmeterol (generic Advair Diskus)</p> <p>Fluticasone/Salmeterol HFA (generic Advair HFA)</p> <p>Fluticasone/vilanterol (generic Breo Ellipta)</p> <p>TRELEGY ELLIPTA (fluticasone furoate/umeclidinium/vilanterol)</p> <p>WIXELA INHUB (fluticasone/salmeterol)</p>	<p>TRELEGY ELLIPTA (fluticasone furoate/umeclidinium/vilanterol) may be approved if the member has trialed/failed three preferred inhaled corticosteroid combination products AND Spiriva. Failure is defined as lack of efficacy with a 6-week trial, allergy, intolerable side effects, significant drug-drug interactions, or dexterity/coordination limitations (per provider notes) that significantly impact appropriate use of a specific dosage form.</p>
--	--	--

Phosphodiesterase Inhibitors (PDEIs)

No PA Required	PA Required	
	<p>DALIRESP (roflumilast) tablet</p> <p>Roflumilast tablet</p>	<p>DALIRESP (roflumilast) may be approved for members when the following criteria are met:</p> <ul style="list-style-type: none"> • Member has severe COPD associated with chronic bronchitis and a history of COPD exacerbations (2 or more per year) AND • Member must be ≥ 18 years of age AND • Member must have failed a trial of TWO of the following (Failure is defined as lack of efficacy, allergy, intolerable side effects or significant drug-drug interaction): <ul style="list-style-type: none"> ○ A long-acting beta2 agonist ○ A preferred inhaled anticholinergic or anticholinergic combination product <p>AND</p> <ul style="list-style-type: none"> • Member does not have moderate to severe liver disease (Child Pugh B or C)